Engineered chimeric fusion protein compositions and methods of use thereof
Patent Information
- Application Number
- JP2023527407
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-10-01
- Filing Date
- 2021-11-04
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2041-11-04
AI Technical Summary
CAR-T cells face limitations such as contamination with malignant T cells, poor penetration into solid tumors, and suppression by the tumor microenvironment, leading to reduced efficacy in treating T-cell malignancies and other diseases.
Engineered bone marrow cells, including macrophages, are programmed to express chimeric fusion proteins (CFPs) that target disease-associated antigens, enhancing phagocytic activity, T-cell activation, and tumor-killing molecule secretion, and facilitating immune cell recruitment.
The engineered bone marrow cells overcome CAR-T cell limitations by effectively targeting and destroying diseased cells, including cancer cells, while avoiding fratricide and prolonged survival issues, making them a safer immunotherapeutic tool for solid tumors.
Smart Images

Figure 00000000_0000_ABST
Abstract
Description
Related applications
[0001] Cross-reference of related applications This application is filed on November 4, 2020, US Provisional Patent Application No. 63 / 109,445; October 1, 2021, each of which is incorporated herein by reference in its entirety. U.S. Provisional Patent Application No. 63 / 251,400, filed June 4, 2021; U.S. Provisional Patent Application No. 63 / 196,994, filed March 17, 2021; Claiming the benefit of Provisional Patent Application No. 63 / 162,205. [Background technology]
[0002]
[0002] Cellular immunotherapy is used to combat difficult-to-treat diseases such as cancer and persistent infections, and also to combat certain diseases that are refractory to other forms of treatment. This is a promising new technology. A major breakthrough has occurred with the discovery of CAR-T cells and their potential use in immunotherapy. CAR-T cells are T lymphocytes that express chimeric antigen receptors that help target T cells to specific diseased cells, such as cancer cells, and that utilize intracellular domains and Depending on the co-expressed immunosuppressive cytokines, T They are lymphocytes. However, several limitations along the way have slowed progress in CAR-T cells and diminished their promise in clinical trials.
[0003]
[0003] Understanding the limitations of CAR-T cells is key to harnessing the technology and continuing to innovate into successful immunotherapy models. Specifically, CAR-T cells appear to be facing major challenges in T-cell malignancies. Because CAR-T cells and malignant T cells share surface antigens in most T-cell lymphomas (TCLs), CAR-T cells, like cancer cells, are subject to cytotoxic effects. In some cases, CAR-T products may be contaminated with malignant T cells. In addition, T cell agenesis is a potential problem due to the prolonged survival of CAR-T cells. Other limitations include the poor ability of CAR-T cells to penetrate solid tumors and the strong tumor microenvironment, where they act to downregulate their antitumor potential. CAR-T cell function is also negatively influenced by the immunosuppressive tumor microenvironment (TME), leading to inactivation and exhaustion of endogenous T cells.
[0004]
[0004] Bone marrow cells, including macrophages, are cells derived from the myeloid lineage and belong to the innate immune system. Bone marrow cells are derived from bone marrow stem cells that escape into the blood and migrate into tissues. Some of their major functions include phagocytosis, activation of T cell responses, and removal of cell debris and extracellular matrix. Bone marrow cells also play an important role in maintaining homeostasis and in the initiation and resolution of inflammation. In addition, bone marrow cells interact with numerous downstream cells, including macrophages, which can present different responses ranging from pro-inflammatory to anti-inflammatory, depending on the type of stimulus they receive from the surrounding microenvironment. Can be differentiated. Additionally, tissue macrophages have been shown to play a wide range of regulatory and activating roles for other immune cell types, including CDT effector cells, NK cells, and regulatory T cells. Macrophages have been shown to be the major immune infiltrate within malignant tumors and have also been shown to exert broad immunosuppressive effects on effector immune infiltrates and immune function.
[0005] Bone marrow cells are the major cellular compartment of the immune system, including monocytes, dendritic cells, tissue macrophages, and granulocytes. Models for the cell ontogeny, activation, differentiation, and tissue-specific functions of myeloid cells have been revisited over the past few years, with surprising results. However, their enormous plasticity and heterogeneity, both in homeostasis and disease, is far from being understood. Bone marrow cells have many functions, including phagocytosis, and their ability to activate T cells, the production of soluble factors, but the exploitation of these functions for therapeutic use remains elusive. It remains as it is. Thus, novel avenues are needed to use other cell types for the development of improved therapeutic agents, including but not limited to T-cell malignancies.
[0006] Engineered bone marrow cells in vivo or ex vivo are also short-lived in vivo, phenotypically diverse, highly sensitive, plastic, and difficult to manipulate in vitro. often found. For example, expression of exogenous genes in monocytes is difficult compared to expression of exogenous genes in non-hematopoietic cells. There are significant technical difficulties associated with transfecting bone marrow cells (eg, monocytes / macrophages). As professional phagocytes, myeloid cells such as monocytes / macrophages contain many powerful degradative enzymes that can destroy the integrity of nucleic acids, making gene transfer into these cells an inefficient process. This is especially true for activated macrophages, which undergo dramatic changes in their physiology after exposure to immune or inflammatory stimuli. Macrophages are generally nondividing, terminal-stage cells, which precludes viral transduction of these cells; for this reason, some vectors that rely on integration into the replicative genome have limited success. limited. Furthermore, macrophages are highly responsive to "danger signals," and some of the original viral vectors used for gene transfer induce strong antiviral responses within these cells, and these vectors are unsuitable for gene delivery. [Summary of the invention]
[0007] The diverse functionality of bone marrow cells makes them ideal cell therapeutic candidates that can be manipulated to exert multiple therapeutic effects. The present disclosure relates to immunotherapy using bone marrow cells of the immune system (eg, CD14+ cells), particularly phagocytes. A number of therapeutic indications using bone marrow cells could be envisaged. For example, immunotherapy with bone marrow cells could be of great importance in cancer, autoimmunity, fibrotic diseases, and infectious diseases. The present disclosure relates to immunotherapy using phagocytic cells of the immune system, particularly bone marrow cells, including macrophages. It is an object of the invention disclosed herein to exploit one or more of these functions of bone marrow cells for therapeutic use. For example, it is an object of the invention disclosed herein to exploit the phagocytic activity of bone marrow cells, including engineered bone marrow cells, for therapeutic uses. For example, it is an object of the invention disclosed herein to exploit the ability of bone marrow cells, including engineered bone marrow cells, to promote T cell activation. For example, it is an object of the invention disclosed herein to exploit the ability of bone marrow cells, including engineered bone marrow cells, to promote secretion of tumor-killing molecules. For example, it is an object of the invention disclosed herein to exploit the ability of bone marrow cells, including engineered bone marrow cells, to facilitate the recruitment and trafficking of immune cells and molecules. The present disclosure discloses methods for transfecting or transducing bone marrow cells with the aim of enhancing the functional aspects of bone marrow cells, while not impairing the differentiation potential of the cells, their maturation potential, and / or plasticity. Novel methods and compositions are presented that may be successful in inducing , or other genetic modifications in bone marrow cells. Bone marrow cells may reside in the body in vivo or may be manipulated ex vivo.
[0008]
[0008] The present disclosure provides programming of bone marrow cells that can directly and / or indirectly attack and kill diseased cells, such as cancer cells and infected cells, in vivo or ex vivo. (ATAK), involves the creation and use of engineered bone marrow cells (e.g., CD14+ cells), such as macrophages or other phagocytes. Engineered bone marrow cells, such as macrophages and other phagocytes, can be produced using recombinant nucleic acid technology, synthetic nucleic acids, gene editing methods (e.g., CRISPR), transduction (e.g., using viral constructs), electroporation, or nucleophores. specific for a disease-associated antigen (e.g., a cancer antigen), e.g., using ex vivo, using mRNA delivery technology, including but not limited to LNP technology, in vivo, A nucleic acid sequence (eg, mRNA, plasmid, viral construct) encoding a chimeric fusion protein (CFP) with an extracellular binding domain can be prepared by integrating into a cell. It has been discovered that bone marrow cells can be engineered to exert a wide and diverse range of activities. For example, it has been discovered that bone marrow cells can be engineered to express chimeric fusion proteins (CFPs) containing antigen-binding domains to exert a broad and diverse range of activities. For example, it has been discovered that bone marrow cells can be engineered to have enhanced phagocytic activity such that upon binding of CFP to an antigen on a target cell, the cell exhibits increased phagocytosis of the target cell. Additionally, myeloid cells promote activation of T cells such that upon binding of CFP to antigen on target cells, the cells promote activation of T cells, such as T cells within the tumor microenvironment. It has also been found that it can be manipulated. Bone marrow cells can be engineered to promote secretion of tumor killing molecules such that upon binding of CFP to an antigen on a target cell, the cells promote secretion of tumor killing molecules from neighboring cells. Bone marrow cells recruit and transport immune cells and molecules such that upon binding of CFP to antigens on target cells, the cells facilitate the recruitment and transport of immune cells and molecules to target cells or the tumor microenvironment. Can be manipulated to facilitate transport.
[0009]
[0009] The present disclosure is an important discovery that engineered bone marrow cells overcome at least some of the limitations of CAR-T cells and are readily recruited to solid tumors; In addition to short survival times, they are manipulable and therefore have a small risk of prolonged survival resulting in aplasia and immunodeficiency; bone marrow cells cannot be contaminated with T cells. Based on discoveries including; that bone marrow cells may avoid fratricide, at least because they do not express the same antigens as malignant T cells; and that bone marrow cells have a large amount of anti-tumor function that can be deployed. In some respects, engineered bone marrow-derived cells may be a safer immunotherapeutic tool for targeting and destroying diseased cells.
[0010] Furthermore, myeloid cells such as macrophages have been found to be ubiquitous within the tumor environment (TME), and are among the most abundant cells in some tumor types. As part of their role in the immune system, bone marrow cells such as macrophages are naturally involved in the removal of diseased cells. The present invention relates to the exploitation of bone marrow cell functions, and in particular to the targeting, killing, and direct and / or indirect removal of diseased cells, as well as the delivery of payloads such as antigens and cytokines.
[0011]
[0011] The present disclosure is also based on the important discovery that engineered bone marrow cells can promote endogenous T cell activity. The present disclosure additionally involves programming of bone marrow cells. Engineered bone marrow cells can be produced by LNPs using recombinant nucleic acid technology, synthetic nucleic acids, gene editing methods (e.g., CRISPR), transduction (e.g., using viral constructs), electroporation, or nucleofection, or in vivo. extracellular binding domains specific for disease-associated antigens (e.g., cancer antigens) in vivo, e.g., ex vivo, using mRNA delivery techniques, including but not limited to techniques. This can be achieved through the integration into a cell of a nucleic acid sequence (eg, mRNA, plasmid, viral construct) encoding a chimeric fusion protein (CFP).
[0012] Engineered bone marrow cells are also often found to be short-lived in vivo, phenotypically diverse, highly sensitive, and plastic, and difficult to manipulate in vitro. For example, expression of exogenous genes in monocytes is difficult compared to expression of exogenous genes in non-hematopoietic cells. There are significant technical difficulties associated with transfecting bone marrow cells (eg, monocytes / macrophages). As professional phagocytes, myeloid cells such as monocytes / macrophages contain many powerful degradative enzymes that can destroy the integrity of nucleic acids, making gene transfer into these cells an inefficient process. This is especially true for activated macrophages, which undergo dramatic changes in their physiology after exposure to immune or inflammatory stimuli. Macrophages are generally nondividing, terminal-stage cells, which precludes viral transduction of these cells; for this reason, some vectors that rely on integration into the replicative genome have limited success. limited. Furthermore, macrophages are highly responsive to "danger signals," and some of the original viral vectors used for gene transfer induce strong antiviral responses within these cells, and these vectors are unsuitable for gene delivery. The present disclosure provides for transfecting or transducing bone marrow cells with the aim of not impairing the differentiation potential of the cells, their maturation potential, and / or plasticity, in addition to enhancing the functional aspects of bone marrow cells. We present novel methods and compositions that can successfully induce or otherwise induce genetic modifications in bone marrow cells.
[0013]
[0013] Defined herein is a therapeutic agent directed to bind to a particular antigen expressed on a diseased cell, eg, a cancer cell. Therapeutic agents are provided in which the binding of a target antigen on a target diseased cell to a target antigen causes a process of destruction of the target cell. A therapeutic agent described herein can be a recombinant nucleic acid that can be expressed in a suitable cell, such as a mammalian cell, such as a human cell, in which case the suitable cell is a bone marrow cell. It's possible. In some embodiments, a therapeutic agent described herein can be a recombinant protein that can bind to a target antigen on a target cell. In some embodiments, a therapeutic agent described herein can be a cell, such as a bone marrow cell, where the bone marrow cell is a bone marrow cell that expresses a target antigen on the cell surface. targeting is possible; the recombinant nucleic acids described herein and / or the combinations described herein such that bone marrow cells lyse or phagocytose diseased cells; express the modified protein.
[0014]
[0014] In some embodiments, the therapeutic agent is a bone marrow cell, such as a bone marrow cell described herein. In some embodiments, the bone marrow cells are bone marrow progenitor cells. In some embodiments, the bone marrow cells are undifferentiated and / or non-polarized myeloid cells. In some embodiments, the bone marrow cells are phagocytes. In some embodiments, the bone marrow cells are CD14+ / CD16- cells.
[0015]
[0015] In some embodiments, the therapeutic agent is a recombinant or engineered nucleic acid. In some embodiments, the nucleic acid is RNA.
[0016]
[0016] In some embodiments, the engineered nucleic acid is mRNA. In some embodiments, a therapeutic agent that is a recombinant or engineered nucleic acid encodes a chimeric fusion receptor protein (CFP).
[0017]
[0017] In some embodiments, the recombinant nucleic acid binds to a target antigen on a diseased cell, eg, by a target binding agent domain placed at one end of the protein; Extracellular proteins, also known as "engagers," capable of binding to effector cells, such as effector myeloid cells, e.g., activated phagocytes, by at least another domain that binds to a structural molecule. or encode a soluble protein. Exemplary engagers are bispecific engagers (BiME), or trispecific engagers (TRiME), as described herein.
[0018] In one aspect herein, (a) a phagocytic or tethered receptor (PR) subunit comprising an intracellular domain comprising (i) a transmembrane domain, or (ii) an intracellular signaling domain; and ( b) contains an extracellular domain containing a CD137 antigen-binding domain that can specifically bind to CD137 on target cells; encodes a chimeric fusion protein (CFP) in which the extracellular domain and the transmembrane domain are operably linked; Compositions comprising recombinant nucleic acids are disclosed.
[0019]
[0019] In one aspect herein, (a) a first CD137 antigen-binding domain that specifically binds to the CD137 antigen on a target cell; and (b) a first CD137 antigen-binding domain that specifically binds to a surface agent on a bone marrow cell. A composition comprising a recombinant nucleic acid encoding a chimeric fusion protein comprising a second binding domain that binds a first antigen binding domain to a CD137 antigen on a target cell and a surface agent on a bone marrow cell. binding of a second binding domain of is disclosed.
[0020] In one aspect herein, (a) a phagocytic or tethered receptor (PR) subunit comprising an intracellular domain comprising (i) a transmembrane domain, or (ii) an intracellular signaling domain; and ( b) contains an extracellular domain containing a Claudin 18.2 antigen-binding domain that can specifically bind to Claudin 18.2 on target cells; a chimeric fusion protein (CFP) in which the extracellular domain and the transmembrane domain are operably linked; Compositions comprising recombinant nucleic acids encoding are disclosed.
[0021]
[0021] In one aspect herein, (a) a first Claudin 18.2 antigen binding domain that specifically binds to a Claudin 18.2 antigen on a target cell; and (b) a first Claudin 18.2 antigen binding domain that specifically binds to a Claudin 18.2 antigen on a A composition comprising a recombinant nucleic acid encoding a chimeric fusion protein comprising a second binding domain that binds to a Claudin 18.2 antigen on a target cell and a surface on a bone marrow cell. Binding of a second binding domain to an agent is disclosed.
[0022] In one aspect herein, (a) a phagocytic or tethered receptor (PR) subunit comprising an intracellular domain comprising (i) a transmembrane domain, or (ii) an intracellular signaling domain; and ( b) contains an extracellular domain containing a Claudin 3 antigen-binding domain that can specifically bind to Claudin 3 on target cells; a chimeric fusion protein (CFP) in which the extracellular domain and the transmembrane domain are operably linked; Compositions comprising recombinant nucleic acids encoding are disclosed.
[0023]
[0023] In one aspect herein, (a) a first Claudin 3 antigen binding domain that specifically binds to a Claudin 3 antigen on a target cell; and (b) a first Claudin 3 antigen binding domain that specifically binds to a Claudin 3 antigen on a A composition comprising a recombinant nucleic acid encoding a chimeric fusion protein comprising a second binding domain that binds to a Claudin 18.2 antigen on a target cell and a surface on a bone marrow cell. Binding of a second binding domain to an agent is disclosed.
[0024] In one aspect herein, (a) a phagocytic or tethered receptor (PR) subunit comprising an intracellular domain comprising (i) a transmembrane domain, or (ii) an intracellular signaling domain; and ( b) contains an extracellular domain containing a CD70 antigen-binding domain that can specifically bind to CD70 on target cells; encodes a chimeric fusion protein (CFP) in which the extracellular domain and the transmembrane domain are operably linked; Compositions comprising recombinant nucleic acids are disclosed.
[0025]
[0025] In one aspect herein, (a) a first CD70 antigen-binding domain that specifically binds to a CD70 antigen on a target cell; and (b) a first CD70 antigen-binding domain that specifically binds to a surface agent on a bone marrow cell. A composition comprising a recombinant nucleic acid encoding a chimeric fusion protein comprising a second binding domain that binds a first antigen binding domain to a CD70 antigen on a target cell and a surface agent on a bone marrow cell. binding of a second binding domain of is disclosed.
[0026] In one aspect herein, (a) a phagocytic or tethered receptor (PR) subunit comprising an intracellular domain comprising (i) a transmembrane domain, or (ii) an intracellular signaling domain; and ( b) Contains an extracellular domain containing a TROP2 antigen-binding domain that can specifically bind to TROP2 on target cells; encodes a chimeric fusion protein (CFP) in which the extracellular domain and the transmembrane domain are operably linked. Compositions comprising recombinant nucleic acids are disclosed.
[0027]
[0027] In one aspect herein, (a) a first TROP2 antigen-binding domain that specifically binds to a TROP2 antigen on a target cell; and (b) a first TROP2 antigen-binding domain that specifically binds to a surface agent on a bone marrow cell. A composition comprising a recombinant nucleic acid encoding a chimeric fusion protein comprising a second binding domain that binds a first antigen binding domain to a TROP2 antigen on a target cell and a surface agent on a bone marrow cell. binding of a second binding domain of is disclosed.
[0028] In one aspect herein, (a) a phagocytic or tethered receptor (PR) subunit comprising an intracellular domain comprising (i) a transmembrane domain, or (ii) an intracellular signaling domain; and ( b) contains an extracellular domain containing a TMPRSS antigen-binding domain that can specifically bind to TMPRSS on target cells; encodes a chimeric fusion protein (CFP) in which the extracellular domain and the transmembrane domain are operably linked; Compositions comprising recombinant nucleic acids are disclosed.
[0029]
[0029] In one aspect herein, (a) a first TMPRSS antigen-binding domain that specifically binds to a TMPRSS antigen on a target cell; and (b) a first TMPRSS antigen-binding domain that specifically binds to a surface agent on a bone marrow cell. A composition comprising a recombinant nucleic acid encoding a chimeric fusion protein comprising a second binding domain that binds a first antigen binding domain to a TMPRSS antigen on a target cell and a surface agent on a bone marrow cell. binding of a second binding domain of is disclosed.
[0030]
[0030] In one aspect herein, a PR subunit comprising (a) an intracellular domain comprising (i) a transmembrane domain, and (ii) an intracellular signaling domain; and (b) a PR subunit comprising: comprising a recombinant nucleic acid encoding a phagocytic or tethered receptor (PR) fusion protein (PFP) comprising an extracellular domain comprising an antigen binding domain of any one of those described above, with strong binding affinity a composition in which a transmembrane domain and an extracellular domain are operably linked; upon binding of PFP to an antigen of a target cell, killing or phagocytic activity of a cell expressing PFP results in a cell expressing PFP; Compositions are disclosed that are increased by at least 20% compared to cells that do not.
[0031]
[0031] In some embodiments, the intracellular signaling domain of any one of the PFPs described herein is derived from a phagocytic or tethered receptor (PR), or The domain includes a phagocytosis activation domain.
[0032]
[0032] In some embodiments, the intracellular signaling domain comprises a pro-inflammatory signaling domain.
[0033]
[0033] In some embodiments, the pro-inflammatory signaling domain comprises a kinase activation domain or a kinase binding domain.
[0034]
[0034] In some embodiments, the intracellular signaling domain comprises a PI3 kinase recruitment domain.
[0035]
[0035] In some embodiments, the pro-inflammatory signaling domain comprises an IL-1 signaling cascade activation domain.
[0036]
[0036] In some embodiments, the pro-inflammatory signaling domain is TLR3, TLR4, TLR7, TLR9, TRIF, RIG-1, MYD88, MAL, IRAK1, MDA-5, IFN receptor, NLRP family member. Intracellular signaling domains derived from certain NLRP1-14, NOD1, NOD2, pilin, AIM2, NLRC4, FCGR3A, FCERIG, CD40, a caspase domain or a procaspase binding domain, or any combination thereof.
[0037]
[0037] In some embodiments, any one of the PFPs described herein further comprises a TM domain derived from the protein transmembrane domain of CD2, CD8, CD28, CD64, or CD68. .
[0038]
[0038] In some embodiments, any one of the PFPs described herein further comprises a hinge domain.
[0039]
[0039] In some embodiments, upon binding of PFP to an antigen of a target cell, the killing activity of cells expressing PFP is increased by at least more than 20% compared to cells that do not express PFP. Ru.
[0040]
[0040] In some embodiments, upon binding of PFP to an antigen of a target cell, the killing activity of cells expressing PFP is increased by at least 1.1-fold compared to cells that do not express PFP.
[0041] In some embodiments, the composition comprises a first binding domain that is a first antibody or a functional fragment thereof that specifically interacts with an antigen on a target cell, and a first binding domain that specifically interacts with an antigen on a target cell. a second binding domain that is a second antibody or a functional fragment thereof that interacts with a second antibody or a functional fragment thereof, wherein (i) the first therapeutic agent or (ii) in some embodiments, the composition comprises an additional therapeutic agent.
[0042] In some embodiments, the therapeutic agent comprises (a) a first binding domain that specifically interacts with the antigen of the target cell; (b) a second binding domain that specifically interacts with bone marrow cells. a binding domain, and (c) a third binding domain that specifically interacts with bone marrow cells.
[0043] In some embodiments, any one of the binding domains of the therapeutic agent is a binding domain of an antibody, a functional fragment of an antibody, a variable domain thereof, a V H domain, V L domain, VNAR domain, V HH domains, single chain variable fragments (scFv), Fabs, single domain antibodies (sdAbs), nanobodies, bispecific antibodies, diabodies, or functional fragments or combinations thereof.
[0044]
[0044] In some embodiments, the antigen on the target cell that the first binding domain binds is a cancer or pathogenic antigen on the target cell, or an autoimmune antigen.
[0045]
[0045] In some embodiments, the first therapeutic agent comprises a polypeptide that is less than 1000 amino acids or 1000 nm in length. In some embodiments, the first therapeutic agent comprises a polypeptide that is less than 500 amino acids or 500 nm in length. In some embodiments, the first therapeutic agent comprises a polypeptide that is 200-1000 amino acids or 200-1000 nm in length.
[0046]
[0046] In some embodiments, engagement of the binding domain of the first therapeutic agent contacts the cancer cell with the bone marrow cell.
[0047]
[0047] In some embodiments, the second binding domain specifically interacts with myeloid cells and promotes phagocytic activity of myeloid cells.
[0048]
[0048] In some embodiments, the second binding domain specifically interacts with myeloid cells and promotes inflammatory signaling in myeloid cells.
[0049]
[0049] In some embodiments, the second binding domain specifically interacts with bone marrow cells or adhesion molecules to promote adhesion of bone marrow cells to target cells.
[0050]
[0050] In some embodiments, the second binding domain specifically interacts with bone marrow cells and inhibits antiphagocytic activity of myeloid cells mediated by target cells.
[0051]
[0051] In some embodiments, the second binding domain specifically interacts with myeloid cells and inhibits the anti-inflammatory activity of myeloid cells mediated by target cells.
[0052]
[0052] In some embodiments, the second binding domain and / or the third binding domain promote phagocytic activity of myeloid cells.
[0053]
[0053] In some embodiments, the second binding domain and / or the third binding domain promote inflammatory signaling in myeloid cells.
[0054]
[0054] In some embodiments, the second binding domain and / or the third binding domain specifically interacts with bone marrow cells or adhesion molecules to promote adhesion of bone marrow cells to target cells. do.
[0055]
[0055] In some embodiments, the second binding domain and / or the third binding domain inhibits anti-phagocytic activity of myeloid cells mediated by target cells.
[0056]
[0056] In some embodiments, the second binding domain and / or the third binding domain inhibits anti-inflammatory activity of myeloid cells mediated by target cells.
[0057] In some embodiments, the third binding domain or additional therapeutic agent is a CD47 antagonist, CD47 blocker, antibody, chimeric CD47 receptor, sialidase, cytokine, pro-inflammatory gene, procaspase, or anti-inflammatory gene. Contains drugs.
[0058] In some embodiments, the third binding domain or additional therapeutic agent is a SIRP alpha antagonist, a SIRPA blocker, an antibody, a chimeric SIRPA receptor, a cytokine, a pro-inflammatory gene, a procaspase, or an anti-cancer Contains agents.
[0059] In some embodiments, the third binding domain or additional therapeutic agent is a PD1 antagonist, a PD1 blocker, an antibody, a chimeric PD1 receptor, a cytokine, a pro-inflammatory gene, a procaspase, or an anti-cancer drug. including.
[0060]
[0060] In some embodiments, the second binding domain and the third binding domain bind distinct, non-identical target antigens.
[0061]
[0061] In some embodiments, the first binding domain, second binding domain, or third binding domain is a ligand binding domain.
[0062]
[0062] In some embodiments, the first, second, or third binding domain is operably linked by one or more linkers.
[0063]
[0063] In some embodiments, the linker is a polypeptide. In some embodiments, the linker is a functional peptide. In some embodiments, the linker is a ligand for a receptor. In some embodiments, the linker is a ligand for a monocyte or macrophage receptor. In some embodiments, the linker activates the receptor. In some embodiments, the linker inhibits the receptor.
[0064]
[0064] In some embodiments, the linker is a ligand for the macrophage M2 receptor. In some embodiments, the linker is a ligand for a TLR receptor, such as TLR4. In some embodiments, the linker activates a TLR receptor. In some embodiments, the first, second and / or third binding domain is associated with a mask that binds to the binding domain.
[0065]
[0065] In some embodiments, the mask is an inhibitor that inhibits the interaction of a binding domain with its target when the mask remains associated with its respective binding domain. In some embodiments, the mask is associated with the binding domain via a peptide linker. In some embodiments, the linker includes a cleavable portion.
[0066]
[0066] In some embodiments, the cleavable moiety is cleaved by a protein or enzyme that is selectively abundant at the site of the cancer or tumor.
[0067]
[0067] In some embodiments, the therapeutic agent is a nucleic acid, eg, an engineered nucleic acid, in which case the nucleic acid is RNA.
[0068]
[0068] In some embodiments, the nucleic acid is mRNA.
[0069]
[0069] In some embodiments, the nucleic acid is a self-replicating RNA designed to target bone marrow cells.
[0070]
[0070] In some embodiments, the engineered nucleic acid is a circRNA designed to target bone marrow cells.
[0071]
[0071] In some embodiments, the engineered recombinant nucleic acid is RNA designed to target bone marrow cells.
[0072]
[0072] In some embodiments, the engineered nucleic acid is an mRNA designed to target bone marrow cells.
[0073]
[0073] In some embodiments, the engineered nucleic acid is a self-replicating RNA designed to target bone marrow cells.
[0074]
[0074] In some embodiments, the engineered nucleic acid is a circRNA designed to target bone marrow cells.
[0075]
[0075] In some embodiments, the engineered recombinant nucleic acid is associated with one or more lipids.
[0076]
[0076] In some embodiments, recombinant nucleic acids are encapsulated within liposomes.
[0077]
[0077] In some embodiments, liposomes are nanoparticles.
[0078]
[0078] In some embodiments, the recombinant nucleic acid is contained within a vector.
[0079]
[0079] Provided herein is a pharmaceutical composition comprising any one of the recombinant nucleic acids of the compositions according to the embodiments described above and an acceptable excipient.
[0080]
[0080] Provided herein are pharmaceutical compositions comprising a polypeptide encoded by a recombinant nucleic acid encoding any one of the recombinant proteins described above.
[0081]
[0081] Provided herein are cells containing a recombinant nucleic acid encoding any one of the recombinant proteins described above.
[0082]
[0082] In some embodiments, the cells are bone marrow cells.
[0083]
[0083] In some embodiments, the cells are CD14+, CD16-.
[0084]
[0084] Included herein is a population of cells comprising a recombinant nucleic acid according to any one of the embodiments described above, wherein at least 50% of the cells are CD14+CD16-. Pharmaceutical compositions are provided.
[0085]
[0085] In some embodiments, less than 10% of the cells of the pharmaceutical composition are dendritic cells.
[0086]
[0086] In some embodiments, the pharmaceutical composition further comprises a suitable excipient.
[0087]
[0087] Provided herein is a method of making any one of the compositions according to any one of the embodiments described above.
[0088]
[0088] In one aspect herein, a method of treating cancer in a subject comprises administering to the subject a pharmaceutical composition according to any one of the embodiments described above. A method is provided.
[0089]
[0089] In one aspect herein, a method of treating cancer in a subject comprises administering to the subject a pharmaceutical composition according to any one of the embodiments described above. A method is provided.
[0090] In some embodiments, the cancer is gastric cancer, ovarian cancer, kidney cancer, breast cancer, prostate cancer, liver cancer, brain cancer, lymphoma, leukemia, skin cancer, pancreatic cancer, selected from the group consisting of colorectal cancer, glioblastoma, and lung cancer.
[0091]
[0091] In one aspect herein, a method of making any one of the compositions described herein is provided.
[0092]
[0092] In one aspect herein, there is provided a method of treating cancer in a subject, the method comprising administering to the subject a pharmaceutical composition described herein.
[0093]
[0093] In one aspect herein, there is provided a method of treating cancer in a subject, the method comprising administering to the subject a pharmaceutical composition described herein.
[0094] In some embodiments, the cancer is gastric cancer, ovarian cancer, kidney cancer, breast cancer, prostate cancer, liver cancer, brain cancer, lymphoma, leukemia, skin cancer, pancreatic cancer, selected from the group consisting of colorectal cancer, glioblastoma, and lung cancer.
[0095]
[0095] One aspect herein provides a composition comprising a recombinant polynucleic acid comprising a sequence encoding a chimeric fusion protein (CFP), wherein the CFP comprises (a) an extracellular domain comprising an antigen-binding domain; and (b) a transmembrane domain operably linked to an extracellular domain; the transmembrane domain being derived from a protein that dimerizes with endogenous FcR gamma receptors in bone marrow cells. A composition is provided, wherein the recombinant polynucleic acid is encapsulated by a nanoparticle delivery vehicle; and after administration of the composition to the human subject, CFP is expressed on the surface of bone marrow cells of the human subject.
[0096]
[0096] In some embodiments, the antigen binding domain comprises a Fab fragment, scFv domain, or sdAb domain. In some embodiments, the transmembrane domain is a transmembrane domain derived from CD8, CD16a, CD64, CD68, or CD89.
[0097]
[0097] In some embodiments, the extracellular domain further comprises a hinge domain derived from CD8, where the hinge domain is operably linked to a transmembrane domain and an antigen binding domain.
[0098] In some embodiments, the transmembrane domain is a transmembrane domain derived from a protein that dimerizes with endogenous FcR gamma receptors within myeloid cells, monocytes, or macrophages; Following administration of the pharmaceutical composition to a human subject, CFP is specifically expressed within the human subject's bone marrow cells, monocytes, or macrophages. In some embodiments, the transmembrane domain is from CD16a, CD64, CD68, or CD89. In some embodiments, the CFP further comprises an intracellular domain, where the intracellular domain comprises one or more intracellular signaling domains, and the one or more intracellular signaling domains are Contains intracellular signaling domains derived from FcγR, FcαR, FcεR, CD40, or CD3 zeta. In some embodiments, the one or more intracellular signaling domains further include a phosphoinositide 3-kinase (PI3K) recruitment domain. In some embodiments, the PI3K recruitment domain comprises a sequence that has at least 90% sequence identity to SEQ ID NO:26. In some embodiments, the intracellular domain comprises an intracellular domain derived from CD16a, CD64, CD68, or CD89.
[0099]
[0099] In some embodiments, the intracellular domain of the CFP described herein comprises an immunoreceptor tyrosine-based activation motif (ITAM) domain. In some embodiments, the intracellular domain of CFP described herein comprises more than one ITAM domain. In some embodiments, the ITAM domain comprises CD3 zeta TCR subunit, CD3 epsilon TCR subunit, CD3 gamma TCR subunit, CD3 delta TCR subunit, TCR zeta chain, Fc epsilon receptor 1 chain, Fc epsilon receptor 2 chain, Fc gamma receptor 1 chain, Fc gamma receptor 2a chain, Fc gamma receptor 2b1 chain, Fc gamma receptor 2b2 chain, Fc gamma receptor 3a chain, Fc gamma receptor 3b chain, Fc beta receptor 1 chain, TYROBP(DAP12), CD5, CD16a, CD16b, CD22, CD23, CD32, CD64, CD79a, CD79b, CD89, CD278, CD66d, functional fragments thereof, and at least one but not more than 20 of these; derived from the intracellular domain of a protein or polypeptide selected from the group consisting of these amino acid sequences with modifications.
[0100]
[0100] In some embodiments, at least one ITAM domain includes a phosphorylation site for a Src family kinase.
[0101]
[0101] In some embodiments, at least one ITAM domain includes a Syk recruitment domain.
[0102]
[0102] In some embodiments, the intracellular signaling subunit further comprises a DAP12 recruitment domain.
[0103]
[0103] In some embodiments, the intracellular domain comprises at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 ITAM domains.
[0104]
[0104] In some embodiments, the recombinant polynucleic acid is mRNA. In some embodiments, mRNA is delivered to cells via a nanoparticle delivery vehicle. In some embodiments, the nanoparticle delivery vehicle comprises lipid nanoparticles. In some embodiments, lipid nanoparticles include polar lipids. In some embodiments, lipid nanoparticles include non-polar lipids. In some embodiments, the lipid nanoparticles are 100-300 nm in diameter. In some embodiments, the antigen binding domain binds to an antigen selected from the group consisting of TROP2, GPC3, CD5, HER2, CD137, CD70, Claudin 3, Claudin 18.2, TMPRSS, CD19, CD22, CD7, and GP75. Join.
[0105]
[0105] Provided herein is a pharmaceutical composition comprising the composition described above and a pharmaceutically acceptable excipient. In some embodiments, the pharmaceutical composition comprises an amount of a composition described herein effective to inhibit cancer growth when administered to a human subject having cancer. include.
[0106]
[0106] In one aspect herein, there is provided a method of treating cancer in a subject in need thereof, the method comprising administering a pharmaceutical composition described herein.
[0107]
[0107] In one aspect herein, a method of introducing a composition described herein into bone marrow cells, comprising: (a) an extracellular domain comprising an anti-TROP2 binding domain; and (b) ) electroporating bone marrow cells in the presence of a recombinant liponucleic acid comprising a sequence encoding a chimeric fusion protein (CFP) comprising a transmembrane domain operably linked to an extracellular domain; The liponucleic acid is (i) present within bone marrow cells, or (ii) encapsulated by a nanoparticle delivery vehicle; the recombinant liponucleic acid configured for expression of the recombinant polynucleic acid within bone marrow cells of a human subject. A method is provided.
[0108] In one aspect herein, (a) at least one of the sequences set forth in SEQ ID NO: 34 and SEQ ID NO: 35, or a sequence that is at least 85% identical to SEQ ID NO: 34 or SEQ ID NO: 35; (b) operably linked to the extracellular domain and derived from the transmembrane domain of an FcγR1 molecule (CD64), an FcγRIIIA molecule (CD16), or an FcαR1 molecule (CD89); and (c) optionally a hinge domain operably linked to the extracellular domain and the transmembrane domain, the hinge domain comprising an amino acid sequence derived from a CD8α hinge domain. Compositions are provided that include recombinant polynucleic acids that include sequences encoding chimeric fusion proteins (CFP).
[0109] In some embodiments, the composition comprises at least the sequence set forth in SEQ ID NO: 26, 27, or 28; or an amino acid sequence selected from the sequence set forth in SEQ ID NO: 26, 27, or 28. Further comprising an intracellular domain comprising an amino acid sequence selected from sequences that are 80% identical. In some embodiments, the recombinant polynucleic acid is mRNA.
[0110]
[0110] Provided herein are cells that are CD14+ cells and include a recombinant polynucleic acid that includes a sequence encoding a chimeric fusion protein with an extracellular domain that includes an anti-TROP2 binding domain.
[0111]
[0111] As used herein, the use of any one of the compositions described herein, or the pharmaceutical compositions herein, or the cells described herein, in the treatment of a disease or disorder. Use provided.
[0112]
[0112] In this specification, gastric cancer, ovarian cancer, kidney cancer, breast cancer, prostate cancer, liver cancer, brain cancer, lymphoma, leukemia, skin cancer, pancreatic cancer, colorectal cancer, neurological Provided is the use of a pharmaceutical composition described herein in the treatment of cancer in a subject selected from the group consisting of glioblastoma, and lung cancer.
[0113]
[0113] In this specification, gastric cancer, ovarian cancer, kidney cancer, breast cancer, prostate cancer, liver cancer, brain cancer, lymphoma, leukemia, skin cancer, pancreatic cancer, colorectal cancer, neurological A composition as described herein, or a pharmaceutical composition as described herein, in the preparation of a medicament for treating cancer in a subject, selected from the group consisting of glioblastoma, and lung cancer; or use of any one of the cells described herein is provided.
[0114]
[0114] Also described herein are: (A) a first nucleic acid sequence encoding an exogenous polypeptide; and (B) a second nucleic acid sequence encoding a chimeric antigen receptor fusion protein (CFP), comprising: CFP is an intracellular signaling subunit that includes (a) an intracellular signaling domain with one or more tyrosine residues that is phosphorylated upon binding to antigen by the receptor; (b) a transmembrane domain. (c) an extracellular binding domain that has binding specificity for components on the surface of the target cell and is operably linked to a transmembrane domain and an intracellular signaling subunit; and (d) protease cleavage. (C ) (i) a protease that cleaves a protease cleavage sequence that operably links the transcriptional activation domain to an intracellular signaling subunit; (ii) binds to a tyrosine residue that is phosphorylated upon activation of CFP. a third nucleic acid sequence encoding a domain; and a third nucleic acid sequence operably linked to a protease that cleaves a protease cleavage sequence and a domain that binds to a tyrosine residue. Items will also be provided.
[0115]
[0115] In some embodiments, the third nucleic acid sequence further encodes (iii) a stimulus-responsive element.
[0116]
[0116] In some embodiments, stimulus-responsive element (iii) is fused to a domain that binds a phosphorylated tyrosine residue.
[0117]
[0117] In some embodiments, the stimuli-responsive element (iii) is responsive to the microenvironment of the cell expressing the nucleic acid sequence.
[0118]
[0118] In some embodiments, one or more recombinant nucleic acids are expressed within bone marrow cells.
[0119]
[0119] In some embodiments, the transcription activation domain further comprises a DNA binding domain.
[0120]
[0120] In some embodiments, the DNA binding domain is selected from the DNA binding domain (DB) of Gal4, ZFHD1, or tet-R.
[0121]
[0121] In some embodiments, the transcriptional activation domain comprises a VP64 transactivation domain.
[0122]
[0122] In some embodiments, the protease that cleaves the protease cleavage sequence that operably links the transcriptional activation domain to the intracellular signaling subunit is hepatitis C virus (HCV) NS3 protease. .
[0123]
[0123] In some embodiments, the domain that binds tyrosine residues that are phosphorylated upon activation of CFP is a phosphotyrosine binding (PTB) domain.
[0124]
[0124] In some embodiments, the PTB is Shc PTB.
[0125]
[0125] In some embodiments, (iii) is a degron operably linked to (ii).
[0126]
[0126] In some embodiments, the degron is a HIF-1a degron.
[0127]
[0127] The present specification provides a pharmaceutical composition comprising the composition listed in paragraphs
[0114] to
[0126] and a pharmaceutically acceptable excipient. The present specification provides cells comprising the compositions listed in paragraphs
[0114] to
[0126] . In some embodiments, the cells are CD14+. Provided herein is a method of treating a disease in a subject, the method comprising administering to the subject any one of (i) a pharmaceutical composition; or (ii) a cell listed in paragraph
[0127] A method is provided that includes steps.
[0128] Inclusion by reference
[0128] All publications, patents, and patent applications mentioned herein are specifically and individually incorporated by reference. is incorporated herein by reference to the same extent as if indicated.
[0129] The novel features of the invention are pointed out with particularity in the appended claims. A better understanding of the features and advantages of the present invention may be gained by reference to the following detailed description and accompanying drawings that illustrate illustrative embodiments in which the principles of the invention are utilized. [Brief explanation of drawings]
[0130]
Figure 1
[0130] The CFP on the left contains an extracellular binding domain, a transmembrane domain, and an intracellular signaling domain, and the CFP on the right contains an extracellular binding domain, a transmembrane domain, and the first intracellular signaling domain. In the figure depicting a schematic showing two exemplary CFPs containing a domain, a second intracellular signaling domain, a third intracellular signaling domain, and one or more additional intracellular signaling domains. be. Signal transduction domains may be derived from other receptors and may be designed to elicit any number of cellular functions. An exemplary binding domain is the CD137 binding domain. An exemplary binding domain is a TROP2 binding domain. [Figure 2A]
[0131] FIG. 6 shows an exemplary CFP dimer containing an intracellular signaling domain containing an FcRγ-derived intracellular domain fused to an anti-CD137 extracellular binding domain, a transmembrane domain, and a PI3K recruitment domain. It is a figure which depicts an outline. [Figure 2B]
[0132] Figure 1 depicts a schematic showing an exemplary CFP dimer containing an anti-CD137 extracellular antigen binding domain, a transmembrane domain, and an intracellular signaling domain that contains a phagocytic domain, a PI3K recruitment domain, and a proinflammatory domain. FIG. [Figure 3]
[0133] An exemplary CFP homodimer (left), where each subunit contains an extracellular domain fused into an scFv that binds a single target, and the first subunit of the heterodimer is a second subunit of the heterodimer contains an extracellular domain fused to an scFv that binds a second target; FIG. 2 is a schematic diagram depicting an exemplary CFP heterodimer (right). [Figure 4A]
[0134] Antigen-specific, fused with an intracellular domain (ICD) of a scavenger receptor, with an extracellular domain (ECD), a transmembrane domain (TMD), and a signaling domain 1, a signaling domain 2, and a signaling domain 3. FIG. 2 is a schematic diagram depicting an exemplary recombinant nucleic acid encoding a CFP containing a signal peptide fused to a targeted scFv. Additionally, an exemplary recombinant nucleic acid is an mRNA with a 5'UTR and a 3'UTR. [Figure 4B]
[0135] With viral gene delivery (left panel), some cell types exhibit poor transduction and cell differentiation, which negatively impacts the potential effects of therapeutic cell function and cell longevity; however, plasmid-mediated delivery (top right) is capable of inducing differentiation and cell death; in this case, data show that mRNA delivery is safe and causes almost negligible immune responses within the cells after delivery. This is a diagram supporting this (lower right). [Figure 5]
[0136] Relative phagocytosis in human primary bone marrow cells transduced with empty vector (control) or vector encoding CFP co-cultured with antigen-coated beads, as depicted in the schematic diagram above. FIG. 3 shows example data depicting prediction results. Phagocytosis is quantified using flow cytometry. [Figure 6A]
[0137] In primary human bone marrow cells transduced with a vector encoding CFP co-cultured with antigen expressing empty vector (control) or target cells labeled with a fluorescent dye, as depicted in the schematic diagram above. FIG. 4 shows exemplary data depicting predicted results for relative phagocytosis in FIG. Phagocytosis is quantified using flow cytometry. The effects of different myeloid cell to target ratios are depicted as expected. [Figure 6B]
[0138] Figure 2 shows data supporting the specificity of the CFP-binding domain (binder); cells expressing a CFP construct that binds to CD19 (CD19-ATAK) exhibit a high degree of phagocytosis only in the presence of CD19+ targets. , which do not harbor CD19 on the surface, do not show this in the presence of CD22+ targets, and vice versa. [Figure 6C]
[0139] Data showing successful chemotaxis and localization of myeloid cells expressing fluorescent CFP constructs within tumors (by imaging; left panel); graphs on the right show in vitro, varying concentrations. Figure 2 shows chemotaxis in the presence of CCL2. [Figure 7A]
[0140] Primary human monocytes expressing anti-CD5 CFP under different polarization conditions (shown in the upper panel), e.g., in the presence of MCSF alone (M0 conditions); or IL-10, IL- 4, and with TGFβ (M2 conditions); or in the presence of IFN and LPS for 24 hours and then incubated with H9 T-cell lymphoma cells, by flow cytometry analysis. Figure 3 depicts a graphical graph, the results indicating that expression of CFP did not alter the ability of cells to become polarized under these conditions. In addition, co-incubation with tumor cells also did not alter polarization. Furthermore, using the same culture conditions, primary human monocytes expressing anti-CD5 CFP were investigated and corroborated to have potent tumor cell phagocytosis / killing activity in the M2 environment (herein (not shown). The same approach can be used to examine the in vitro efficacy of any of the binding agents described herein in an M1-promoting environment or an M2-promoting environment. [Figure 7B]
[0141] FIG. 2 depicts a schematic diagram showing an exemplary experimental flowchart for an animal model experiment for peripheral T-cell lymphoma treatment. 1 x 106 CD5-HU9 Sézary syndrome tumor line cells were injected subcutaneously into mice. Treatment with the indicated amounts of human primary monocytes expressing anti-CD5 CFP began 11 days after injection of tumor line cells. A total of 5 injections were performed, once every 3 days. The same approach can be used to examine the in vitro efficacy of any of the binding agents described herein in an appropriate experimental tumor model in vivo. [Figure 7C]
[0142] FIG. 4 depicts a graph of relative tumor size (radiance) in relation to relative tumor size (radiance). [Figure 8]
[0143] FIG. 3 shows an exemplary modular design (ECD=extracellular domain; H=hinge; TMD=transmembrane domain; ICD=intracellular domain) for CFP constructs for monocyte-specific expression. [Figure 9]
[0144] Anti-GPC3 with an anti-GPC3 or anti-TROP2 antibody domain, a FLAG extracellular domain, a human CD16 transmembrane (TM) domain or a human CD89 transmembrane domain, and a human CD16 intracellular (cyto) domain or a human CD89 intracellular domain FIG. 3 depicts a representative workflow and functional analysis for the expression of exemplary CFP constructs, including CFP constructs and anti-TROP2 CFP constructs. As depicted, 200 ug / mL of RNA encoding the construct can be electroporated (EP) into PBMC and analyzed for expression, target tumor cell killing, and cytokine / chemokine production. [Figure 10A]
[0145] FIG. 3 depicts flow cytometry data analyzing the expression of the indicated anti-TROP2 CFP constructs in various cell types. As shown in the bottom panel, expression of the indicated anti-TROP2 CFP constructs was observed in CD14+ bone marrow cells, but not in CD19+ B cells, CD3+ T cells, or CD56+ NK cells. [Figure 10B]
[0146] FIG. 3 depicts flow cytometry data analyzing the expression of the indicated anti-GPC3 CFP constructs in various cell types. As shown in the bottom panel, expression of the indicated anti-GPC3 CFP constructs was observed in CD14+ bone marrow cells, but not in CD19+ B cells, CD3+ T cells, or CD56+ NK cells. [Figure 11A]
[0147] FIG. 3 depicts data from a luciferase assay measuring killing of SKOV3 cells by PBMCs transfected with the indicated anti-TROP2 CFP constructs. PBMCs transfected with the indicated anti-TROP2 CFP constructs were co-cultured with SKOV3-Luc cells at 5:1 effector cells:target cells for 3 days. PBMCs transfected with the indicated anti-TROP2 CFP constructs demonstrated specific killing of SKOV3 cells compared to controls. [Figure 11B]
[0148] FIG. 3 depicts data analyzing expression, tumor-specific phagocytosis, and anti-tumor cytokine production using bone marrow cells contacted with LNPs containing mRNA encoding the indicated anti-TROP2 CFP constructs. The left panel depicts flow cytometry data analyzing the expression of the indicated anti-TROP2 CFP constructs in various cell types contacted with LNPs containing mRNA encoding the indicated anti-TROP2 CFP constructs. Expression of the indicated anti-TROP2 CFP constructs is observed in CD14+ bone marrow cells, but not in CD19+ B cells, CD3+ T cells, or CD56+ NK cells. The middle panel depicts a graph of data from a luciferase assay measuring killing of SKOV3 cells by PBMCs contacted with LNPs containing mRNA encoding the indicated anti-TROP2 CFP constructs. PBMCs contacted with LNPs containing mRNA encoding the indicated anti-TROP2 CFP constructs and co-cultured with SKOV3-Luc cells demonstrated specific killing of SKOV3 cells compared to controls. The right panel depicts a graph of the production of TNF alpha by the samples derived from the middle panel. [Figure 12A]
[0149] FIG. 3 depicts data on cytokine production using bone marrow cells contacted with LNPs containing mRNA encoding the indicated anti-TROP2 CFP constructs. Figure 2: Production of IL-1beta and IL-18 from samples in which PBMCs contacted with LNPs containing mRNA encoding the indicated anti-TROP2 CFP constructs were cultured alone or co-cultured with SKOV3 cells. Show a graph. [Figure 12B]
[0150] FIG. 3 depicts data on cytokine production using bone marrow cells contacted with LNPs containing mRNA encoding the indicated anti-TROP2 CFP constructs. Figure 3 shows graphs of CCL2 and TNF alpha production from samples in which PBMCs were contacted with LNPs containing mRNA encoding the indicated anti-TROP2 CFP constructs, either cultured alone or co-cultured with SKOV3 cells. [Figure 12C]
[0151] FIG. 11 outlines the successful use of CD89 (FcR alpha chain) to drive myeloid cell-specific programming in vivo. mRNA encoding CFP with scFv conjugated to CD89 was formulated in LNPs and injected into mice. Figure 3 shows a graph of the percentage of myeloid cells and lymphocytes expressing CFP. Expression of CFP was observed in CD14+ bone marrow cells compared to controls, but not in lymphocytes. [Figure 13A]
[0152] FIG. 3 depicts an exemplary schematic for different VH and VL domain configurations for two exemplary anti-TROP2 CFP constructs with scFvs. [Figure 13B]
[0153] THP-1 cells electroporated with RNA encoding the indicated CFP constructs of different VH and VL domain configurations for two exemplary anti-TROP2 CFP constructs with scFv shown in Figure 13A. FIG. 3 depicts exemplary flow cytometry data showing the effect on expression of . [Figure 13C]
[0154] Exemplary graphs showing phagocytosis of SKOV3 cells by THP-1 cells expressing the indicated constructs on the X-axis, as quantified by the increase in pHrhodo Red signal, at the indicated effector:target cell (E:T) ratios. FIG. [Figure 13D]
[0155] FIG. 3 depicts exemplary flow cytometry data showing expression of the indicated anti-TROP2 CFP constructs with the indicated combinations of transmembrane and intracellular domains. Mock transfect set and anti-HER2 CFP construct transfect set are used as negative and positive controls, respectively. [Figure 13E]
[0156] Figure 3 depicts exemplary data showing expression of the indicated anti-HER2 CFP construct (right) and anti-TROP2 CFP construct (left) by the indicated combination of the transmembrane domain and the intracellular domain. be. [Figure 14A]
[0157] FIG. 2 depicts a schematic for an exemplary anti-GP75 (αGP75) CFP construct. An exemplary anti-GP75-FLAG-hCD8-Fcg-PI3K construct (first generation ATAK receptor) is shown above. Each of the other anti-GP75 CFP constructs depicted contains a sequence encoding the indicated domain, encoding GFP, separated from a sequence encoding the intracellular domain by a coding sequence encoding the T2A peptide. Also shown are the arrays. The schematic on the left shows the multimerization of the CD16 transmembrane domain or the CD89 transmembrane domain of the anti-GP75 CFP construct with endogenous Fcγ receptor protein and the multimerization of the anti-GP75 CFP construct to the GP75 antigen on tumor cells. Draw a bond. [Figure 14B]
[0158] were used to analyze the expression of the indicated CFP constructs in various types of mouse lung cells in vivo following injection into mice of LNPs containing RNA encoding the indicated CFP constructs; FIG. 3 depicts an exemplary flow cytometric gating strategy. [Figure 14C]
[0159] Immunoassay in mouse lung cells of the indicated types in vivo after single or double injection into mice of LNPs containing RNA encoding a CFP construct, and gating depicted in Figure 14B. FIG. 3 depicts a graph for CFP expression constructs as measured by the percentage of cells positive for GFP fluorescence or flag expression as determined by flow cytometry analysis according to the strategy. Expression is observed within myeloid cells of the lung, but not within lymphocytes or CD45- cells. [Figure 14D]
[0160] were used to analyze the expression of the indicated CFP constructs in various types of mouse hepatocytes in vivo following injection into mice of LNPs containing RNA encoding the indicated CFP constructs; FIG. 3 depicts an exemplary flow cytometric gating strategy. [Figure 14E]
[0161] Immunoassay in vivo in the indicated types of mouse hepatocytes after single or double injection into mice of LNPs containing RNA encoding the CFP construct and gating depicted in Figure 14D. FIG. 3 depicts a graph for CFP expression constructs as measured by the percentage of cells positive for GFP fluorescence or flag expression as determined by flow cytometry analysis according to the strategy. Expression was observed within liver bone marrow cells. [Figure 14F]
[0162] FIG. 3 depicts exemplary flow cytometry data showing expression of the indicated anti-GP75 CFP constructs in mouse monocytes contacted in vitro with LNPs containing mRNA encoding the CFP constructs. [Figure 15A]
[0163] FIG. 3 depicts an exemplary in vitro assay measuring phagocytosis of pHrhodoRed-labeled B16 cells by bone marrow cells expressing an anti-GP75 CFP construct. Bone marrow cells were contacted with LNPs containing mRNA encoding the CFP construct (eg, the bone marrow cells were electroporated with LNPs). The flow cytometry data depicted shows phagocytosis of pHrhodoRed labeled B16 cells by CD11b positive monocytes. [Figure 15B]
[0164] Figure 15A depicts exemplary data using monocytes expressing the indicated anti-GP75 CFP constructs after LNPs containing mRNA encoding the CFP constructs were electroporated using the assay described in Figure 15A. FIG. Graphs are shown for phagocytosis index and flow cytometry data. MYL157 construct = GP75-FLAG-mouse CD16 TMD-mouse CD16 ICD-T2A-GFP (also depicted as GP75-CD16a). MYL158 construct = GP75-FLAG-mouseCD89 TMD-mouseCD89 ICD-T2A-GFP (also depicted as GP75-CD89). [Figure 15C]
[0165] Figure 15A depicts exemplary data using monocytes expressing the indicated anti-GP75 CFP constructs after LNPs containing mRNA encoding the CFP constructs were electroporated using the assay described in Figure 15A. FIG. Constructs are displayed graphically in the top panel. Data depicting phagocytosis index based on flow cytometry analysis is shown in the graph. Constructs containing the CD8 hinge showed slightly better expression. [Figure 15D]
[0166] FIG. 15 depicts data on cytokine production by bone marrow cells electroporated with LNPs containing mRNA encoding the indicated anti-GP75 CFP constructs using the assay described in FIG. 15A. Graphs for the production of TNF alpha, CCL3, CCL4, and CCL7 from B16 cells alone or from monocytes contacted with LNPs containing mRNA encoding the indicated anti-GP75 CFP constructs and co-cultured with B16 cells. show. [Figure 16]
[0167] FIG. 3 depicts an exemplary schematic for the preparation of LNPs containing mRNA encoding various CFP constructs for in vivo delivery. [Figure 17A]
[0168] FIG. 3 depicts an exemplary LNP administration schedule for establishing and monitoring tumor growth in the B16 syngeneic mouse model. On day 0, tumor cells were injected and tumor establishment was allowed to occur for 10 days after injection in the mice. After tumor establishment, mice are injected multiple times with LNP formulations containing mRNA encoding the CFP construct and tumor size is monitored. [Figure 17B]
[0169] FIG. 3 depicts an exemplary schematic for the preparation of jet PEI-mediated transfection complexes containing mRNA encoding various CFP constructs and delivery of the complexes in vivo via injection. [Figure 18A]
[0170] Expression data for the indicated CFP constructs supporting positive expression of the indicated CFP constructs in lung, liver, and splenic bone marrow cells in vivo following tail vein injection of LNPs containing mRNA encoding the CFP constructs. FIG. No expression was observed in non-myeloid cell types of lung, liver, and spleen. [Figure 18B]
[0171] Immunoassay in mouse lung cells and mouse hepatocytes of the indicated types in vivo after single or double injection into mice of LNPs containing RNA encoding a CFP construct, and FIG. 14B or FIG. 14D Expression of an exemplary CFP construct (graphed above) as measured by the percentage of cells positive for GFP fluorescence or FLAG expression as determined by flow cytometry analysis following the gating strategy depicted in FIG. [Figure 18C]
[0172] FIG. 3 depicts offset histograms for GFP and FLAG showing distinct GFP expression within monocytes and neutrophils. [Figure 18D]
[0173] Immunoassay in mouse lung cells of the indicated types and mouse hepatocytes in vivo after injection of LNPs containing RNA encoding a CFP construct into mice, and the game depicted in FIG. 14B or FIG. 14D. FIG. 3 depicts flow cytometry data for CFP expression constructs, as measured by the percentage of cells positive for GFP fluorescence or FLAG expression, as determined by flow cytometry analysis following a testing strategy. [Figure 19]
[0174] FIG. 3 depicts histopathological analysis of tumors in B16 mice treated with LNPs containing RNA encoding an anti-GP75 construct. Two out of four mice showed a complete anti-tumor response and no tumors were detected. [Figure 20A]
[0175] FIG. 3 depicts data on cytokine production by cells derived from naïve mice or mouse tumor models treated with vehicle or bone marrow cells expressing anti-GP75-ATAK CFP constructs. Figure 3 shows a graph of CCL2 and IL-1 alpha production from mice. In treated mice, CCL7, which promotes tumor progression, is reduced, whereas IL-1 alpha, which is associated with tumor cell death, is increased. ATAK: Acronym for antigen targeting and killing. [Figure 20B]
[0176] FIG. 3 depicts data on cytokine production by cells derived from naïve mice or mouse tumor models treated with vehicle or bone marrow cells expressing anti-GP75 CFP constructs. Graphs are shown for the production of IL23, eotaxin, CXCL1, IL17a, G-CSF, and CXCL5 from mice, indicating increased activation of T cells and myeloid cells. [Figure 20C]
[0177] FIG. 3 shows that CAR-expressing monocytes recruit T cells upon stimulation. In in vitro assays, CD5-ATAK cells induce T cell chemotaxis. [Figure 21]
[0178] FIG. 3 depicts data on cytokine production by cells derived from naïve mice or mouse tumor models treated with vehicle or bone marrow cells expressing anti-GP75 CFP constructs. Flow cytometry data are shown for the production of IFN gamma, TNF alpha, and IL-2 from cells isolated from each mouse. Also shown are graphs for the percentage of CD4+ T cells resulting in IFN gamma, TNF alpha, and IL-2 production. [Figure 22]
[0179] FIG. 4 depicts a graph of tumor volume over time following treatment with LNPs containing mRNA encoding the indicated anti-GP75 CFP constructs at the indicated time points (indicated by arrows below the X-axis). . Nine days after treatment, five mice were selected from each group. Organs: tumor-bearing organs, lung, liver, and spleen were removed for flow cytometry analysis. RNA samples derived from tumor samples were saved for NanoString gene expression analysis. A T cell restimulation assay with Ova peptide was also performed. [Figure 23]
[0180] FIG. 3 shows that LNP treatment altered tumor infiltration of immune cells. For the percentage of the indicated cell type among all CD45+ immune cells in the tumor microenvironment of mice treated with the percentage of the indicated cell type among all CD45+ immune cells in the tumor microenvironment. A graph will be drawn. Treatment resulted in a clear increase in inflammatory monocytes within the tumor, as well as a slight increase in macrophages and T cells. [Figure 24]
[0181] FIG. 3 shows that LNP treatment resulted in a significant increase in CD8 cytotoxic T cells and a reduction in Treg cells. A graph is depicted for the percentage of the indicated cell type among all CD45+ immune cells for mice treated with the percentage of the indicated cell type among all CD45+ immune cells. Treatment increased the presence of CD8+ cytotoxic T cells while reducing immunosuppressive Tregs. [Figure 25]
[0182] FIG. 3 shows that LNP treatment resulted in a reduction in immune checkpoint expression by CD8 T cells. Graphs are depicted of the expression levels of the indicated immune checkpoint molecules by CD8+ T cells derived from the tumor microenvironment of mice treated with LNPs containing mRNA encoding the indicated anti-GP75 CFP constructs. Treatment resulted in a reduction in PD1 expression levels and a slight increase in LAG3 expression. [Figure 26]
[0183] FIG. 3 shows the conversion of the tumor microenvironment to an inflammatory phenotype upon in vivo administration of a nucleic acid encoding CFP in a LNP composition. [Figure 27]
[0184] FIG. 3 shows that LNP treatment resulted in reduced expression of Ki-67 and perforin in CD8+ T cells. A graph is depicted of the expression levels of the indicated molecules by CD8+ T cells derived from the tumor microenvironment of mice treated with LNPs containing mRNA encoding the indicated anti-GP75 CFP constructs. [Figure 28]
[0185] FIG. 3 shows flow cytometry data showing a CFP expression construct in THP-1 cells into which CFP-encoding mRNA was electroporated. [Figure 29]
[0186] FIG. 2 is a diagram showing the production of mouse anti-GP75 (Trp-1) CFP ATAK cells. Anti-GP75 CFP is efficiently expressed in mouse monocytes via electroporation of mRNA encoding anti-GP75 CFP, and cells expressing anti-GP75 CFP have phagocytic activity. [Figure 30]
[0187] FIG. 3 shows data supporting that anti-GP75 ATAK monocytes suppress tumors in a syngeneic B16 mouse model. Data shows graphs of tumor volume over time following treatment with mouse monocytes expressing anti-GP75 CFP in a mouse tumor model that is refractory to CAR T and checkpoint inhibitors. Mice received 8 injections of 2 x 106 ATAK cells versus vehicle (1 daily x 4 day injection, 3 days off, 1 daily x 4 day injection; ± SD (Mann-Whitney test)). [Figure 31]
[0188] Following injection into a mouse tumor model, mouse monocytes expressing anti-GP75 CFP infiltrate into the tumor, maintain CFP expression, and differentiate into effector cells such as inflammatory cells, dendritic cells, and macrophages. It is a figure which shows the graph which supports this. The left graph shows that approximately 40% of mouse monocytes expressing anti-GP75 CFP maintained expression of CFP over 5 days after injection. The upper right graph shows that ATAK cells (cells expressing CFP) infiltrate the tumor and spleen and become dendritic cells. The lower right graph shows ATAK cells infiltrating the tumor and spleen and becoming macrophage cells. [Figure 32]
[0189] FIG. 3 depicts data on cytokine production by cells derived from naïve mice or mouse tumor models treated with vehicle or bone marrow cells expressing anti-GP75 CFP constructs. Graphs are shown for the production of the indicated cytokines / chemokines. Response to treatment correlated with cytokine profile in anti-tumor serum. Analysis includes responder animals within treatment groups at the end of the study. [Figure 33]
[0190] FIG. 3 depicts data showing cross-presentation of tumor antigens by mouse monocytes expressing anti-GP75 CFP. Mouse monocytes expressing anti-GP75 CFP phagocytosed and processed a surrogate tumor neoantigen, in this case derived from the OVA protein, and cognate against a class I restriction peptide (SIINFEKL) derived from OVA. derived from the same mouse, ATAK Monocytes, which do not express the receptor, are not capable of this. This demonstrates that mouse monocytes expressing anti-GP75 CFP are able to process and cross-present antigens to acquired immune cells such as CD8 T cells. ATAK-GP75 (also known as TRP-1 ATAK) construct. [Figure 34]
[0191] FIG. 2 depicts data showing that human monocytes expressing CFP harness innate immunity and stimulate anti-tumor acquired immune responses. Data confirm that human monocytes expressing CFP infiltrate, accumulate within, and recognize tumors (top left). Data confirm that human monocytes expressing CFP result in myeloid cell activation, cytokine production, chemokine production, and inflammatory polarization (top right graph). Data confirm that human monocytes expressing CFP directly kill tumor cells through phagocytosis (bottom left), cytokines, and death receptor (CD95L). Data confirm that human monocytes expressing CFP exert long-term tumor control through antigen presentation, epitope spreading, and T-cell engagement (lower right graph), thereby allowing full activation of the immune repertoire. It is supported by ensuring that the [Figure 35]
[0192] Figure 2 depicts data showing that human monocytes expressing anti-CD5 CFP exhibit potent activity in suppressive tumor microenvironment (TME) conditions in vitro. Human monocytes expressing anti-CD5 CFP were incubated overnight in the absence or presence of cognate antigen in medium containing IL10, IL4, and TGF-b. The phagocytic activity of the cells is shown in the top left graph. The indicated cytokines / chemokines were measured in culture supernatants. [Figure 36]
[0193] Figure 2 depicts data showing that human monocytes expressing anti-CD5 CFP inhibit proliferation and prolong survival in a CD5+ CTCL xenograft model despite having no adaptive immune system. . [Figure 37]
[0194] Injection of LNPs containing RNA encoding the anti-GP75 CFP construct together with the CD89 (FcR alpha) chain into mice selectively programs bone marrow cells in vivo, resulting in potent antitumor activity. FIG. 2 is a diagram depicting data showing that A 75% reduction in tumor burden (measured in volume: mm3) in an established cold tumor model was observed. [Figure 38]
[0195] Figure 2 depicts data showing that injection of LNPs containing RNA encoding an anti-GP75 CFP construct together with the CD89 (FcR alpha) chain into mice results in expression of CFP by inflammatory monocytes within the TME. FIG. Of the intratumoral bone marrow cells, >15% were observed to express anti-GP75 CFP. [Figure 39]
[0196] We present data showing that injection of LNPs containing RNA encoding an anti-GP75 CFP construct together with the CD89 (FcR alpha) chain into mice results in modifications of the TME, characterized by the accumulation of inflammatory cells. FIG. Treatment induces inflammatory monocytes (left) and dendritic cells (right) within tumors in vivo, as measured postmortem of treated animals. Treatment expanded immune cells associated with bridging innate and acquired immunity. [Figure 40]
[0197] We show that injection of LNPs containing RNA encoding an anti-GP75 CFP construct together with the CD89 (FcR alpha) chain into mice results in a modification of the TME, characterized by an increase in CTLs and a decrease in Tregs. FIG. 2 is a diagram depicting data shown in FIG. Treatment promoted anti-tumor CD8 T cells and reduced tumor-associated Tregs. [Figure 41]
[0198] The anti-GP75 CFP construct was injected into mice with LNPs containing RNA encoding the CD89 (FcR alpha) chain, and 24 hours after these two injections, and 72 hours after these four injections. FIG. 3 depicts data on the production of the indicated pro-inflammatory serum cytokines over time. [Figure 42]
[0199] The anti-GP75 CFP construct was injected into mice with LNPs containing RNA encoding the CD89 (FcR alpha) chain, and 24 hours after these two injections, and 72 hours after these four injections. FIG. 3 depicts data on the production of the indicated serum chemokines over time. [Figure 43]
[0200] FIG. 3 depicts the experimental design and tumor growth. On day 0, tumors were inoculated and allowed to grow to 75 mm3. LNP-mRNA was administered at 2 mg / kg. [Figure 44]
[0201] FIG. 3 depicts exploration of T cell subsets and phenotypes within tumors. [Figure 45]
[0202] FIG. 3 depicts data that mRNA-LNP treatment induces changes in T cell subset frequency within tumors. Treatment caused a reduction in Treg% within the tumor. [Figure 46A]
[0203] Figure 2 depicts a graph showing flow cytometry analysis of CD8 exhaustion marker (PD1) and CD8 maturation / effector T cell marker (CD44) by % CD8+ T cells in mice injected with GP75-CD89-LNP. be. [Figure 46B]
[0204] FIG. 2 depicts flow cytometry data for the expression of PD1 and CD44 in T cells. [Figure 47A]
[0205] FIG. 3 depicts a graph showing flow cytometry analysis of CD8 exhaustion markers (TIM3 and TOX) by % CD8+ T cells in mice injected with GP75-CD89-LNP. [Figure 47B]
[0206] FIG. 3 depicts flow cytometry data for TIM3 and TOX expression in T cells. [Figure 48A]
[0207] Figure depicting a graph showing flow cytometry analysis of Ki67, a cell proliferation marker, and granzyme B, an activation marker of T cells, by % CD8+ T cells in mice injected with GP75-CD89-LNPs. It is. [Figure 48B]
[0208] FIG. 2 depicts flow cytometry data for Ki67 and granzyme B in CD8T cells from mice injected with GP75-CD89-LNP. [Figure 49]
[0209] Figure 2 shows data for cell lineage searches; panels for markers and fluorophores are indicated on the left. [Figure 50]
[0210] FIG. 3 depicts data indicating that mRNA / LNP treatment did not induce a significant shift in immune cell populations. [Figure 51]
[0211] FIG. 3 shows data on receptor expression. [Figure 52]
[0212] FIG. 3 shows a dot plot showing the expression of FLAG (ie, receptor) within (ie, receptor). [Figure 53]
[0213] FIG. 3 shows a dot plot showing FLAG expression in Ly6Chi inflammatory monocytes. [Figure 54]
[0214] FIG. 3 shows a dot plot showing FLAG expression within Ly6Clo resident bone marrow cells. [Figure 55]
[0215] Figure 2 depicts data indicating that treatment in mice significantly increased CD40 and CD206 levels within Ly6Chi and CCR2hi inflammatory monocytes. [Figure 56]
[0216] FIG. 3 depicts the levels of PDL1, CD40, CD86, and CD206 in Ly6Clo and CCR2lo resident bone marrow cells. Data indicate that treatment in mice significantly increased CD40 and CD206 levels. [Figure 57]
[0217] Figure 2 shows levels of PDL1, CD40, CD86, and CD206; results indicate that treatment slightly reduced PDL1 levels within tumor resident macrophages. [Figure 58]
[0218] Treatment significantly increased DC activation markers including MHCII, CD86, and CD40, but also increased PD-L1 levels in splenic dendritic cells of CD103+ CD11b- phenotype. FIG. [Figure 59]
[0219] Treatment significantly increased DC activation markers including MHCII, CD86, and CD40, but also increased PD-L1 levels in splenic dendritic cells with a CD103-CD11b+ phenotype. FIG. [Figure 60]
[0220] encodes a chimeric receptor protein comprising a protease-cleavable, inducible, gene transcription activating protein in bone marrow cells that is specifically activated when the bone marrow cells are contacted with cancer cells; Graphical representation of an exemplary expression vector design for expressing a first vector; and a second vector that expresses a target gene induced by a gene transcription activator encoded by the first vector. FIG. [Figure 61A]
[0221] 61 shows a graphical representation of an exemplary chimeric protein produced by expression of the vector of FIG. 60. FIG. Figure 61A also shows that when PTB does not bind to the phosphotyrosine residues of the ITAM motif in the intracellular domain of the chimeric receptor, the degron complex fused to PTB is triggered by the degron complex fused to PTB-HIF-degron. It is also concretely proven that the protease used is easily degraded. [Figure 61B]
[0222] FIG. 61A illustrates that the predicted mode of action for the chimeric protein of FIG. 61A results in target gene expression. Upon binding of HIF-degron protease to the phosphorylated ITAM motif of the receptor, the protease is activated and cleaves the transcriptional activator GAL-VP64. [Figure 62A]
[0223] FIG. 2 shows a graphical illustration of a nucleic acid construct encoding an inducible cytotoxic protein. The construct was designed for expression and secretion by bone marrow (eg, macrophages) cells. The construct contains the acidic and cytotoxic domains of human eosinophil major basic protein. The two domains are interspersed with sequences encoding MMP-recognizing peptides; MMP-recognizing peptides are cleavable by MMPs, which are abundant within the tumor microenvironment. In the absence of MMPs, secreted cytotoxic proteins are maintained in an inactive form by association with acidic domains and held together by MMP recognition peptides. [Figure 62B]
[0224] FIG. 3 shows a graphical representation of the activation of cytotoxic domain proteins by MMPs, upon cleavage of the MMP recognition sequence, within the tumor microenvironment, resulting in lysis of tumor cells. [Form for carrying out the invention]
[0131]
[0225] All terms are intended to be understood as they are understood by one of ordinary skill in the art. Unless defined otherwise, technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure pertains.
[0132]
[0226] The section headings used herein are for organizational purposes only and shall not be construed as limiting the subject matter described.
[0133]
[0227] Although various features of the disclosure may be described in the context of a single embodiment, the features can also be provided individually or in any suitable combination. Conversely, although the disclosure may be described herein for clarity in the context of separate embodiments, the disclosure can also be practiced in a single embodiment.
[0134]
[0228] References herein to "some embodiments," "an embodiment," "an embodiment," or "other embodiments" refer to features, structures, or structures described in the context of the embodiments. , or feature is included in at least some, but not necessarily all, embodiments of the present disclosure.
[0135]
[0229] As used herein and in the claims, "comprising" (as well as "comprise", "comprises" and "comprised") any form of ``comprising,'' such as ''), ``including'' (and any form of ``including'', such as ``include'' and ``includes'') ), or "containing" (and any form of "containing", such as "contain" and "contains") or open-ended and does not exclude further, unlisted elements or method steps. It is envisioned that any embodiment discussed herein may be implemented with respect to any method or composition of the present disclosure, and vice versa. Additionally, the compositions of the present disclosure can be used to accomplish the methods of the present disclosure. The method of the invention can be achieved.
[0136]
[0230] As used herein, the term "about" or "approximately" when referring to a measurable value such as a parameter, amount, duration over time, etc. ±30% or less, ±20% or less, ±10% or less, ±5% or less, or ±1% or less of the specified value, as appropriate; and are intended to subsume these variations from the specified values. It is to be understood that values referred to by the modifiers "about" or "approximately" may also be specifically disclosed.
[0137]
[0231] "Agent" may refer to any cell, small molecule, antibody, or fragment thereof, nucleic acid molecule, or polypeptide.
[0138]
[0232] "Modification" or "change" may refer to increase or decrease. For example, changes may be 1%, 2%, 3%, 4%, 5%, 10%, 20%, 30%, or 40%, 50%, 60%, or 70%, 75%, 80%, It can be an increase or decrease of up to 90% or even 100%. For example, the changes may be 1x, 2x, 3x, 4x, 5x, 10x, 20x, 30x, or 40x, 50x, 60x, or 70x, 75x, 80x, It can be an increase or decrease of up to 90-fold or even 100-fold.
[0139]
[0233] As used herein, "antigen-presenting cells" or "APCs" refer to professional antigen-presenting cells (e.g., B lymphocytes, macrophages, monocytes, dendritic cells, Langerhans cells) as well as other antigen-presenting cells. (eg, keratinocytes, endothelial cells, astrocytes, fibroblasts, oligodendrocytes, thymic epithelial cells, thyroid epithelial cells, neuroglial cells (brain), pancreatic beta cells, and vascular endothelial cells). APCs are capable of expressing major histocompatibility complex (MHC) molecules on their surface that can be recognized by T cells and trigger T cell activation and immune responses. can present antigen complexed with. Professional antigen-presenting cells, especially dendritic cells, play a key role in stimulating naive T cells. Non-professional antigen presenting cells such as fibroblasts may also contribute to this process. APCs can also cross-present peptide antigens by processing exogenous antigens and presenting the processed antigens on class IMHC molecules. Antigens that result in proteins recognized upon association with class I MHC molecules are generally proteins produced intracellularly, and these antigens are processed and associated with class I MHC molecules.
[0140]
[0234] "Biological sample" may refer to any tissue, cell, body fluid, or other material derived from an organism.
[0141]
[0235] The term "epitope" refers to any protein determinant, such as a sequence or structure or amino acid residue, that is capable of binding to an antibody or binding fragment thereof, a T-cell receptor, and / or an antibody-like molecule. There are cases. Epitopic determinants typically consist of chemically active surface groupings of molecules such as amino acids or sugar side chains and generally have specific three-dimensional structural characteristics, as well as specific charge characteristics. "T cell epitope" may refer to a peptide or peptide-MHC complex that is recognized by a T cell receptor.
[0142]
[0236] An engineered cell, such as an engineered bone marrow cell, may refer to a cell that has at least one exogenous nucleic acid sequence within the cell, even when transiently expressed. Expression of exogenous nucleic acids may be performed by a variety of methods, including those known in the art, as described elsewhere. The present disclosure relates to the preparation and use of engineered cells, eg, engineered bone marrow cells, such as engineered phagocytes. The present disclosure relates, among other things, to engineered cells containing exogenous nucleic acids encoding, for example, chimeric fusion proteins (CFPs).
[0143]
[0237] The term "immune response" includes, but is not limited to, a T cell-mediated immune response, a NK cell-mediated immune response, and / or a B cell-mediated immune response. These responses may be influenced by modulation of T cell costimulation and NK cell costimulation. Exemplary immune responses include T cell responses, such as cytokine production and cell-mediated cytotoxicity. In addition, the immune response is influenced indirectly by NK cell activation, B cell activation, and / or T cell activation, such as antibody production (humoral response), and cytokine production. Including activation of responsive cells such as macrophages. Immune responses include acquired immune responses. The adaptive immune system can respond to foreign molecular structures, such as antigens of invading organisms. Unlike the innate immune system, the acquired immune system is highly specific for pathogens. Acquired immunity can also provide long-lasting protection. Acquired immune responses include humoral and cell-mediated immune responses. In a humoral immune response, antibodies secreted into body fluids by B cells bind to pathogen-derived antigens and result in the elimination of the pathogen through various mechanisms, such as complement-mediated lysis. A cell-mediated immune response activates T cells that can destroy other cells. For example, if proteins associated with a disease are present within a cell, they are fragmented intracellularly into peptides by proteolysis. Specific cellular proteins then conjugate to the antigens or peptides thus formed and transport them to the surface of the cell, where the antigens or peptides are exposed to molecular defense mechanisms such as T cells. Presented by Cytotoxic T cells can recognize these antigens and kill cells bearing these antigens.
[0144]
[0238] "Ligand" may refer to a molecule that is capable of binding to or forming a complex with another molecule, such as a receptor. Ligands can include, but are not limited to, proteins, glycoproteins, carbohydrates, lipoproteins, hormones, fatty acids, phospholipids, or any component that binds to a receptor. In some embodiments, the receptor has a specific ligand. In some embodiments, a receptor may bind broadly to a ligand, in which case the receptor has at least one characteristic in its structural organization, charge distribution, or any other physicochemical characteristic. May bind to several ligands that share similarities. A ligand can be a biomolecule. The ligand can be a non-biological material. For example, the ligand can be a ligand for a negatively charged particle, which is the scavenger receptor MARCO. For example, the ligand is the scavenger receptor SRA1, TiO 2 can be a ligand for
[0145]
[0239] The term "major histocompatibility complex (MHC)," "MHC molecule," or "MHC protein" refers to a protein capable of binding to and presenting antigenic peptides to T lymphocytes. refers to Such antigenic peptides may represent T cell epitopes. Human MHC may also be referred to as the HLA complex. Therefore, the terms "human leukocyte antigen (HLA)," "HLA molecule," or "HLA protein" are interchangeable with the terms "major histocompatibility complex (MHC)," "MHC molecule," and "MHC protein." , used interchangeably. HLA proteins are sometimes classified as HLA class I and sometimes as HLA class II. Although the two HLA classes of proteins are structurally very similar; they have quite different functions. Class I HLA proteins are present on the surface of nearly every cell in the body, including most tumor cells. Class I HLA proteins are typically loaded with endogenous proteins or pathogen-derived antigens present within the cell and then presented to naive or cytotoxic T-lymphocytes (CTLs). HLA class II proteins are present on antigen presenting cells (APCs), including but not limited to dendritic cells, B cells, and macrophages. HLA class II proteins primarily present processed peptides from external, eg, antigen sources external to the cell, to helper T cells.
[0146]
[0240] In the HLA class II system, phagocytic cells, such as macrophages and immature dendritic cells, phagocytose entities by phagocytosis, lysosomes whose acidic enzymes cleave the engulfed proteins into many different peptides (but not the lysosomes). , B cells exhibit more general endocytosis into endosomes). Autophagy is another source of HLA class II peptides. The most studied subclass II HLA genes are HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQB1, HLA-DRA, and HLA-DRB1.
[0147]
[0241] Presentation of peptides by HLA class II molecules to CD4+ helper T cells results in an immune response against foreign antigens. Once activated, CD4+ T cells can promote B cell differentiation and antibody production as well as CD8+ T cell (CTL) responses. CD4+ T cells can also secrete cytokines and chemokines that activate and induce the differentiation of other immune cells. HLA class II molecules are typically heterodimers with alpha and beta chains that interact to form a peptide-binding groove that is more open than the class I peptide-binding groove.
[0148]
[0242] HLA alleles are typically expressed in a codominant manner. For example, each person carries two alleles of each of the three class I genes (HLA-A, HLA-B, and HLA-C) and thus expresses six different types of class II HLA. I can do it. At class II HLA loci, each person has one gene, HLA-DP (DPA1 and DPB1, encoding alpha and beta chains), HLA-DQ (DQA1 and DQB1, for alpha and beta chains), One inherits a pair of genes, HLA-DRα (DRA1), and one or more genes, HLA-DRβ (DRB1 and DRB3, DRB4, or DRB5). HLA-DRB1, for example, has over about 400 known alleles. This means that one heterozygous individual can inherit six or eight functional class II HLA alleles: three or more alleles from each parent. Therefore, HLA genes are highly polymorphic; many different alleles are present in different individuals within a population. The genes encoding HLA proteins have many possible variations, allowing each person's immune system to respond to a wide range of foreign invaders. For some HLA genes, hundreds of versions (alleles) have been identified, each of which is given a specific number. In some embodiments, the class I HLA alleles are HLA-A*02:01, HLA-B*14:02, HLA-A*23:01, HLA-E*01:01 (non-classical) It is. In some embodiments, the class II HLA alleles include HLA-DRB*01:01, HLA-DRB*01:02, HLA-DRB*11:01, HLA-DRB*15:01, and HLA-DRB *07:01.
[0149]
[0243] "Myeloid cells" broadly refer to cells of the myeloid lineage among hematopoietic cell lineages, and may exclude, for example, lymphoid lineages. Bone marrow cells include, for example, cells of the granulocytic and monocytic lineage. Bone marrow cells are differentiated from a common progenitor cell derived from hematopoietic stem cells in the bone marrow. Myeloid cell lineage commitment may be governed by activation of distinct transcription factors, and thus myeloid cells have the ability to further differentiate into terminal cell types based on extracellular and intracellular stimuli. Cells can be characterized as having a level of plasticity that can be described as . Bone marrow cells can be rapidly recruited to local tissues via a variety of chemokine receptors on their surface. Bone marrow cells are responsive to a variety of cytokines and chemokines.
[0150]
[0244] Bone marrow cells are cells derived from hematopoietic stem cells, e.g., within the bone marrow and under the influence of one or more cytokines and chemokines, such as G-CSF, GM-CSF, Flt3L, CCL2, VEGF, and S100A8 / 9. sell. In some embodiments, the bone marrow cells are progenitor cells. In some embodiments, the bone marrow cell can be a common myeloid progenitor, or a cell that has characteristics of a granulocyte progenitor, a myeloblast, or a monocyte-dendritic cell progenitor, or a combination thereof. Bone marrow may contain granulocytes or monocytes, or their precursor cells. Bone marrow may contain immature granulocytes, immature monocytes, immature macrophages, immature neutrophils, and immature dendritic cells. Bone marrow may contain monocytes or promonocytic cells or monocyte precursors. In some cases, bone marrow cells as used herein may refer to monocytes having an M0, M1, or M2 phenotype. Bone marrow can contain dendritic cells (DCs), mature DCs, monocyte-derived DCs, plasmacytoid DCs, pre-dendritic cells, or DC precursors. Bone marrow can contain neutrophils, which can be mature neutrophils, neutrophil precursors, or polymorphonuclear cells (PMNs). Bone marrow can contain macrophages, monocyte-derived macrophages, tissue macrophages, M0, M1, or M2 phenotype macrophages. Bone marrow may contain tumor-infiltrating monocytes (TIMs). Bone marrow may contain tumor-associated monocytes (TAMs). Bone marrow can contain myeloid-derived suppressor cells (MDSCs). Bone marrow may contain tissue-resident macrophages. Bone marrow can contain tumor-associated DCs (TADCs). Therefore, bone marrow cells have one or more cell surface markers, e.g. , CD1c, CD83, CD141, CD209, CD205, P-selectin, integrin, ICAMS, VCAMS, MHC-II, CD123, CD303, CD304, SIGLEC family proteins, and CLEC family proteins. In some cases, bone marrow cells are labeled with cell surface markers such as CD11b, CD14, CD15, CD16, CD66, Lox-1, CD11c, CD64, CD68, CD163, CCR2, CCR5, HLA-DR, CD1c, CD83, CD141, CD209 , MHC-II, CD123, CD303, CD304, or a combination thereof.
[0151]
[0245] "Phagocytosis" is sometimes used interchangeably with "pinocytosis" and refers to the process by which cells engulf particles, such as cancer cells or infected cells. This process can result in an internal compartment (phagosome) containing particles. This process can be used to take up particles such as cancer cells or infected cells and / or remove them from the body. Phagocytic receptors may be involved in the phagocytic process. The phagocytic process can be closely linked to immune response and antigen presentation. Processing of exogenous antigens follows their uptake into professional antigen presenting cells by some type of endocytic event. Phagocytosis may also facilitate antigen presentation. For example, antigens derived from phagocytosed cells or pathogens, including cancer antigens, can be processed and presented on the cell surface of APCs.
[0152]
[0246] "Polypeptide" may refer to molecules containing amino acids linked together via peptide bonds, such as glycoproteins, lipoproteins, cellular proteins, or membrane proteins. A polypeptide can include one or more subunits of a protein. Polypeptides can be encoded by recombinant nucleic acids. In some embodiments, a polypeptide can include more than one peptide sequence within a single amino acid chain, which can be separated by spacers, linkers, or peptide cleavage sequences. A polypeptide can be a fusion polypeptide. A polypeptide may contain one or more domains, modules, or portions.
[0153]
[0247] "Receptor" may refer to a chemical structure comprised of a signal-transmitting polypeptide, such as a polypeptide that transmits extracellular signals into a cell. Receptors are used to convey information within a cell, the formation of a cell or an organism. A receptor comprises at least one receptor unit, and may contain two or more receptor units, where each receptor unit comprises a protein molecule, such as a glycoprotein molecule. A receptor may contain a structure capable of binding and forming a complex with a ligand. Signaling information may be conveyed by conformational changes in receptors following binding to ligands on the surface of cells.
[0154]
[0248] The term "antibody" refers to the class of proteins commonly known as immunoglobulins, including IgG (including IgG1, IgG2, IgG3, and IgG4), IgA (including IgA1 and IgA2), IgD, IgE, IgM , and refers to a class of proteins including, but not limited to, IgY. The term "antibody" includes, but is not limited to, full-length antibodies, single chain antibodies, single domain antibodies (sdAbs), and antigen-binding fragments thereof. Antigen-binding antibody fragments include Fab, Fab', and F(ab')2, Fd(V H and C H 1), single chain variable fragments (scFv), single chain antibodies, disulfide-linked variable fragments (dsFv), and V L domain and / or V HIncluding, but not limited to, fragments containing domains. Antibodies can be derived from any animal. Antigen-binding antibody fragments, including single chain antibodies, may include variable region(s) alone or in combination with one or more of the following: hinge region, CH1 domain, CH2 domain, and CH3 domain. It may also include variable region(s). Also included are any combinations of variable region(s) and hinge region, CH1, CH2, and CH3 domains. Antibodies can be, for example, monoclonal, polyclonal, chimeric, humanized, and human monoclonal and polyclonal antibodies that specifically bind to HLA-related polypeptides or HLA-peptide complexes. As used herein, "binding agent" refers to a polypeptide that includes a binding domain capable of binding a target, where the target for the binding agent is a protein, e.g., a cancer antigen, a glycoprotein, etc. It can be. A binding agent is often used to refer to a CFP, eg, a CAR, and is named by the target it binds (eg, a CD5 binding agent that includes a binding domain for the CD5 antigen). In some cases, the same binding agent is alternatively or interchangeably referred to (anti-CD5 binding agent or anti-TROP2 binding agent). As commonly used, the term binding agent refers to any molecule that has a binding domain. Optionally, depending on the context described, the binding agent may be BiME or TRiME.
[0155]
[0249] The term "recombinant nucleic acid" refers to a nucleic acid that is prepared, expressed, created, or isolated by recombinant means. Recombinant nucleic acids may contain nucleotide sequences that are not naturally occurring. Recombinant nucleic acids can be synthesized in the laboratory. Recombinant nucleic acids can be prepared by using recombinant DNA techniques, such as enzymatic modification of DNA, such as enzymatic restriction digestion, ligation, and DNA cloning. Recombinant nucleic acids can be DNA, RNA, analogs thereof, or combinations thereof. Recombinant DNA may be transcribed ex vivo or in vitro, such as to create messenger RNA (mRNA). Recombinant mRNA can be isolated, purified, and used to transfect cells. Recombinant nucleic acids may encode proteins or polypeptides.
[0156]
[0250] The process of introducing or integrating nucleic acids into cells can be through transformation, transfection, or transduction. Transformation is the process of uptake of foreign nucleic acids by bacterial cells. This process is adapted for plasmid DNA propagation, protein production, and other applications. Transformation introduces recombinant plasmid DNA into competent bacterial cells that take up extracellular DNA from the environment. Some bacterial species are naturally competent under certain environmental conditions, but competence is induced artificially in laboratory situations. Transfection is the introduction of small molecules such as DNA, RNA, or antibodies into eukaryotic cells. Transfection may also refer to the introduction of bacteriophage into bacterial cells. "Transduction" is often used to describe the introduction of recombinant viral vector particles into target cells, whereas "infection" refers to the introduction of wild-type virus into humans or animals. Refers to natural infection.
[0157]
[0251] The term "vector" may refer to a nucleic acid molecule capable of autonomous replication within a host cell, allowing cloning of the nucleic acid molecule. As known to those skilled in the art, vectors include, but are not limited to, plasmids, cosmids, phagemids, viral vectors, phage vectors, yeast vectors, mammalian vectors, and the like. For example, a vector for transforming an exogenous gene can be a plasmid. In certain embodiments, vectors include a nucleic acid sequence that contains an origin of replication and other elements necessary for the replication and / or maintenance of the nucleic acid sequence within a host cell. In some embodiments, a vector or plasmid provided herein is an expression vector. Expression vectors are capable of directing the expression of genes and / or nucleic acid sequences to which they are operably linked. In some embodiments, the expression vector or plasmid is in the form of a circular double-stranded DNA molecule. A vector or plasmid may or may not be integrated into the host cell's genome. In some embodiments, the nucleic acid sequence of the plasmid is not integrated into the genome or chromosome of the host cell after introduction. For example, a plasmid may contain elements for transient or stable expression of a nucleic acid sequence, such as a gene or open reading frame carried by the plasmid, in a host cell. In some embodiments, the vector is a transient expression vector. In some embodiments, the vector is a stable expression vector that replicates autonomously within the host cell. In some embodiments, the plasmid's nucleic acid sequence is integrated into the host cell's genome or chromosome upon introduction into the host cell. Expression vectors that can be used in the methods disclosed herein include, but are not limited to, plasmids, episomes, bacterial artificial chromosomes, yeast artificial chromosomes, bacteriophages, or viral vectors. The vector may be a DNA vector or an RNA vector. In some embodiments, the vectors provided herein are RNA vectors that, upon introduction into the host cell, are capable of integration into the genome of the host cell (e.g., via reverse transcription), e.g. It is a retroviral vector or lentiviral vector. Other forms of expression vectors known by those skilled in the art that serve equivalent functions, such as autonomously replicating extrachromosomal vectors or vectors capable of integration into the host genome, may also be used. Exemplary vectors are those capable of autonomous replication and / or expression of nucleic acids to which they are linked.
[0158]
[0252] The term "spacer" or "linker" used in reference to a fusion protein refers to a peptide sequence that connects two other peptide sequences of the fusion protein. In some embodiments, the linker or spacer connects protein or RNA sequences or is used for purposes other than preserving some minimal distance or other spatial relationship between protein or RNA sequences. Has no activity. In some embodiments, the amino acids that are components of the spacer may be selected to affect some molecular property, such as the folding, flexibility, net charge, or hydrophobicity of the molecule. Linkers suitable for use in embodiments of the present disclosure are well known to those skilled in the art and include, but are not limited to, carbon linkers that are linear or branched, heterocyclic carbon linkers, or peptide linkers. In some embodiments, the linker separates two or more polypeptides, e.g., two antigenic peptides, by a distance sufficient to ensure proper folding of each antigenic peptide. used for. Exemplary peptide linker sequences adopt a flexible, extended conformation and exhibit no tendency toward the development of ordered secondary structures. The amino acids within the flexible linker protein region can include Gly, Asn, and Ser, or any permutation of amino acid sequences containing Gly, Asn, and Ser. Other near-neutral amino acids, such as Thr and Ala, may also be used within the linker sequence.
[0159]
[0253] Terms such as "treat", "treated", "treating", "treatment" and the like refer to the disorder and / or the symptoms associated therewith (e.g., neoplasms or tumors, or infectious agents). or autoimmune disease). "Treatment" may refer to the administration of a treatment to a subject after the onset or suspected onset of a disease (e.g., cancer, or infection with an infectious agent, or an autoimmune disease). be. "Treatment" may refer to reducing the frequency or severity of the occurrence or recurrence of any symptoms or effects of other diseases associated with the disease, and / or side effects associated with treatment. , the concept of "mitigating" and the term "treating" also encompasses. reducing the severity of a disease or disorder in a patient, e.g. increasing the lifespan or survival of a patient with the disease, or delaying its recurrence, e.g. Includes the concept of ``managing,'' which refers to prolonging the duration of remission in a patient. It is appreciated that treatment of a disorder or condition does not require, but does not exclude, that the disorder, condition, or symptoms associated therewith are completely eliminated. As used herein, the terms "preventing," "preventing," "prevention," and their grammatical equivalents, refer to such terms at the time administration of the drug or compound begins. It may refer to avoiding or delaying the onset of symptoms associated with a disease or condition in a subject who has not yet developed the symptoms. In certain embodiments, the treatment of a subject or patient described herein is a therapeutic composition, such as a drug, metabolite, preventative moiety, nucleic acid, peptide, or protein, comprising: administration of therapeutic compositions encoding or otherwise forming therapeutic agents or preventative components. In some embodiments, the treatment includes administering the cell or population of cells to a subject in need thereof. In some embodiments, the treatment is applied to the subject, such as one or more of the engineered cells described herein, e.g., bone marrow cells, such as one or more engineered phagocytes. the step of administering. Treatment includes treatment of a disease, condition, or syndrome, which may be a pathological disease, condition, or syndrome, or a subclinical disease, condition, or syndrome. Optionally, treatment as used herein may include administering a therapeutic vaccine. In some embodiments, engineered phagocytes are administered to a patient or subject. In some embodiments, cells administered to human subjects result in reduced immunogenicity. For example, engineered phagocytes may result in no or reduced graft-versus-host disease (GVHD) or fratricide effects. In some embodiments, the engineered cells administered to a human subject are immunocompetent (i.e., have a match to the HLA subtype naturally expressed in the subject) for the subject. . A subject-specific HLA allele, or a subject's HLA genotype, can be determined by any method known in the art. In an exemplary embodiment, the method includes the step of determining a genetic polymorphism of reads extracted from sequencing a dataset relative to a genetic reference set that includes allelic variants having the genetic polymorphism. generating an alignment; determining a first posterior probability or a score derived from the posterior probability for each allelic variant in the alignment; determining a first posterior probability or a score derived from the posterior probability for each allelic variant; identifying an allelic variant that is a first allelic variant, one or more allelic variants aligned by the first allelic variant and one or more other allelic variants; identifying duplicate reads; determining a second posterior probability or a score derived from the posterior probability for the one or more other allelic variants using a weighting factor; When the genetic variant and the second allelic variant define the genotype of the genetic polymorphism, selecting the allelic variant with the largest second posterior probability or the score derived from the posterior probability. identifying a second allelic variant, and providing output for the first allelic variant and the second allelic variant.
[0160]
[0254] "Fragment" may refer to a portion of a protein or nucleic acid. In some embodiments, the fragment retains at least 50%, 75%, or 80%, or 90%, 95%, or even 99% of the biological activity of the reference protein or reference nucleic acid.
[0161]
[0255] The terms "isolated," "purified," "biologically pure," and their grammatical equivalents refer to the constituents normally associated therewith, as found in their natural state. refers to materials that are free of to varying degrees. "Isolate" refers to the degree of isolation from the original source or environment. "Purify ~" refers to a degree of isolation that is higher than isolation. A protein that is "purified" or "biologically pure" is one in which impurities do not materially affect the biological properties of the protein or cause other deleterious consequences. , sufficiently free of other materials. That is, the nucleic acids or peptides of the present disclosure are substantially free of cellular material, viral material, or culture media when produced by recombinant DNA methods, or chemically synthesized when produced by recombinant DNA methods. Purified material is purified when it is substantially free of chemical precursors or other chemicals. Purity and homogeneity are typically determined using analytical chemistry methods, such as polyacrylamide gel electrophoresis or high performance liquid chromatography. The term "purified" may indicate that a nucleic acid or protein yields essentially one band within an electrophoretic gel. For proteins that can be subjected to modifications, such as phosphorylation or glycosylation, different modifications can result in different isolated proteins that can be purified separately.
[0162]
[0256] The term "neoplasm" or "cancer" refers to any disease caused by or resulting from inappropriately high levels of cell division, inappropriately low levels of apoptosis, or both. refers to Glioblastoma is one non-limiting example of a neoplasm or cancer. The term "cancer" or "tumor" or "hyperproliferative disorder" refers to a disorder characterized by uncontrolled growth, immortality, metastatic potential, rapid growth, and growth rate, as well as certain characteristic morphological features. , refers to the presence of cells that possess characteristics typical of cancer-causing cells. Cancer cells are often in the form of tumors, but such cells may exist alone in animals or may be non-tumorigenic cancer cells, such as leukemia cells.
[0163]
[0257] The term "vaccine" is understood to mean a composition for generating immunity for the prevention and / or treatment of diseases (e.g. neoplasms / tumors / infectious agents / autoimmune diseases). Should. Accordingly, a vaccine as used herein includes a recombinant nucleic acid, or a cell containing and expressing a recombinant nucleic acid, which is administered to a human or A drug intended for use in animals. A "vaccine composition" may include a pharmaceutically acceptable excipient, carrier, or diluent. Aspects of the present disclosure relate to the use of the technology in the preparation of phagocyte-based vaccines.
[0164]
[0258] The term "pharmaceutically acceptable" means approved or approvable by a U.S. federal or state regulatory agency for use in animals, including humans, or approved by the U.S. Pharmacopoeia or other It means that the drug is listed in the generally recognized pharmacopoeia. "Pharmaceutically acceptable excipient, carrier, or diluent" means a drug that can be administered to a subject together with the drug, does not destroy its pharmacological activity, and delivers a therapeutic amount of the drug. Refers to an excipient, carrier, or diluent that is non-toxic when administered in sufficient doses to cause
[0165]
[0259] Nucleic acid molecules useful in the methods of the present disclosure include, but are not limited to, any nucleic acid molecule that has an activity or encodes a polypeptide. A polynucleotide having substantial identity to an endogenous sequence is typically capable of hybridizing with at least one strand of a double-stranded nucleic acid molecule. "Hybridize" refers to when nucleic acid molecules pair between complementary polynucleotide sequences, or portions thereof, to form a double-stranded molecule under conditions of varying stringency. (See, eg, Wahl, G. M. and S L. Berger (1987), Methods Enzymol., 152:399; Kimmel, A. R. (1987), Methods Enzymol., 152:507). For example, the exact salt concentration is typically less than about 750mM NaCl and 75mM trisodium citrate, less than about 500mM NaCl and 50mM trisodium citrate, or less than about 250mM NaCl and 25mM trisodium citrate. It's possible. Low stringency hybridization can be obtained in the absence of an organic solvent, such as formamide, whereas high stringency hybridization can be obtained in the presence of at least about 35% formamide, or at least about 50% formamide. of formamide. Stringent temperature conditions can typically include temperatures of at least about 30°C, at least about 37°C, or at least about 42°C. Variations in additional parameters are also well known to those skilled in the art, such as hybridization time, concentration of detergents such as sodium dodecyl sulfate (SDS), and inclusion or exclusion of carrier DNA. Various levels of rigor can be achieved by combining these various conditions as needed. In an exemplary embodiment, hybridization may occur at 30°C in 750mM NaCl, 75mM trisodium citrate, and 1% SDS. In another exemplary embodiment, hybridization is performed at 37°C in 500mM NaCl, 50mM trisodium citrate, 1% SDS, 35% formamide, and 100μg / ml denatured salmon sperm DNA (ssDNA). It can occur. In another exemplary embodiment, hybridization can occur at 42° C. in 250 mM NaCl, 25 mM trisodium citrate, 1% SDS, 50% formamide, and 200 μg / ml ssDNA. Useful variations in these conditions will be readily apparent to those skilled in the art. For most applications, the wash steps that follow hybridization can also vary in stringency. Wash stringency conditions can be defined by salt concentration and temperature. As noted above, the stringency of the wash may be increased by decreasing the salt concentration and may be increased by increasing the temperature. For example, the exact salt concentration for the wash step may be less than about 30mM NaCl and 3mM trisodium citrate, or less than about 15mM NaCl and 1.5mM trisodium citrate. Stringent temperature conditions for the washing step can include temperatures of at least about 25°C, at least about 42°C, or at least about 68°C. In an exemplary embodiment, the wash step may occur at 25°C in 30mM NaCl, 3mM trisodium citrate, and 0.1% SDS. In other exemplary embodiments, the wash step may occur at 42°C in 15mM NaCl, 1.5mM trisodium citrate, and 0.1% SDS. In another exemplary embodiment, the wash step will occur at 68°C in 15mM NaCl, 1.5mM trisodium citrate, and 0.1% SDS. Further variations in these conditions will be readily apparent to those skilled in the art. Hybridization methods are well known to those skilled in the art, for example, Benton and Davis (Science, 196:180, 1977); Grunstein and Hogness (Proc. Natl. Acad. Sci., USA, 72:3961, 1975); Ausubel et al. (“Current Protocols in Molecular Biology”, Wiley Interscience, New York, 2001); Berger and Kimmel (“Guide to Molecular Cloning Techniques”, 1987, Academic Press, New York); and Sambrook et al., “Molecular Cloning: A Laboratory Manual," Cold Spring Harbor Laboratory Press, New York.
[0166]
[0260] "Substantially homologous" refers to a reference amino acid sequence (e.g., any one of the amino acid sequences described herein) or a reference nucleic acid sequence (e.g., any one of the nucleic acid sequences described herein). a polypeptide or nucleic acid molecule that exhibits at least 50% identity to any one of the following: Such sequences must be at least 60%, 80%, or 85%, 90%, 95%, 96%, 97%, 98%, or even at least 60%, 80%, or 85%, at the amino acid or nucleic acid level, of the sequences used for comparison. Can be 99% or more identical. Sequence homology is typically determined using sequence analysis software (e.g., Sequence Analysis Software Package of the Genetics Computer Group, University of Wisconsin Biotechnology Center, 1710 University Avenue, Madison, Wis. 53705, BLAST program, BESTFIT program, GAP program, or the PILEUP / PRETTYBOX program). Such software matches identical or similar sequences by assigning degrees of homology to various substitutions, deletions, and / or other modifications. Conservative substitutions typically include substitutions within the following groups: glycine, alanine; valine, isoleucine, leucine; aspartic acid, glutamic acid, asparagine, glutamine; serine, threonine; lysine, arginine; and phenylalanine, tyrosine. An exemplary approach to determining the degree of identity may use the BLAST program, where a probability score between e-3 and e-m may indicate closely related sequences. A "reference" is a standard of comparison. It will be appreciated that the numbering of specific positions or residues within each sequence will depend on the particular protein and numbering scheme used. The numbering may be different, for example, for the precursor of the mature protein and the mature protein itself, and sequence differences between species may affect the numbering. Those skilled in the art will be able to identify each in any homologous protein and in the nucleic acids encoding each by methods well known in the art, e.g., by sequence alignment against reference sequences and determination of homologous residues. It would be possible to identify the residue.
[0167]
[0261] The term "subject" or "patient" refers to an organism, such as an animal (eg, a human), for the purpose of treatment, observation, or experimentation. By way of example only, a subject includes a human or non-human mammal, such as a non-human primate, murine, bovine, equine, canine, ovine, or feline. including, but not limited to, mammals.
[0168]
[0262] The term "therapeutic effect" refers to a degree of alleviation of one or more of the symptoms of a disorder (e.g., a neoplasm, tumor, or infection by an infectious agent, or an autoimmune disease) or its associated condition. . As used herein, "therapeutically effective amount" means, upon administration to a cell or subject, in a single dose or in multiple doses, more than what would be expected in the absence of such treatment. the amount of the drug that is effective to prolong survival, reduce one or more signs or symptoms of the disorder, prevent or delay the disorder in patients with such disorder. Point. "Therapeutically effective amount" is intended to quantify the amount required to achieve a therapeutic effect. An attending physician or veterinarian having ordinary skill in the medical arts can readily determine and prescribe the required "therapeutically effective amount" (eg, ED50) of a pharmaceutical composition.
[0169]
[0263] Herein, engineered bone marrow cells, including neutrophils, monocytes, myeloid dendritic cells (mDCs), mast cells, and macrophages, are designed to specifically bind to target cells. (without limitation) are provided. The engineered bone marrow cells may attack and kill target cells directly (e.g., by phagocytosis) and / or indirectly (e.g., by activating T cells). However, it may even kill it. In some embodiments, the target cell is a cancer cell.
[0170]
[0264] Although cancer is one exemplary embodiment that is described in detail in this disclosure, the methods and techniques described herein target infected or otherwise diseased cells within the body. It is assumed that this method will be useful in Similarly, described herein are therapeutic and vaccine compositions that use engineered cells.
[0171]
[0265] Compositions and methods are provided herein for treating diseases or conditions such as cancer. The compositions and methods provided herein utilize human bone marrow cells, including but not limited to neutrophils, monocytes, myeloid dendritic cells (mDCs), mast cells, and macrophages, to target diseased cells such as cancer cells. The compositions and methods provided herein are effective in activating and recruiting T cells, activating effector immune cells (e.g., activation of CD8 T cells and NK cells), cross-presenting antigens, and enhancing inflammatory responses. They can be used to eliminate diseased cells, such as cancer cells, and / or diseased tissue by a variety of mechanisms, including phagocytosis, reduction of regulatory T cells, and phagocytosis. For example, bone marrow cells can be used to maintain an immune response against cancer cells.
[0172]
[0266] Herein, phagocytic receptor (PR) fusion protein (PFP), scavenger receptor (SR) fusion protein (SFP), integrin receptor (IR) fusion protein (IFP), or caspase-recruited receptor (caspase-CAR Compositions are provided that include recombinant nucleic acids encoding chimeric fusion proteins (CFPs), such as ) fusion proteins. CFP encoded by a recombinant nucleic acid may include an extracellular domain (ECD) that includes an antigen binding domain that binds to an antigen on a target cell. The extracellular domain can be fused to a hinge domain or an extracellular domain derived from a receptor, such as a hinge domain or an extracellular domain. The CFP encoded by the recombinant nucleic acid may further include a transmembrane domain, such as a transmembrane domain derived from CD2, CD8, CD28, CD68, a phagocytic receptor, a scavenger receptor, or an integrin receptor. In some embodiments, the CFP encoded by the recombinant nucleic acid has an intracellular domain that includes an intracellular signaling domain, such as an intracellular signaling domain derived from a phagocytic receptor, a scavenger receptor, or an integrin receptor. Including further. For example, the intracellular domain can include one or more intracellular signaling domains derived from phagocytic receptors, scavenger receptors, or integrin receptors. For example, intracellular domains may be involved in phagocytic activity, inflammatory responses, nitric oxide production, integrin activation, enhancement of effector cell migration (e.g., via chemokine receptor expression), antigen presentation, and / or cross-presentation. It may contain one or more intracellular signaling domains that facilitate potentiation. In some embodiments, the CFP is a phagocytic receptor fusion protein (PFP). In some embodiments, the CFP is a phagocytic scavenger receptor fusion protein (PFP). In some embodiments, the CFP is an integrin receptor fusion protein (IFP). In some embodiments, the CFP is an inflammatory receptor fusion protein. In some embodiments, the CFP encoded by the recombinant nucleic acid further comprises an intracellular domain that includes a recruitment domain. For example, the intracellular domain can include one or more PI3K recruitment domains, caspase recruitment domains, or caspase activation / recruitment domains (CARDs).
[0173]
[0267] As used herein, a phagocytic or tethered receptor (PR) subunit comprising (i) a transmembrane domain and (ii) an intracellular domain comprising a phagocytic receptor intracellular signaling domain; and an antigen, e.g., an antigen of a target cell. , or contains an extracellular antigen-binding domain that is specific for the antigen presented on the target cell; antigen binding to the target by the extracellular antigen-binding domain of the fusion receptor triggers intracellular signaling of the phagocytic receptor. Compositions are provided that include a recombinant nucleic acid encoding a CFP (e.g., a phagocytic receptor fusion protein (PFP)) having a transmembrane domain and an extracellular antigen binding domain operably linked to activate the domain. be done.
[0174]
[0268] In some embodiments, the extracellular domain of CFP includes an Ig binding domain. In some embodiments, the extracellular domain comprises IgA, IgD, IgE, IgG, IgM, FcRγI, FcRγIIA, FcRγIIB, FcRγIIC, FcRγIIIA, FcRγIIIB, FcRn, TRIM21, FcRL5 binding domain. In some embodiments, the extracellular domain of CFP comprises an FcR extracellular domain. In some embodiments, the extracellular domain of CFP comprises the extracellular domain of FcRα, FcRβ, FcRε, or FcRγ. In some embodiments, the extracellular domain comprises an FcRα (FCAR) extracellular domain. In some embodiments, the extracellular domain comprises an FcRβ extracellular domain. In some embodiments, the extracellular domain comprises an FCER1A extracellular domain. In some embodiments, the extracellular domain comprises the extracellular domain of FCGR1A, FCGR2A, FCGR2B, FCGR2C, FCGR3A, or FCGR3B. In some embodiments, the extracellular domain comprises an integrin domain or an integrin receptor domain. In some embodiments, the extracellular domain is one or more integrin domains: α1, α2, αIIb, α3, α4, α5, α6, α7, α8, α9, α10, α11, αD, αE, including αL, αM, αV, αX, β1, β2, β3, β4, β5, β6, β7, or β8.
[0175]
[0269] In some embodiments, the CFP further comprises an extracellular domain operably linked to a transmembrane domain and an extracellular antigen binding domain. In some embodiments, the extracellular domain further comprises an extracellular domain of the receptor, a hinge, a spacer, and / or a linker. In some embodiments, the extracellular domain comprises the extracellular portion of a phagocytic receptor. In some embodiments, the extracellular portion of CFP is derived from the same receptor from which the intracellular signaling domain is derived. In some embodiments, the extracellular domain comprises an extracellular domain of a scavenger receptor. In some embodiments, the extracellular domain comprises an immunoglobulin domain. In some embodiments, the immunoglobulin domain comprises an immunoglobulin extracellular domain or an immunoglobulin hinge region. In some embodiments, the extracellular domain comprises a phagocytic domain. In some embodiments, the extracellular domain comprises a structure capable of multimeric assembly. In some embodiments, the extracellular domain includes a platform for multimerization. In some embodiments, the extracellular domain is at least 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 300, 300, 400, or 500 amino acids in length. be. In some embodiments, the extracellular domain is up to 500, 400, 300, 200, or 100 amino acids long. In some embodiments, the extracellular antigen binding domain specifically binds an antigen on a target cell. In some embodiments, the extracellular antigen binding domain comprises an antibody domain. In some embodiments, the extracellular antigen binding domain comprises a receptor domain, an antibody domain, where the antibody domain is a single chain variable fragment (scFv), a Fab, a single domain antibody (sdAb), a nano body, V H domain, V L domain, VNAR domain, V HH includes functional antibody fragments that are domains, bispecific antibodies, diabodies, or functional fragments or combinations thereof. In some embodiments, the extracellular antigen binding domain comprises a ligand, an extracellular domain of a receptor, or an adapter. In some embodiments, the extracellular antigen binding domain comprises a single extracellular antigen binding domain that is specific for a single antigen. In some embodiments, the extracellular antigen binding domain comprises at least two extracellular antigen binding domains, where each of the at least two extracellular antigen binding domains is specific for a different antigen. .
[0176]
[0270] In some embodiments, the antigen is a cancer-associated antigen, a lineage-associated antigen, a pathogenic antigen, or an autoimmune antigen. In some embodiments, the antigen includes a viral antigen. In some embodiments, the antigen is a T lymphocyte antigen. In some embodiments, the antigen is an extracellular antigen. In some embodiments, the antigen is an intracellular antigen. In some embodiments, the antigen is thymidine kinase (TK1), hypoxanthine-guanine phosphoribosyltransferase (HPRT), receptor tyrosine kinase-like orphan receptor 1 (ROR1), mucin 1, mucin 16 (MUC16), MUC1, epidermal growth factor receptor vIII (EGFRvIII), mesothelin, human epidermal growth factor receptor 2 (HER2), EBNA-1, LEMD1, phosphatidylserine, carcinoembryonic antigen (CEA), B cell maturation antigen (BCMA), Glypican 3 (GPC3), follicle-stimulating hormone receptor, fibroblast activation protein (FAP), erythropoietin-producing hepatocellular carcinoma A2 (EphA2), EphB2, natural killer 2D (NKG2D) group ligand, disialoganglioside 2 (GD2) , CD2, CD3, CD4, CD5, CD7, CD8, CD19, CD20, CD22, CD24, CD30, CD33, CD38, CD44v6, CD45, CD56CD79b, CD97, CD117, CD123, CD133, CD138, CD171, CD179a, CD213A2, CD248 , CD276, PSCA, CS-1, CLECL1, GD3, PSMA, FLT3, TAG72, EPCAM, IL-1, integrin receptor, PRSS21, VEGFR2, PDGFRβ, SSEA-4, EGFR, NCAM, prostase, PAP, ELF2M, GM3 , TEM7R, CLDN6, TSHR, GPRC5D, ALK, Dsg1, Dsg3, IGLL1, and combinations thereof. In some embodiments, the antigen is a protein antigen selected from the group consisting of CD2, CD3, CD4, CD5, CD7, CCR4, CD8, CD30, CD45, and CD56. In some embodiments, the antigen is an ovarian cancer antigen or a T lymphoma antigen. In some embodiments, the antigen is an integrin receptor antigen. In some embodiments, the antigen is α1, α2, αIIb, α3, α4, α5, α6, α7, α8, α9, α10, α11, αD, αE, αL, αM, αV, αX, β1, β2, An integrin receptor or integrin antigen selected from the group consisting of β3, β4, β5, β6, β7, and β8. In some embodiments, the antigen is an integrin receptor ligand antigen. In some embodiments, the antigen is a fibronectin, vitronectin, collagen, or laminin antigen. In some embodiments, an antigen binding domain can bind two or more different antigens.
[0177]
[0271] In some embodiments, the antigen binding domain comprises a self-antigen or a fragment thereof, such as Dsg1 or Dsg3. In some embodiments, the extracellular antigen binding domain comprises a receptor domain or an antibody domain, where the antibody domain binds a self-antigen, such as Dsg1 or Dsg3.
[0178]
[0272] In some embodiments, the transmembrane domain and the extracellular antigen binding domain are operably linked via a linker. In some embodiments, the transmembrane domain and the extracellular antigen binding domain are operably linked via a linker, such as a CD8α, IgG1, or IgG4 hinge region.
[0179]
[0273] In some embodiments, the extracellular domain includes a multimerization platform.
[0180]
[0274] In some embodiments, the transmembrane domain comprises a CD8 transmembrane domain. In some embodiments, the transmembrane domain comprises a CD28 transmembrane domain. In some embodiments, the transmembrane domain comprises a CD68 transmembrane domain. In some embodiments, the transmembrane domain comprises a CD2 transmembrane domain. In some embodiments, the transmembrane domain comprises an FcR transmembrane domain. In some embodiments, the transmembrane domain comprises an FcRγ transmembrane domain. In some embodiments, the transmembrane domain comprises an FcRα transmembrane domain. In some embodiments, the transmembrane domain comprises an FcRβ transmembrane domain. In some embodiments, the transmembrane domain comprises an FcRε transmembrane domain. In some embodiments, the transmembrane domain comprises a transmembrane domain derived from a syntaxin, such as syntaxin 3 or syntaxin 4 or syntaxin 5. In some embodiments, the transmembrane domain oligomerizes with the transmembrane domain of the endogenous receptor when CFP is expressed within a cell. In some embodiments, the transmembrane domain oligomerizes with the transmembrane domain of an exogenous receptor when CFP is expressed within a cell. In some embodiments, the transmembrane domain dimerizes with the transmembrane domain of an endogenous receptor when CFP is expressed within a cell. In some embodiments, the transmembrane domain dimerizes with the transmembrane domain of an exogenous receptor when CFP is expressed within a cell. In some embodiments, the transmembrane domain is derived from a different protein than the intracellular signaling domain is derived from. In some embodiments, the transmembrane domain is derived from a different protein than the extracellular domain is derived from. In some embodiments, the transmembrane domain comprises a transmembrane domain of a phagocytic receptor. In some embodiments, the transmembrane domain and extracellular domain are derived from the same protein. In some embodiments, the transmembrane domain is derived from the same protein as the intracellular signaling domain. In some embodiments, the recombinant nucleic acid encodes a DAP12 recruitment domain. In some embodiments, the transmembrane domain comprises a transmembrane domain that oligomerizes with DAP12.
[0181]
[0275] In some embodiments, the transmembrane domains are at least 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 , 31, or 32 amino acids in length. In some embodiments, the transmembrane domains are at most 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 , 30, 31, or 32 amino acids in length.
[0182]
[0276] In some embodiments, the intracellular signaling domain comprises an intracellular signaling domain derived from a phagocytic receptor. In some embodiments, the intracellular signaling domain comprises an intracellular signaling domain derived from a phagocytic receptor other than a phagocytic receptor selected from Megf10, MerTk, FcRα, or Bai1. In some embodiments, the intracellular signaling domain is TNFR1, MDA5, CD40, lectin, Dectin1, CD206, scavenger receptor A1 (SRA1), MARCO, CD36, CD163, MSR1, SCARA3, COLEC12, SCARA5, SCARB1 , SCARB2, CD68, OLR1, SCARF1, SCARF2, CXCL16, STAB1, STAB2, SRCRB4D, SSC5D, CD205, CD207, CD209, RAGE, CD14, CD64, F4 / 80, CCR2, CX3CR1, CSF1R, Tie2, HuCRIg(L), Intracellular signals derived from phagocytic receptors selected from the group consisting of CD64, CD32a, CD16a, CD89, Fc alpha receptor I, CR1, CD35, CD3ζ, CR3, CR4, Tim-1, Tim-4, and CD169 Contains the transmission domain. In some embodiments, the intracellular signaling domain comprises a PI3K recruitment domain. In some embodiments, the intracellular signaling domain comprises an intracellular signaling domain derived from a scavenger receptor. In some embodiments, the intracellular domain includes a CD47 inhibition domain. In some embodiments, the intracellular domain comprises a Rac inhibition domain, a Cdc42 inhibition domain, or a GTPase inhibition domain. In some embodiments, the Rac inhibition domain, Cdc42 inhibition domain, or GTPase inhibition domain inhibits Rac, Cdc42, or GTPase in the phagocytic cup of cells expressing PFP. In some embodiments, the intracellular domain comprises an F-actin disassembly activation domain, an ARHGAP12 activation domain, an ARHGAP25 activation domain, or a SH3BP1 activation domain. In some embodiments, the intracellular domain includes a phosphatase inhibition domain. In some embodiments, the intracellular domain comprises an ARP2 / 3 inhibitory domain. In some embodiments, the intracellular domain comprises at least one ITAM domain. In some embodiments, the intracellular domain comprises at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more ITAM domains. In some embodiments, the intracellular domain is CD3 zeta, CD3 epsilon, CD3 gamma, CD3 delta, Fc epsilon receptor 1 chain, Fc epsilon receptor 2 chain, Fc gamma receptor 1 chain, Fc gamma receptor 2a chain, Fc gamma receptor 2b1 chain, Fc gamma receptor 2b2 chain, Fc gamma receptor 3a chain, Fc gamma receptor 3b chain, Fc beta receptor 1 chain, TYROBP (DAP12), CD5, CD16a, CD16b, CD22, selected from CD23, CD32, CD64, CD79a, CD79b, CD89, CD278, CD66d, functional fragments thereof, and ITAM domains of these amino acid sequences with at least one but not more than 20 modifications thereto; Contains at least one ITAM domain. In some embodiments, at least one ITAM domain includes a phosphorylation site for a Src family kinase. In some embodiments, at least one ITAM domain includes a Syk recruitment domain. In some embodiments, the intracellular domain comprises an F-actin depolymerization activation domain. In some embodiments, the intracellular domain lacks enzymatic activity.
[0183]
[0277] In some embodiments, the intracellular domain does not include a domain derived from a CD3 zeta intracellular domain. In some embodiments, the intracellular domain does not include a domain derived from a MerTK intracellular domain. In some embodiments, the intracellular domain does not include a domain derived from a TLR4 intracellular domain. In some embodiments, the intracellular domain includes a CD47 inhibition domain. In some embodiments, the intracellular signaling domain comprises a domain that activates an integrin, such as the intracellular region of PSGL-1.
[0184]
[0278] In some embodiments, the intracellular signaling domain comprises a domain that activates the GTPase Rap1, such as a domain derived from EPAC and C3G. In some embodiments, the intracellular signaling domain is derived from paxillin. In some embodiments, the intracellular signaling domain activates focal adhesion kinase. In some embodiments, the intracellular signaling domain is derived from a single phagocytic receptor. In some embodiments, the intracellular signaling domain is derived from a single scavenger receptor. In some embodiments, the intracellular domain includes a phagocytosis-enhancing domain.
[0185]
[0279] In some embodiments, the intracellular domain comprises a pro-inflammatory signaling domain. In some embodiments, the pro-inflammatory signaling domain comprises a kinase activation domain or a kinase binding domain. In some embodiments, the pro-inflammatory signaling domain comprises an IL-1 signaling cascade activation domain. In some embodiments, the pro-inflammatory signaling domain is TLR3, TLR4, TLR7, TLR9, TRIF, RIG-1, MYD88, MAL, IRAK1, MDA-5, IFN receptor, STING, NLRP family member Intracellular signaling derived from NLRP1-14, NOD1, NOD2, Pirin, AIM2, NLRC4, FCGR3A, FCERIG, CD40, Tank1-binding kinase (TBK), caspase domain, procaspase-binding domain, or any combination thereof Contains domains.
[0186]
[0280] In some embodiments, the intracellular domain comprises a signaling domain, such as an intracellular signaling domain derived from a connexin (Cx) protein. For example, the intracellular domains are Cx43, Cx46, Cx37, Cx40, Cx33, Cx50, Cx59, Cx62, Cx32, Cx26, Cx31, Cx30.3, Cx31.1, Cx30, Cx25, Cx45, Cx47, Cx31.3, Cx36 , Cx31.9, Cx39, Cx40.1, or Cx23. For example, the intracellular domain can include a signaling domain, such as an intracellular signaling domain derived from Cx43.
[0187]
[0281] In some embodiments, the intracellular domain comprises a signaling domain, such as an intracellular signaling domain derived from a SIGLEC protein. For example, intracellular domains include Siglec-1 (sialoadesin), Siglec-2 (CD22), Siglec-3 (CD33), Siglec-4 (MAG), Siglec-5, Siglec-6, Siglec-7, Siglec-8 , a signaling domain such as an intracellular signaling domain derived from Siglec-9, Siglec-10, Siglec-11, Siglec-12, Siglec-13, Siglec-14, Siglec-15, Siglec-16, or Siglec-17. may include.
[0188]
[0282] In some embodiments, the intracellular domain comprises a signaling domain, such as an intracellular signaling domain derived from a C-type lectin protein. For example, the intracellular domain can include a signaling domain, such as an intracellular signaling domain derived from a mannose receptor protein. For example, the intracellular domain can include a signaling domain, such as an intracellular signaling domain derived from an asialoglycoprotein receptor protein. For example, intracellular domains include macrophage galactose-type lectin (MGL), DC-SIGN (CLEC4L), langerin (CLEC4K), myeloid DAP12-associated lectin (MDL) 1 (CLEC5A), and DC-associated C-type lectin 1 (Dectin 1). ) subfamily protein, Dectin 1 / CLEC7A, DNGR1 / CLEC9A, myeloid C-type lectin-like receptor (MICL) (CLEC12A), CLEC2 (CLEC1B), CLEC12B, DC immune receptor (DCIR) subfamily protein, DCIR / CLEC4A , Dectin 2 / CLEC6A, Blood DC Antigen 2 (BDCA2) (CLEC4C), Mincle (macrophage inducible C type lectin) (CLEC4E), NOD-like receptor protein, NOD-like receptor MHC class II transactivator (CIITA) , IPAF, BIRC1, RIG-I-like receptor (RLR) protein, RIG-I, MDA5, LGP2, NAIP5 / Birc1e, NLRP protein, NLRP1, NLRP2, NLRP3, NLRP4, NLRP5, NLRP6, NLRP7, NLRP89, NLRP9, NLRP10 , NLRP11, NLRP12, NLRP13, NLRP14, NLR proteins, NOD1 or NOD2, or any combination thereof.
[0189]
[0283] In some embodiments, the intracellular domain comprises a signaling domain, such as an intracellular signaling domain derived from a cell adhesion molecule. For example, the intracellular domain can include a signaling domain, such as an intracellular signaling domain derived from the molecules IgCAM, cadherin, integrin, C-type lectin-like domain protein (CTLD), and / or proteoglycans. For example, intracellular domains include signaling domains such as intracellular signaling domains derived from E-cadherin, P-cadherin, N-cadherin, R-cadherin, B-cadherin, T-cadherin, or M-cadherin. sell. For example, the intracellular domain can include a signaling domain, such as an intracellular signaling domain derived from a selectin such as E-selectin, L-selectin, or P-selectin.
[0190]
[0284] In some embodiments, the CFP does not include a full-length intracellular signaling domain. In some embodiments, the intracellular domain is at least 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 300, 300, 400, or 500 amino acids long. It is. In some embodiments, the intracellular domain is up to 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 300, 300, 400, or 500 amino acids in length. It is.
[0191]
[0285] In some embodiments, the recombinant nucleic acid encodes an FcRα chain extracellular domain, an FcRα chain transmembrane domain, and / or an FcRα chain intracellular domain. In some embodiments, the recombinant nucleic acid encodes an FcRβ chain extracellular domain, an FcRβ chain transmembrane domain, and / or an FcRβ chain intracellular domain. In some embodiments, the FcRα or FcRβ chain forms a complex with FcRγ when expressed within a cell. In some embodiments, the FcRα or FcRβ chain forms a complex with endogenous FcRγ when expressed within a cell. In some embodiments, the FcRα or FcRβ chains are not integrated into the membrane of cells that do not express FcRγ. In some embodiments, the CFP does not include an FcRα chain intracellular signaling domain. In some embodiments, the CFP does not include an FcRβ chain intracellular signaling domain. In some embodiments, the recombinant nucleic acid encodes a TREM extracellular domain, a TREM transmembrane domain, and / or a TREM intracellular domain. In some embodiments, the TREM is TREM1, TREM2, or TREM3.
[0192]
[0286] Provided herein are methods and compositions for producing therapeutic bone marrow cells, such as therapeutic bone marrow cells engineered to target and kill diseased cells, such as cancer cells. While this disclosure richly exemplifies compositions and methods for killing cancer or tumor cells, one skilled in the art will be able to target other diseased cells, such as infected cells, without unnecessary experimentation. Thus, it would be possible to design such macrophages.
[0193]
[0287] In some embodiments, macrophages are isolated from a subject in need thereof, engineered to express one or more proteins of interest, and administered to the subject. In some embodiments, the subject has cancer or a tumor. Macrophages isolated from a subject, engineered to express one or more proteins of interest, and then administered to the subject target and kill cancer or tumor cells of the subject. This is a therapeutic macrophage.
[0194]
[0288] In one aspect herein, (A) a first nucleic acid sequence encoding an exogenous polypeptide; and (B) a second nucleic acid sequence encoding a myeloid cell chimeric antigen receptor fusion protein (CFP), comprising: , CFP is an intracellular signaling subunit comprising (a) an intracellular signaling domain with a tyrosine residue that is phosphorylated upon binding to an antigen by the receptor; (b) a transmembrane domain; and (c) a target. (d) an extracellular binding domain that has binding specificity for components on the surface of the cell and is operably linked to transmembrane domains and intracellular signaling subunits; and (d) a protease cleavage sequence that allows intracellular a second nucleic acid sequence operably linked to the signal transduction subunit and comprising a transcription activation domain that promotes transcription of the first nucleic acid sequence encoding an exogenous polypeptide; (C) (a) transcription; a protease that cleaves a protease cleavage sequence that operably links the activation domain to an intracellular signaling subunit; (b) encodes a domain that binds to a tyrosine residue that is phosphorylated upon activation of CFP; A composition comprising one or more recombinant nucleic acid sequences comprising a third nucleic acid sequence operably linked to a protease that cleaves a protease cleavage sequence and a domain that binds a tyrosine residue is provided. .
[0195]
[0289] In some embodiments, the third nucleic acid sequence further encodes (c) a stimulus-responsive element. In some embodiments, the stimuli-responsive element (c) is fused to a domain that binds a phosphorylated tyrosine residue. In some embodiments, the stimulus-responsive element is responsive to the microenvironment of the cell expressing the nucleic acid sequence. In some embodiments, (c) is a degron operably linked to (b). In some embodiments, the degron is a HIF-1a degron.
[0196]
[0290] In some embodiments, one or more recombinant nucleic acids are expressed within bone marrow cells. In some embodiments, the bone marrow cells are macrophage cells. In some embodiments, the target cell is a cancer cell.
[0197]
[0291] In some embodiments, the first nucleic acid encodes a prophagocytic polypeptide or a proinflammatory polypeptide, or both. In some embodiments, the CFP is a phagocytosis receptor fusion protein having one or more phagocytosis receptor domains, or fragments thereof. In some embodiments, the one or more phagocytic receptor domains, or fragments thereof, are lectin, dectin 1, CD206, scavenger receptor A1 (SRA1), MARCO, CD36, CD163, MSR1, SCARA3, COLEC12, SCARA5, SCARB1, SCARB2, CD68, OLR1, SCARF1, SCARF2, CXCL16, STAB1, STAB2, SRCRB4D, SSC5D, CD205, CD207, CD209, RAGE, CD14, CD64, F4 / 80, CCR2, CX3CR1, CSF1R, Tie2, HuCRIg( L), CD64, CD32a, CD16a, CD89, Fc alpha receptor I, CR1, CD35, CR3, CR4, Tim-1, Tim-4, and CD169.
[0198]
[0292] In some embodiments, the intracellular domain of CFP is derived from a phagocytic receptor.
[0199]
[0293] In some embodiments, the intracellular signaling domain is derived from a receptor other than a phagocytic receptor selected from Megf10, MerTk, FcR alpha, or Bai1. In some embodiments, the intracellular signaling subunit that includes an intracellular signaling domain with a tyrosine residue includes at least one ITAM domain. In some embodiments, the intracellular signaling subunit comprises more than one ITAM domain. In some embodiments, the at least one ITAM domain is a CD3 zeta TCR subunit, a CD3 epsilon TCR subunit, a CD3 gamma TCR subunit, a CD3 delta TCR subunit, a TCR zeta chain, an Fc epsilon receptor 1 chain, an Fc Epsilon receptor 2 chain, Fc gamma receptor 1 chain, Fc gamma receptor 2a chain, Fc gamma receptor 2b1 chain, Fc gamma receptor 2b2 chain, Fc gamma receptor 3a chain, Fc gamma receptor 3b chain, Fc beta receptor 1 chain, TYROBP (DAP12), CD5, CD16a, CD16b, CD22, CD23, CD32, CD64, CD79a, CD79b, CD89, CD278, CD66d, functional fragments thereof, and at least one of these, but 20 selected from the group consisting of these amino acid sequences with modifications not exceeding . In some embodiments, at least one ITAM domain includes a phosphorylation site for a Src family kinase. In some embodiments, at least one ITAM domain includes a Syk recruitment domain.
[0200]
[0294] For various aspects described herein, in some embodiments, the intracellular signaling subunit further comprises a DAP12 recruitment domain. In some embodiments, the intracellular domain comprises at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 ITAM domains.
[0201]
[0295] In some embodiments, the intracellular signaling subunit further comprises a pro-inflammatory signaling domain that includes an IL-1 signaling cascade activation domain. In some embodiments, the pro-inflammatory signaling domain is TLR3, TLR4, TLR7, TLR9, TRIF, RIG-1, MYD88, MAL, IRAK1, MDA-5, IFN receptor, NLRP family member NLRP1~ 14, NOD1, NOD2, pilin, AIM2, NLRC4, FCGR3A, FCERIG, CD40, a caspase domain or a procaspase binding domain, or an intracellular signaling domain derived from any combination thereof.
[0202]
[0296] In some embodiments, the intracellular signaling domain further comprises a domain that activates an integrin, such as an intracellular region of PSGL-1.
[0203]
[0297] In some embodiments, the intracellular signaling domain further comprises a domain that activates the GTPase Rap1, such as a domain derived from EPAC and C3G. In some embodiments, the intracellular signaling domain further comprises a domain derived from paxillin.
[0204]
[0298] In some embodiments, the intracellular signaling domain activates focal adhesion kinase.
[0205]
[0299] In some embodiments, the extracellular binding domain with binding specificity for a component on the surface of a target cell comprises an antibody or a functional fragment thereof. In some embodiments, the extracellular binding domain comprises a single chain variable fragment (scFv).
[0206]
[0300] In some embodiments, the components on the surface of the target cell include thymidine kinase (TK1), hypoxanthine-guanine phosphoribosyltransferase (HPRT), receptor tyrosine kinase-like orphan receptor 1 (ROR1), mucin 1 , mucin 16 (MUC16), MUC1, epidermal growth factor receptor vIII (EGFRvIII), mesothelin, human epidermal growth factor receptor 2 (HER2), mesothelin, EBNA-1, LEMD1, phosphatidylserine, carcinoembryonic antigen (CEA) , B cell maturation antigen (BCMA), glypican 3 (GPC3), follicle-stimulating hormone receptor, fibroblast activation protein (FAP), erythropoietin-producing hepatocellular carcinoma A2 (EphA2), EphB2, natural killer 2D (NKG2D) group Ligand, disialoganglioside 2 (GD2), CD2, CD3, CD4, CD5, CD7, CD8, CD19, CD20, CD22, CD24, CD30, CD33, CD38, CD44v6, CD45, CD56CD79b, CD97, CD117, CD123, CD133, CD138, CD171, CD179a, CD213A2, CD248, CD276, PSCA, CS-1, CLECL1, GD3, PSMA, FLT3, TAG72, EPCAM, IL-1, integrin receptor, PRSS21, VEGFR2, PDGFR beta, SSEA-4, EGFR , NCAM, prostase, PAP, ELF2M, GM3, TEM7R, CLDN6, TSHR, GPRC5D, ALK, IGLL1, and combinations thereof.
[0207]
[0301] In some embodiments, the component on the surface of the target cell is an antigen selected from the group consisting of CD2, CD3, CD4, CD5, CD7, CCR4, CD8, CD30, CD45, CD56.
[0208]
[0302] In some embodiments, the component on the surface of the target cell is an ovarian cancer antigen or a T lymphoma antigen.
[0209]
[0303] In some embodiments, the component on the surface of the target cell is an integrin receptor.
[0210]
[0304] In some embodiments, the components on the surface of the target cell are α1, α2, αIIb, α3, α4, α5, α6, α7, α8, α9, α10, α11, αD, αE, αL, αM, αV , αX, β1, β2, β3, β4, β5, β6, β7, and β8.
[0211]
[0305] In some embodiments, components on the surface of the target cell include two or more distinct antigens.
[0212]
[0306] In some embodiments, the transmembrane domains are at least 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 , 31, or 32 amino acids in length. In some embodiments, the transmembrane domains are at most 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 , 30, 31, or 32 amino acids in length. In some embodiments, the transmembrane domain comprises a transmembrane domain that oligomerizes with DAP12. In some embodiments, the transmembrane domain and the extracellular antigen binding domain are operably linked via a linker. In some embodiments, the linker comprises a peptide. In some embodiments, the linker comprises a CD8α, IgG1, or IgG4 hinge region. In some embodiments, the linker is a synthetic linker. In some embodiments, the transmembrane domain comprises an FcR transmembrane domain.
[0213]
[0307] A composition according to any embodiment described above, wherein the transcriptional activation domain further comprises a DNA binding domain. In some embodiments, the DNA binding domain is selected from the DNA binding domain (DB) of Gal4, ZFHD1, or tet-R. In some embodiments, the transcriptional activation domain comprises a VP64 transactivation domain.
[0214]
[0308] In some embodiments, the protease that cleaves the protease cleavage sequence that operably links the transcriptional activation domain to the intracellular signaling subunit is hepatitis C virus (HCV) NS3 protease. In some embodiments, the domain that binds tyrosine residues that are phosphorylated upon activation of CFP is a phosphotyrosine binding (PTB) domain. In some embodiments, the PTB is Shc PTB.
[0215]
[0309] In some embodiments, the recombinant nucleic acid is DNA.
[0216]
[0310] In some embodiments, the recombinant nucleic acid is RNA. In some embodiments, the recombinant nucleic acid is mRNA. In some embodiments, the recombinant nucleic acid is a circRNA. In some embodiments, the recombinant nucleic acid is associated with replicon RNA.
[0217]
[0311] In one aspect herein, there is provided a vector encoding one or more recombinant nucleic acids according to any one of the embodiments described above.
[0218]
[0312] In one aspect herein, bone marrow cells expressing vectors according to the embodiments described above are provided.
[0219]
[0313] In one aspect herein, there is provided a pharmaceutical composition comprising the bone marrow cells of the embodiments described above.
[0220]
[0314] One aspect herein comprises (a) a cytotoxic polypeptide; (b) a protease cleavage sequence; and (c) an inhibitory polypeptide domain, wherein the inhibitory polypeptide domain inhibits the cytotoxic polypeptide. In this case, a cell is provided that contains a recombinant nucleic acid encoding a chimeric protein in which a cytotoxic polypeptide, a protease cleavage sequence, and an inhibitory polypeptide domain are operably linked.
[0221]
[0315] In some embodiments, the cells are bone marrow cells.
[0222]
[0316] In some embodiments, the cytotoxic polypeptide is human eosinophil major basic protein cytotoxic domain. In some embodiments, the cytotoxic polypeptide is human eosinophil major basic protein acidic domain.
[0223]
[0317] In some embodiments, the protease cleavage sequence is an MMP recognition sequence.
[0224]
[0318] In some embodiments, the protease cleavage sequence is cleaved by MMP.
[0225]
[0319] In one aspect herein, there is provided a pharmaceutical composition comprising any one of the cells according to the embodiments described herein.
[0226]
[0320] In one aspect herein, there is provided a recombinant nucleic acid according to any one of the embodiments described herein.
[0227]
[0321] In one aspect herein, vectors encoding recombinant nucleic acids according to embodiments described herein are provided.
[0228]
[0322] In one aspect herein, a method for preparing a bone marrow cell that is therapeutic for cancer comprises: (A) a first nucleic acid sequence encoding an exogenous polypeptide; (B) a second nucleic acid sequence encoding a myeloid cell chimeric antigen receptor (CFP), wherein the CFP has a tyrosine residue that is phosphorylated upon activation of (a) the CFP for intracellular signaling; (b) a transmembrane domain; and (c) an intracellular signaling subunit that has binding specificity for components on the surface of the target cell and acts on the transmembrane domain and the intracellular signaling subunit. an extracellular binding domain operably linked to an intracellular signaling subunit; and (d) a protease cleavage sequence to facilitate transcription of a first nucleic acid sequence encoding an exogenous polypeptide. a second nucleic acid sequence comprising a transcription activation domain; (C) a protease that cleaves a protease cleavage sequence operably linking the transcription activation domain to an intracellular signaling subunit; b) a third nucleic acid encoding a domain that binds to a tyrosine residue that is phosphorylated upon activation of the CAR; a protease that cleaves a protease cleavage sequence and a domain that binds to a tyrosine residue are operably linked; A method is provided comprising expressing a recombinant nucleic acid comprising a sequence.
[0229]
[0323] In one aspect herein, there is provided a method for preparing bone marrow cells that are therapeutic against cancer, comprising: (a) human eosinophil major basic protein acidic domain; ) an MMP recognition sequence; and (c) a human eosinophil major basic protein cytotoxic domain.
[0230]
[0324] In one aspect herein, a method for treating a subject having cancer, comprising administering to a subject in need thereof a medicament according to any one of the embodiments described herein. A method is provided that includes administering a composition.
[0231]
[0325] In one aspect herein, there is provided a method of inducing tumor regression in a subject in need thereof, the method comprising the step of intravenously administering to the subject a pharmaceutical composition comprising bone marrow cells, wherein the bone marrow cells are , expressing one or more recombinant nucleic acids encoding one or more polypeptides, at least one of the one or more polypeptides being functionally active within the tumor microenvironment. However, within a non-tumor environment, methods are provided that are not functionally active. For some aspects described herein, in some embodiments, the pharmaceutical composition is a pharmaceutical composition according to embodiments described herein. For some aspects described herein, in some embodiments, the pharmaceutical composition is a pharmaceutical composition according to embodiments described herein.
[0232]
[0326] In some embodiments, for some aspects described herein, the target cell is a cancer cell that is a glioblastoma cell.
[0233]
[0327] Provided herein is a method for treating a subject having cancer, the method comprising administering to the subject in need thereof a pharmaceutical composition as described above.
[0234]
[0328] In some embodiments, the recombinant nucleic acid includes a sequence encoding a pro-inflammatory polypeptide. In some embodiments, the composition further comprises a pro-inflammatory nucleotide or nucleotides, such as ATP, ADP, UTP, UDP, and / or UDP-glucose, within the recombinant nucleic acid. In some embodiments, the transcriptional activation domain comprises a VP64 transactivation domain. In some embodiments, the protease that cleaves the protease cleavage sequence that operably links the transcriptional activation domain to the intracellular signaling subunit is hepatitis C virus (HCV) NS3 protease. In some embodiments, the domain that binds tyrosine residues that are phosphorylated upon activation of CFP is a phosphotyrosine binding (PTB) domain. In some embodiments, the PTB is Shc PTB. In some embodiments, the third nucleic acid encodes a degron that can be operably linked to CFP. In some embodiments, the degron is a HIF-1a degron. In some embodiments, the recombinant nucleic acid is DNA. In some embodiments, the recombinant nucleic acid is RNA. In some embodiments, the recombinant nucleic acid is mRNA. In some embodiments, the recombinant nucleic acid is a circRNA.
[0235]
[0329] In some embodiments, the recombinant nucleic acid is associated with replicon RNA. Described herein is a method for preparing bone marrow cells that are therapeutic against cancer, comprising: (A) a first nucleic acid sequence encoding an exogenous polypeptide; ) a second nucleic acid sequence encoding a myeloid cell chimeric antigen receptor (CFP), wherein the CFP comprises (a) an intracellular signaling domain having a tyrosine residue that is phosphorylated upon activation of the CFP; (b) a transmembrane domain; and (c) an intracellular signaling subunit with binding specificity for a component on the surface of a target cell and operably linked to the transmembrane domain and the intracellular signaling subunit. and (d) a transcriptional activation domain operably linked to an intracellular signaling subunit by a protease cleavage sequence to facilitate transcription of a first nucleic acid sequence encoding an exogenous polypeptide. a second nucleic acid sequence comprising a domain; (C) a protease that cleaves a protease cleavage sequence operably linking (a) the transcriptional activation domain to an intracellular signaling subunit; (b) a protease of CFP; a third nucleic acid sequence encoding a domain that binds to a tyrosine residue that is phosphorylated upon activation; and a third nucleic acid sequence in which the protease that cleaves the protease cleavage sequence and the domain that binds to the tyrosine residue are operably linked. A method is provided that includes expressing a recombinant nucleic acid. Described herein is a method for preparing bone marrow cells that are therapeutic against cancer, comprising: (a) human eosinophil major basic protein acidic domain; (b) MMP recognition in bone marrow cells; and (c) expressing a recombinant nucleic acid encoding a chimeric protein comprising a human eosinophil major basic protein cytotoxic domain.
[0236]
[0330] Provided herein is a method for treating a subject having cancer, the method comprising administering to the subject in need thereof a pharmaceutical composition as described above. Provided herein is a method for treating a subject having cancer, the method comprising administering to the subject in need thereof a pharmaceutical composition described herein. . Described herein is a method of inducing tumor regression in a subject in need thereof, the method comprising the step of intravenously administering to the subject a pharmaceutical composition comprising bone marrow cells, wherein the bone marrow cells are or expressing one or more recombinant nucleic acids encoding a plurality of polypeptides, wherein at least one of the one or more polypeptides is functionally active but non-active within the tumor microenvironment. Within the tumor environment, methods are provided that are not functionally active.
[0237]
[0331] In some embodiments, the composition further comprises a pro-inflammatory polypeptide. In some embodiments, the pro-inflammatory polypeptide is a chemokine, cytokine. In some embodiments, the chemokine is IL-1, IL3, IL5, IL-6, IL-8, IL-12, IL-13, IL-23, TNF, CCL2, CXCL9, CXCL10, CXCL11, IL- 18, IL-23, IL-27, CSF, MCSF, GMCSF, IL17, IP-10, RANTES, and interferon. In some embodiments, the cytokines are IL-1, IL3, IL5, IL-6, IL-12, IL-13, IL-23, TNF, CCL2, CXCL9, CXCL10, CXCL11, IL-18, IL- 23, IL-27, CSF, MCSF, GMCSF, IL17, IP-10, RANTES, and interferon.
[0238]
[0332] In some embodiments, bone marrow cells are specifically targeted for delivery. Bone marrow cells can be targeted using specialized biodegradable polymers such as PLGA (poly(lactic-co-glycolic acid)) and / or polyvinyl alcohol (PVA). In some embodiments, one or more compounds can be selectively incorporated within such polymeric structures to affect bone marrow cell function. In some embodiments, the targeting structure is multilayered, eg, with one or more PLGA layers and one or more PVA layers. In some embodiments, the targeting structures are assembled into an order for layered activity. In some embodiments, the targeted polymer structure attaches to the surface of bone marrow cells and contains molecules such as growth factors and cytokines, such as to maintain bone marrow cells within a microenvironment that confers specific polarization. Organized into specifically shaped components, such as flexible structures, capable of delivering one or more components. In some embodiments, the polymeric structure is such that it is not phagocytosed by bone marrow cells and can maintain attachment on the surface. In some embodiments, the one or more growth factors can be M1 polarizing factors, such as cytokines. In some embodiments, the one or more growth factors can be M2 polarizing factors, such as cytokines. In some embodiments, the one or more growth factors can be macrophage activating cytokines, such as IFNγ. In some embodiments, the polymeric structure is capable of sustained release of one or more growth factors in an in vivo environment, such as within a solid tumor.
[0239]
[0333] In some embodiments, the recombinant nucleic acid includes a sequence encoding a homeostatic regulator of inflammation. In some embodiments, the homeostatic regulator of inflammation is a sequence within the untranslated region (UTR) of the mRNA. In some embodiments, a sequence within the UTR is a sequence that binds an RNA binding protein. In some embodiments, translation is inhibited or blocked upon binding of the RNA binding protein to sequences within the untranslated region (UTR). In some embodiments, the sequence within the UTR comprises a consensus sequence of WWWU(AUUUA)UUUW [where W is A or U]. In some embodiments, recombinant nucleic acids are expressed on bicistronic vectors.
[0240]
[0334] In some embodiments, the target cell is a mammalian cell. In some embodiments, the target cells are human cells. In some embodiments, the target cells include cells infected by a pathogen. In some embodiments, the target cell is a cancer cell. In some embodiments, the target cell is a cancer cell that is a lymphocyte. In some embodiments, the target cell is a cancer cell that is an ovarian cancer cell. In some embodiments, the target cell is a cancer cell that is a mammary gland cell. In some embodiments, the target cell is a cancer cell that is a pancreatic cell. In some embodiments, the target cell is a cancer cell that is a glioblastoma cell.
[0241]
[0335] In some embodiments, the recombinant nucleic acid is DNA. In some embodiments, the recombinant nucleic acid is RNA. In some embodiments, the recombinant nucleic acid is mRNA. In some embodiments, the recombinant nucleic acid is unmodified mRNA. In some embodiments, the recombinant nucleic acid is a modified mRNA. In some embodiments, the recombinant nucleic acid is a circRNA. In some embodiments, the recombinant nucleic acid is tRNA. In some embodiments, the recombinant nucleic acid is a microRNA. In some embodiments, the recombinant nucleic acid is self-replicating RNA.
[0242]
[0336] Also provided herein are vectors containing recombinant nucleic acid sequences encoding the CFPs described herein. In some embodiments, the vector is a viral vector. In some embodiments, the viral vector is a retroviral or lentiviral vector. In some embodiments, the vector further comprises a promoter operably linked to at least one nucleic acid sequence encoding one or more polypeptides. In some embodiments, the vector is a polycistronic vector. In some embodiments, each of the at least one nucleic acid sequence is operably linked to a separate promoter. In some embodiments, the vector further comprises one or more internal ribosome entry sites (IRES). In some embodiments, the vector further comprises a 5'UTR and / or a 3'UTR flanked by at least one nucleic acid sequence encoding one or more polypeptides. In some embodiments, the vector further comprises one or more regulatory regions.
[0243]
[0337] Also provided herein are polypeptides encoded by the recombinant nucleic acids of the compositions described herein.
[0244]
[0338] As used herein, phagocytic or tethered receptor (PR) subunits include an intracellular domain that includes a transmembrane domain, and an intracellular signaling domain; and an extracellular domain that includes an antigen-binding domain specific for the antigen of a target cell. A composition comprising a recombinant nucleic acid sequence encoding a CFP (e.g., a phagocytosis receptor fusion protein (PFP)) comprising a CFP domain, the transmembrane domain and the extracellular domain being operably linked; Killing or phagocytic activity of myeloid cells such as neutrophils, monocytes, myeloid dendritic cells (mDCs), mast cells, or macrophages that express CFP, but not CFP, upon binding to target cell antigens at least 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19 %, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 100%, 150%, 200%, 250%, 300%, 350%, 400%, 450%, 500%, 550%, 600%, 650%, 700%, 750%, 800%, 850%, 900%, 950% , or increased by more than 1000%.
[0245]
[0339] Table 1 shows exemplary sequences of chimeric fusion protein domains and / or fragments thereof, the disclosure of which is intended to be non-limiting.
[0246] [Table 1-1]
[0247] [Table 1-2]
[0248] [Table 1-3]
[0249] [Table 1-4]
[0250] [Table 1-5]
[0251] [Table 1-6]
[0252] [Table 1-7]
[0253] [Table 1-8]
[0340] As used herein, phagocytic or tethered receptor (PR) subunits include an intracellular domain that includes a transmembrane domain, and an intracellular signaling domain; and an extracellular domain that includes an antigen-binding domain specific for the antigen of a target cell. A composition comprising a recombinant nucleic acid sequence encoding a CFP (e.g., a phagocytic receptor fusion protein (PFP)) comprising a CFP domain, the transmembrane domain and the extracellular domain being operably linked; Upon binding to target cell antigen, killing or phagocytic activity of myeloid cells such as neutrophils, monocytes, myeloid dendritic cells (mDCs), mast cells, or macrophages that express CFP but do not express CFP At least 1.1x, 1.5x, 2x, 2.5x, 3x, 3.5x, 4x, 4.5x, 5x, 5.5x, 6x, 6.5x, 7x, 7.5x, 8x compared to cells times, 8.5 times, 9 times, 9.5 times, 10 times, 11 times, 12 times, 13 times, 14 times, 15 times, 16 times, 17 times, 18 times, 19 times, 20 times, 25 times, 30 times, Compositions are provided that are increased 40 times, 50 times, 75 times, or 100 times.
[0254] CD137 binding protein and CD137 binding domain
[0341] In one aspect, provided herein are recombinant proteins capable of binding to CD137 on target cells. As used herein, such recombinant proteins capable of binding to CD137 on target cells are referred to as CD137 binding agents. In some embodiments, the CD137 binding agent comprises the extracellular domain of a chimeric fusion protein (CFP). In some embodiments herein, there is provided a recombinant nucleic acid sequence encoding a chimeric CD137 binding receptor fusion protein (CFP), referred to as CD137-CFP, as used herein. In some embodiments, a recombinant nucleic acid encoding a chimeric receptor fusion protein, eg, a CD137-binding receptor fusion protein, can be expressed in a suitable cell, such as a bone marrow cell. In some embodiments, once CD137-CFP is expressed on appropriate cells, such as bone marrow cells, the CD137-binding agent is capable of binding to target cells that express CD137 and express the binding agent. bone marrow cells are activated. In some embodiments, CD137-CFP, upon engagement with CD137, activates the intracellular signaling domain of CD137-CFP, which activates myeloid cells expressing recombinant nucleic acid encoding CD137-CFP. become In some embodiments, the bone marrow cells are phagocytes. In some embodiments, a bone marrow cell that is a phagocytic cell and expresses a CD137 binding agent is activated and activated when the CD137 binding agent binds to CD137 expressed on another cell (the target cell). It is possible to devour. In some embodiments, the target cell can be any cell that expresses CD137. In some embodiments, the target cells are lymphocytes. In some embodiments, the target cells are T lymphocytes (T cells). In some embodiments, the target cell can be a malignant cell. In some embodiments, the target cell can be a malignant T cell. In some embodiments, bone marrow cells expressing the CD137 binding agent CFP can be used to create therapeutic compositions for T-cell lymphoma.
[0255]
[0342] Provided herein is a recombinant polynucleic acid that includes a sequence encoding a chimeric fusion protein (CFP), wherein the CFP protein is capable of binding to CD137 on T lymphocytes. In some embodiments herein, a CFP capable of binding to a target on a T cell is provided, wherein the target is CD137. In some embodiments, the target T cell is an activated T cell. In some embodiments, CFP targets activated T cells expressed within T cell lymphomas. Described herein is a recombinant nucleic acid encoding CFP that targets CD137, wherein the CFP is agonistically directed to (i) an extracellular domain comprising an anti-CD137 binding domain, and (ii) an extracellular domain. and (b) a pharmaceutically acceptable carrier. , a recombinant nucleic acid exhibiting at least a 1.1-fold increase is provided. In some embodiments, the CD137-binding domain is a CD137-binding protein, including an antigen-binding fragment of an antibody, a Fab fragment, an scFv domain, or an sdAb domain. In some embodiments, the CD137 binding domain comprises the sequence of SEQ ID NO: 31, or a CD137 ligand sequence having at least 90% sequence identity to SEQ ID NO: 31.
[0256]
[0343] Provided herein are recombinant proteins that are chimeric fusion proteins capable of binding to CD137. CD137 is a surface marker for activated T cells. Therefore, a chimeric fusion protein capable of binding CD137 is capable of specifically binding activated T cells, in which case CFP has (i) an extracellular domain comprising an anti-CD137 binding domain, and ( ii) comprises a transmembrane domain operably linked to an extracellular domain. In some embodiments, the CD137-binding domain is a CD137-binding protein that includes an antigen-binding fragment of an antibody, a Fab fragment, an scFv domain, or an sdAb domain. In some embodiments, the CD137 binding domain comprises an scFv. Herein, bone marrow cells expressing a recombinant protein that is a chimeric fusion protein capable of binding to CD137 expressed on T cells, wherein CFP comprises (i) an extracellular domain comprising an anti-CD137 binding domain; , and (ii) a transmembrane domain operably linked to the extracellular domain; capable of specifically targeting CD137-expressing T cells, phagocytosing and lysing CD137-expressing T cells; This provides bone marrow cells to lyse. In some embodiments, bone marrow cells expressing a recombinant protein that is a chimeric fusion protein capable of binding to CD137 are therapeutic agents for CD137-positive cancers, such as T-cell lymphomas.
[0257]
[0344] Generally, CD137 is expressed on activated immune cells. CD137 is expressed on both innate and acquired cells of the immune cascade. In healthy individuals, T cells can be abundant within lymph nodes (eg, tonsils, where T cells are found in an activated state). CD137-positive T cells can also be abundant within tumors.
[0258]
[0345] It is noted that CD137-positive T cells can contribute to graft-versus-host and host-versus-graft rejection. Additionally, in the case of allogeneic cell therapy, CD137 can also be targeted for destruction to reduce host versus graft rejection. In some embodiments, the methods and compositions described herein provide an allogeneic bone marrow expressing a chimeric receptor that (i) binds a cancer antigen and lyses cancer cells expressing the cancer antigen; and (ii) administering bone marrow cells that express a chimeric antigen capable of binding to CD137 and lyse CD137-positive T cells, thereby inducing the use of allogeneic bone marrow cells by CD137-positive T lymphocytes of the host. and reducing kill.
[0259]
[0346] In one aspect herein, the chimeric fusion protein is capable of binding to CD137, and the second binding domain also binds to a second extracellular moiety, a third extracellular moiety, or a further extracellular moiety. , a third binding domain, or even an additional binding domain, and the extracellular portion can be a cell surface molecule. In some embodiments, any one of the second binding domain, or the third binding domain, or the additional binding domain is an additional cell surface molecule on the target cell, e.g., cancer. It may contain binding domains for cell surface molecules other than CD137, such as cell surface molecules on cells or activated T cells. The second binding domain, or the third binding domain, or the additional binding domain targets a target, such as CD5, or an antigen on any other target cell described elsewhere herein. It may contain binding domains for any additional cell surface molecules on the cell.
[0260]
[0347] In some embodiments, any one of the second binding domain, or the third binding domain, or the additional binding domain comprises a binding domain for a cell surface molecule on a bone marrow cell. sell. In some embodiments, any one of the second binding domain, or the third binding domain, or the additional binding domain, including a binding domain for bone marrow cells, upon binding, can be activated.
[0261]
[0348] In some embodiments, the CD137 binding protein is a chimeric fusion protein that includes an extracellular domain capable of binding CD137 and further includes a hinge domain derived from CD8, in which case the hinge domain On the side, it is operatively linked to a transmembrane domain, and on the outside of the cell, it is operably linked to a CD137 binding domain. In some embodiments, the transmembrane domain comprises a sequence set forth in any one of SEQ ID NO: 15, 16, 17, 18, or 19. In some embodiments, the transmembrane domain comprises sequences derived from the CD8 alpha (CD8a) transmembrane domain. In some embodiments, the transmembrane domain is the sequence set forth in SEQ ID NO: 15, or at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93% relative to SEQ ID NO: 15. , 94%, 95%, 96%, 97%, 98%, or 99% sequence identity. In some embodiments, the transmembrane domain is the sequence set forth in SEQ ID NO: 16, or at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93% relative to SEQ ID NO: 16. , 94%, 95%, 96%, 97%, 98%, or 99% sequence identity. In some embodiments, the transmembrane domain comprises sequences derived from the CD2 transmembrane domain. In some embodiments, the transmembrane domain is the sequence set forth in SEQ ID NO: 17, or at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93% relative to SEQ ID NO: 17. , 94%, 95%, 96%, 97%, 98%, or 99% sequence identity. In some embodiments, the transmembrane domain comprises sequences derived from the CD28 transmembrane domain. In some embodiments, the transmembrane domain is the sequence set forth in SEQ ID NO: 18, or at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93% relative to SEQ ID NO: 18. , 94%, 95%, 96%, 97%, 98%, or 99% sequence identity. In some embodiments, the transmembrane domain comprises sequences derived from the CD68 transmembrane domain. In some embodiments, the transmembrane domain is the sequence set forth in SEQ ID NO: 19, or at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93% relative to SEQ ID NO: 19. , 94%, 95%, 96%, 97%, 98%, or 99% sequence identity. In some embodiments, the ECD of CFP is a transmembrane domain selected from any one of the sequences set forth in SEQ ID NO: 15, 16, 17, 18, or 19, or SEQ ID NO: 15, 16. , 17, 18, or 19 at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97 %, 98%, or 99% sequence identity; the amino acid sequence depicted in SEQ ID NO: 31, or at least 70%, 75%, 80% to 31. , 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity.
[0262]
[0349] In some embodiments, the extracellular hinge domain and the transmembrane domain are at least 70%, 75%, 80%, 85% of the sequence of SEQ ID NO: 20 or SEQ ID NO: 21, or each of SEQ ID NO: 20 or SEQ ID NO: 21. , 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity. In some embodiments, the CFP is the transmembrane domain of SEQ ID NO: 20, or at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94% relative to SEQ ID NO: 20. , an extracellular domain fused to a transmembrane domain with 95%, 96%, 97%, 98%, or 99% sequence identity. In some embodiments, the CFP is the transmembrane domain of SEQ ID NO: 21, or at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94% relative to SEQ ID NO: 21. , an extracellular domain fused to a transmembrane domain with 95%, 96%, 97%, 98%, or 99% sequence identity. In some embodiments, the CFP is at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96% relative to SEQ ID NO: 20 or 21; fused to a hinge domain and a transmembrane domain having amino acid sequences with 97%, 98%, 99%, or 100% sequence identity; at least 70%, 75%, 80%, 85 to SEQ ID NO: 31. %, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity.
[0263]
[0350] In some embodiments, the CFP was operably linked to a TM domain comprising the sequence of a CD16 transmembrane domain (e.g., including the short hinge domain) set forth in Table 4; 31. In some embodiments, the CFP is operably linked to a TM domain comprising a CD64 transmembrane domain sequence; the sequence set forth in SEQ ID NO:31, or at least 80% relative to the sequence set forth in SEQ ID NO:31. contains an extracellular domain containing sequences with sequence identity of . In some embodiments, the CFP was operably linked to a TM domain comprising the sequence of a CD89 transmembrane domain (e.g., including the short hinge domain) set forth in Table 4; Contains an extracellular domain containing the indicated sequences. In some embodiments, the CFP is an ECD with the sequence set forth in SEQ ID NO: 31, or a sequence having at least 80% sequence identity to the sequence set forth in SEQ ID NO: 31; the TM domain of the CD16 protein; or a TM domain comprising a sequence derived from the TMD of the CD64 protein, or the TMD of the CD89 protein; and optionally in addition to other distinct ICDs described herein, e.g., CD16 protein, CD64 protein, or the corresponding intracellular domain (ICD) or portion thereof derived from each of the CD89 proteins. Exemplary ICD sequences for CD16 and CD89 are presented in Table 4.
[0264]
[0351] In some embodiments, the CFP comprises one or more intracellular signaling domains, including one intracellular signaling domain. In some embodiments, the intracellular signaling domain comprises a phagocytic signaling domain. In some embodiments, the phagocytic signaling domain comprises an intracellular signaling domain derived from a receptor other than Megf10, MerTk, FcRα, and Bai1. In some embodiments, the phagocytic signaling domain comprises an intracellular signaling domain derived from a receptor other than Megf10, MerTk, FcR, and Bai1. In some embodiments, the intracellular signaling domain comprises a domain derived from a receptor other than CD3ζ. In some embodiments, the phagocytic signaling domain comprises an intracellular signaling domain derived from FcRγ, FcRα, or FcRε.
[0265]
[0352] In some embodiments, the CFP is any one of SEQ ID NO: 22, 23, 24, or 25, or at least 70% relative to any one of SEQ ID NO: 22, 23, 24, or 25. , 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity. contains an intracellular signaling domain derived from the FcR gamma protein (FcRγ chain). In some embodiments, the one or more intracellular signaling domains further include a pro-inflammatory signaling domain. In some embodiments, the pro-inflammatory signaling domain comprises a PI3 kinase (PI3K) recruitment domain. In some embodiments, the pro-inflammatory signaling domain is the sequence of SEQ ID NO: 26, or at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93% relative to SEQ ID NO: 26. , 94%, 95%, 96%, 97%, 98%, or 99% sequence identity. In some embodiments, the pro-inflammatory signaling domain is derived from the intracellular signaling domain of CD40. In some embodiments, the pro-inflammatory signaling domain is the sequence of SEQ ID NO: 27, or at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93% relative to SEQ ID NO: 27. , 94%, 95%, 96%, 97%, 98%, or 99% sequence identity. In some embodiments, the CFP is the sequence of SEQ ID NO: 28, or at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95% relative to SEQ ID NO: 28. %, 96%, 97%, 98%, or 99% sequence identity. In some embodiments, the CFP is the sequence of SEQ ID NO: 29, or at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95% relative to SEQ ID NO: 29. %, 96%, 97%, 98%, or 99% sequence identity. In some embodiments, the CFP is the sequence of SEQ ID NO: 30, or at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95% relative to SEQ ID NO: 30. %, 96%, 97%, 98%, or 99% sequence identity.
[0266]
[0353] In some embodiments, the CFP comprises (a) an scFv that specifically binds (i) CD137, and (ii) a hinge domain derived from CD8; a hinge domain derived from CD28; or an extracellular (b) a CD8 transmembrane domain, a CD28 transmembrane domain, a CD2 transmembrane domain, or a CD68 transmembrane domain; and (c) at least two intracellular signaling domains. , the at least two intracellular signaling domains are (i) a first intracellular signaling domain derived from FcRα, FcRγ, or FcRε; and (ii) a second intracellular signaling domain: a PI3K recruitment domain. (A) or derived from CD40 (B). In some embodiments, the CFP comprises at least two intracellular signaling domains, as an alternative (c) to the above, wherein the at least two intracellular signaling domains are (i) intracellular domains of phagocytic receptors; (ii) from the intracellular domain of the scavenger receptor of the phagocytic receptor and containing a PI3K recruitment domain (A) or from CD40 (B). comprising an intracellular domain comprising a second intracellular signaling domain. In some embodiments, the CFP comprises an intracellular signaling domain derived from an intracellular signaling domain of an innate immune receptor.
[0267]
[0354] In some embodiments, a chimeric fusion protein can have more than one extracellular antigen binding domain.
[0268]
[0355] In some embodiments, the chimeric fusion protein comprises a CD137 binding domain and a second cell surface molecule, such as an extracellular protein or glycoprotein, a membrane protein or glycoprotein present on the surface of a cancer cell or target cell. may include a second binding domain for. In some embodiments, the second binding domain binds any target described herein. In some embodiments, the second binding domain can be designed such that the second binding domain binds to a protein on the extracellular matrix of the target cell or nearby cells. In some embodiments, the extracellular domain can include a second binding domain that can bind a soluble target, such as a molecule released into the extracellular space of a neighboring cell or a target cell.
[0269]
[0356] In one aspect herein, chimeric fusion proteins are provided that can bind to CD137 (also known as 4-1BB) on target cells. In some embodiments, a recombinant nucleic acid encoding CFP capable of binding CD137 can be integrated into bone marrow cells such that the cells express CD137-binding CFP. In some embodiments, bone marrow cells can be CD14+ cells. In some embodiments, the bone marrow cells can be CD14+ / CD16-. In some embodiments, the bone marrow cells can be CD14+ / CD16low. Bone marrow cells expressing CFP that binds CD137 can be used in a variety of ways: alone; in combination with other bone marrow cells that express CFP in therapeutic compositions; may be used individually in combination therapy regimens; may be used alone and include other nucleic acid, peptide, protein, or small molecule therapeutics; It may also be used in combination with other therapeutic agents.
[0270]
[0357] CD137 is a member of tumor necrosis factor receptor superfamily member 9 (TNFRSF9) and is expressed on the surface of certain immune cells. CD137 is a cell surface protein expressed on activated T cells. The interaction of CD137 with its ligand (CD137L; also known as TNFSF9 or 4-1BBL) on activated antigen-presenting cells (APCs) is a bidirectional mechanism that promotes immunity against cancer. It can bring about activation. For example, it has been shown that signals through the CD137 receptor can result in T cell activation and survival. Conversely, engaged CD137L can affect the cells that express it, such as myeloid cells, dendritic cells, resulting in their activation and maturation. The use of agonistic CD137 antibodies, such as urelumumab and utmilumab, appears to be a promising immunotherapy for treating a variety of tumor types. In some embodiments, CD137L-containing CFP is expressed within bone marrow cells and may be used for anti-tumor therapy, and CD137L signaling to monocytes is expressed in CD137L-DCs. induce differentiation into CD137L-DCs preferentially induce polarization to type 1 helper T (Th1) cells and strong type 1 CD8+ T cell (Tc1) responses against tumors.
[0271]
[0358] CD137 agonistic antibodies, or CD137 binding regions thereof, can be used to design CFPs to activate immune responses in vivo. Alternatively, CD137L or a fragment thereof can be used to design CFP to activate an immune response in vivo. In certain embodiments, CD137-binding CFP comprising a CD137 agonist antibody or fragment thereof or CD137L as the extracellular domain may be used to activate an immune response and may be used as an antineoplastic agent. In some cases, it may be done. As used herein, the antibody comprises a CD137-binding extracellular domain, including a CD137 agonistic antibody or a fragment thereof, and the antibody is an scFv, bispecific antibody, Fab, Fab fragment, F(ab')2 fragment, monovalent antibody. , scFv fragment, scRv-Fc fragment, IgNAR, hcIgG, V HH Chimeric fusion proteins are provided, which can be antibodies, nanobodies, and alphabodies. In some embodiments, the CD137 agonistic antibody is a human or humanized antibody, or a fragment thereof. In some embodiments, the CD137 agonistic antibody is urelumumab or a fragment thereof. As used herein, the antibody comprises a CD137-binding extracellular domain, including a CD137 agonistic antibody or a fragment thereof, and the antibody is an scFv, bispecific antibody, Fab, Fab fragment, F(ab')2 fragment, monovalent antibody. , scFv fragment, scRv-Fc fragment, IgNAR, hcIgG, V HH Nucleic acid constructs are provided that encode chimeric fusion proteins, which can be antibodies, nanobodies, and alphabodies. Provided herein are chimeric fusion proteins comprising a CD137-binding extracellular domain comprising CD137L or a fragment thereof. In some embodiments, therapeutic cells are produced by expressing the full-length CD137L protein, which can be expressed in cells such as bone marrow cells such that the cells bind to and activate lymphocytes. It can be done. In some embodiments, therapeutic cells can be created by designing and expressing CFP that expresses at least one extracellular fragment of CD137L. In some embodiments, a CFP that includes CD137L as an extracellular domain may further include an intracellular domain of CD137L. The CFP described in this paragraph may be used for any therapeutic purpose that stimulates an immune response when administered to a subject as a therapeutic cell expressing CFP or a nucleic acid construct encoding CFP. In this case, the nucleic acid construct is taken up by cells in vivo and administered such that the cells express CFP. In some embodiments, the nucleic acid construct that is administered may include a targeting moiety to a target and can be taken up by specific cell types or specific tissues. In some embodiments, the nucleic acid construct may encode an extracellular protein that includes a CD137 binding domain, such as an extracellular soluble protein. In some embodiments, the CFP that includes a CD137 binding domain is an extracellular soluble protein that functions as an immunostimulatory CD137 agonistic protein, and thus, when administered and expressed in a subject in vivo, Can activate lymphocytes. In some embodiments, the chimeric fusion protein is a receptor protein. Thus, a CFP receptor that includes a CD137-binding extracellular domain includes a transmembrane domain and, optionally, an intracellular domain. Cells expressing fusion proteins having CD137 agonist binding domains and / or transmembrane domains can be used to activate T lymphocytes and activate anti-tumor responses in vivo.
[0272]
[0359] In some embodiments, CD137 binding fusion proteins can be designed and expressed in bone marrow cells, such as DC cells, to create DC vaccines, such as anti-cancer DC vaccines. Provided herein are bone marrow cells (eg, DCs) that express CFP that includes an extracellular domain that includes a CD137 binding ligand, such as human CD137L or a binding fragment thereof.
[0273]
[0360] However, CD137 can also be targeted in CD137-positive cancers such as T-cell lymphomas. CD137-targeted bone marrow cells designed to express the CD137-binding chimeric fusion proteins described herein act as potent, safe, and effective tumor-killing agents in CD137+ tumors. It can be used for adoptive cell therapy in T-cell lymphoma as well as other cancers, such as lung cancer, pancreatic cancer, leukemia, and other cancers.
[0274]
[0361] In some embodiments, the chimeric fusion proteins described herein are targeted to bind to the CD137 receptor on lymphocytes and NK cells. Once expressed in appropriate bone marrow cells, further curing of the cells under appropriate culture conditions for a limited period of time allows for the creation of killer bone marrow cells and ex vivo development of the cells as therapeutic agents. becomes possible. The killer myeloid cells described herein that express CD137-binding CFP can be used for treatment in subjects who have a CD137 cell malignancy or who may have a disease or condition resulting from CD137 cell function. sell.
[0275]
[0362] In some embodiments, the chimeric fusion proteins described herein are expressed in vivo by a suitable cell upon uptake of the nucleic acid; A therapeutic agent that can be administered in the form of a nucleic acid construct in a therapeutic composition such that the cell can bind to a cell that expresses CD137. Additional domains (e.g., intracellular signaling domains) within the CD137-binding CFP fusion protein render the cells in which the protein is expressed potently cytotoxic, e.g., cells with enhanced phagocytic activity, thereby , cells expressing the protein can be "attack cells" or killer cells, targeted for destruction of cells expressing CD137, such as lymphocytes or NK cells.
[0276]
[0363] In some embodiments, the CD137-binding chimeric fusion protein can include a heterologous transmembrane domain and / or one or more heterologous intracellular domains, so as to create potent immunoreactive cells. , in appropriate cells, such as bone marrow cells. In some embodiments, binding of CFP with a CD137 binding agent causes a phagocytic response, an inflammatory response, and / or Activate the intracellular domain of the chimeric fusion protein (receptor), which activates the cytotoxic response. Examples of target cells expressing CD137 can be lymphocytes, such as T lymphocytes or NK cells, in CD137-positive cell cancers, such as lung cancer, leukemia, pancreatic cancer, colorectal cancer, and lymphoma.
[0277]
[0364] In some embodiments, CD137-binding CFP is directed to appropriate cells such that CD137-expressing cells can act as modulators of the immune response by binding to and killing activated CD137+ lymphocytes. (eg, bone marrow cells). In such embodiments, CD137-targeted CFP is used therapeutically to reduce an activated immune response, such as an alloimmune response.
[0278]
[0365] In some embodiments, killer cells, such as activated phagocytes, engineered to express anti-CD137 extracellular portions can be used as adjunctive therapy to some non-autologous cell-based immunotherapies. Such combination therapy can be used to treat a wide variety of cancers, including but not limited to melanoma, glioblastoma, sarcoma, renal cell carcinoma, ovarian cancer, lung cancer, pancreatic cancer, breast cancer, and many other cancers. It can be used in cancer.
[0279]
[0366] In some embodiments, the CD137-targeting CFP nucleic acid construct is incorporated into bone marrow cells to express CFP, and the bone marrow cells expressing CD137-binding CFP are CAR-expressing cells have been shown to reduce CD5, CD19-expressing tumor-suppressive lymphocytes and enhance the tumor-killing function of cancer-targeting CAR-expressing cells (CAR-P or CAR-T). , targeting cancer antigens other than CD137, such as CD40, can be used as helper cells in CAR-P (e.g., phagocytes expressing CAR or CFP) therapy, or CAR-T (CAR-expressing T cell) therapy. . Thus, CD137-binding CFP is a cytotoxic cell in which the helper cell has been incorporated with a nucleic acid construct encoding CD137-binding CFP, and the cell expresses the extracellular domain of CFP, which is a CD137-binding agent. It can be used to develop helper cells for co-administration in any adoptive cell therapy. Cells expressing the CD137 binding agent CFP can be bone marrow cells. Cells expressing the CD137 binding agent CFP can be phagocytic myeloid cells. Cells expressing the CD137 binding agent CFP can be lymphoid cells. Cells expressing the CD137 binding agent CFP can be cytotoxic cells.
[0280]
[0367] In some embodiments, CD137-binding CFP allows CD137-expressing cells to act as modulators of immune responses, such as in allogeneic cell therapy responses, host versus graft disease, or autoimmune diseases or conditions. may be expressed in appropriate cells (eg, bone marrow cells). For example, CD137-binding CFP is a cognate cell in which CAR-P or CAR-T targets diseased cells such as cancer cells that express cancer antigens other than CD137, such as CD5, CD19, and CD40. -Can be used in combination with P therapy or CAR-T therapy. In some embodiments, the CD137-binding CFP is a cytotoxic cell in which the helper cell comprises CD137-binding CFP and expresses an extracellular domain of CFP that is a CD137-binding agent. It can be used to develop helper cells for co-administration in therapy. Cells expressing the CD137 binding agent CFP can be bone marrow cells. Cells expressing the CD137 binding agent CFP can be phagocytic myeloid cells. Cells expressing the CD137 binding agent CFP can be lymphoid cells. Cells expressing the CD137 binding agent CFP can be cytotoxic cells.
[0281]
[0368] In some embodiments, CD137-targeted CFP is expressed in bone marrow cells and can be used with CART therapy, where the CART cells can be allogeneic or autologous. In some embodiments, CD137-targeted CFP is expressed within bone marrow cells and can be used with CART therapy to target cancer cells other than CD137+ cells, where CART cells are In some cases, autologous cells may be used. In some embodiments, CD137-targeted CFP is expressed within bone marrow cells and may be used with CART therapy, where the CART cells and / or bone marrow cells may be allogeneic or autologous. In some cases. In some embodiments, the cells expressing CD137-targeted CFP can be allogeneic or autologous compared to the subject to which the cells are administered therapeutically.
[0282]
[0369] In some embodiments, a CD137-targeted CFP can include a CD137-binding extracellular domain comprised of a CD137 agonist antibody or fragment thereof. In some embodiments, the CD137 binding extracellular domain comprised of a CD137 agonist antibody or fragment thereof can include an scFv, VHH, diabody, bispecific antibody, or a ligand for CD137 or a fragment thereof. In some embodiments, the CD137-targeting CFP is transmembrane derived from the transmembrane domain of CD3z, CD2, CD8α, CD28, CD68, FcgR, FcG, FcRgamma, FcRalpha, or any other suitable domain. It may further include a domain (TMD). In some embodiments, the CD137-targeting CFP described above can further include an intracellular domain that includes one or more signaling domains. In some embodiments, the CD137-targeting CFP is a PI3K recruitment domain, a scavenger receptor intracellular signaling domain, a CD40 intracellular domain, an FcR-derived signaling domain, a TLR intracellular domain, a NLRP3 intracellular domain, a CD3-derived It can include intracellular domains, and intracellular domains derived from other intracellular domains. In Tables 1 and 4, this disclosure lists sequence information for various individual domains described in various embodiments herein, but various combinations of these It is within the scope of this disclosure that the information can be incorporated into a single biomolecule to develop chimeric fusion proteins using molecular biology methods known in the art. is assumed.
[0283]
[0370] In some embodiments, the chimeric fusion protein (CFP) has an extracellular domain (ECD) targeted to bind to CD137 and comprises an amino acid sequence of SEQ ID NO: 31, or at least 80 amino acids relative to SEQ ID NO: 31. %, 85%, 90%, 95%, 96%, 97%, 98%, 99% sequence identity. MEFGLSWLFLVAILKGVQCGLLDLRQGMFAQLVAQNVLLIDGPLSWYSDPGLAGVSLTGGLSYKEDTKELVVAKAGVYYVFFQLELRRVVAGEGSGSVSLALHLQPLRSAAGAAALALTVDLPPASSEARNSAFGFQGRLLHLSAGQRLGVHLHTEARARHAWQLTQGATVLGLFRVTPEIPAGLPSPRSE (SEQ ID NO: 31).
[0284]
[0371] In one aspect, a chimeric fusion protein can include a soluble protein that has a binding domain that binds CD137. In one embodiment, the chimeric fusion protein has at least one binding domain that binds to CD137 and one or more additional binding domains, at least one of which binds to a cell surface molecule on a bone marrow cell. A soluble protein having a domain. In some embodiments, the chimeric fusion protein includes a binding domain that can bind to CD137 and a binding domain that can bind to a cell surface molecule on a bone marrow cell. In some embodiments, the chimeric fusion protein includes a binding domain that can bind to CD137 and a binding domain that can bind to a cell surface molecule on a bone marrow cell. In some embodiments, the CFP also comprises a third binding domain, or any number of additional binding domains, that binds to a third extracellular moiety, or an additional extracellular moiety, in which case: The extracellular portion may be a cell surface molecule or a soluble component within the extracellular environment. In some embodiments, a chimeric fusion protein described herein may be referred to as a bispecific engager (e.g., bispecific myeloid cell engager: BiME), in which Specificity engagers include two "engager" parts, where the engager parts are binding domains for two different targets, and the first binding domain is a binding domain for two different targets, e.g. It binds to CD137 on any CD137+ cell, such as on a NK cell or on a cancer cell, and the second binding domain binds to a surface molecule on myeloid cells. In some aspects, the chimeric fusion proteins described herein are referred to as trispecific engagers (trispecific myeloid cell engagers, TRiME), in which case the trispecific engagers are It contains three engager moieties, binding domains for three different targets, the first binding domain being binding domains for any CD137+ cell, such as an activated T cell, an activated NK cell, or a CD137-expressing cancer cell. the second binding domain binds to a cell surface molecule on bone marrow cells, the third binding domain binds to a third element, the third element binds to CD137, Or it can be a different cell surface molecule other than the cell surface molecule on bone marrow cells that the second binding domain binds. In some embodiments, the third binding domain binds to a cell surface molecule other than CD137 on CD137+ cells. In some embodiments, the third binding domain binds to a cell surface molecule on the bone marrow cell and binds to a molecule other than the molecule that the second binding domain binds. In some embodiments, BiME or TriME juxtaposes target cells with bone marrow cells such that the bone marrow cells can attack, phagocytose, and lyse the target cells. In some embodiments, engagement of BiME or TRiME to bone marrow cells not only brings the bone marrow cells and target cells into close proximity, but also efficiently engages and brings the target cells into Bone marrow cells may also be activated to kill them efficiently. In some embodiments, the second binding domain and / or the third binding domain described herein activate myeloid cells upon binding. In some embodiments, BiME or TriME is a secreted fusion protein. In some embodiments, the engager, or any binding domain described herein, is an antigen-binding fragment (Fab), a single chain variable fragment (scFv), a nanobody, a V H domain, V L domains, single domain antibodies (sdAbs), VNAR domains, and V HH It may be a domain, a bispecific antibody, a diabody, or a functional fragment of any of these. In some embodiments, the engager can be a ligand, such as the ligand for CD137 (SEQ ID NO: 31), or a fragment thereof, that binds to CD137.
[0285]
[0372] In some embodiments, CFPs that include a binding domain capable of binding to CD137 on tumor cells are designed for use in anti-tumor activity. A recombinant nucleic acid encoding a fusion protein containing a binding domain capable of binding to CD137 is expressed in bone marrow cells, where the chimeric fusion protein is a transmembrane protein and the bone marrow cells , are phagocytic cells; upon engagement of CFP to CD137, a target expressed on a cell, e.g., a tumor cell, the myeloid cell is activated and phagocytizes the target cell, e.g., a tumor cell; It lyses, thereby slowing or stalling tumor growth, reducing tumor size, and / or causing tumor disappearance.
[0286]
[0373] In some embodiments, CFP comprising a binding domain capable of binding CD137 on activated CD137-expressing cells is associated with host-versus-graph-disease (HVGD), Alternatively, they are designed for use in immunosuppression, such as in the treatment of allo-reactions, or conditions associated with acute or persistent severe inflammation. In some embodiments, the CD137 expressing cells are activated T cells or activated NK cells. In some embodiments, the ligand for CD137 or a fragment thereof on the extracellular domain of CFP, which is expressed in bone marrow cells, upon binding to CD137 on activated T cells or activated NK cells, Activates cells, activates phagocytosis, lyses activated T cells or activated NK cells, and reduces inflammation.
[0287]
[0374] Some embodiments herein describe therapeutic agents, such as pharmaceutical compositions, where the pharmaceutical composition comprises (i) a CFP comprising a binding domain capable of binding CD137; ii) a recombinant nucleic acid encoding a CFP that includes a binding domain that is capable of binding CD137; or (iii) a cell that expresses a CFP that includes a binding domain that is capable of binding CD137. .
[0288]
[0375] In some embodiments, a CFP comprising a binding domain capable of binding CD137; a recombinant nucleic acid encoding a CFP comprising a binding domain capable of binding CD137; The described pharmaceutical composition; or a therapeutic agent, such as a cell expressing a CFP containing a binding domain capable of binding to CD137, comprises (i) one or more additional CFPs; or (ii) one or (iii) each of a cell expressing one or more additional CFPs, or any combination thereof. By way of example for the above, the pharmaceutical compositions described herein comprising bone marrow cells expressing CFP that include a binding domain capable of binding to CD137, CD5, or It may be used in combination with bone marrow cells expressing CFP containing a binding domain that is capable of binding any other binding domain described elsewhere herein. Similarly, any combination of the compositions described herein, combined or mixed in a therapeutic agent, is contemplated and would be within the scope of this disclosure.
[0289] CD70 binding protein and CD70 binding domain
[0376] CD70 is commonly used in colorectal cancer (CRC), lung cancer, T-cell lymphoma, glioma, thyroid cancer, head and neck cancer, gastric cancer, liver cancer, pancreatic cancer, urothelial cancer, ovarian cancer, and may be highly expressed in certain cancers, including but not limited to melanoma. Provided herein are chimeric fusion proteins capable of binding to CD70 on cancer cells and designed for therapeutic use against diseases involving overexpression of CD70, such as cancer.
[0290]
[0377] In one aspect herein, a chimeric fusion protein is provided that has an extracellular binding domain capable of binding CD70 (CD70 binding agent CFP). In some embodiments, the CD70 binding agent CFP comprises an extracellular binding domain having an amino acid sequence of SEQ ID NO: 32, or a sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 32. sell. CD70-binding domains can be antigen-binding fragments (Fab), single-chain variable fragments (scFv), nanobodies, V H domain, V L domains, single domain antibodies (sdAbs), VNAR domains, and V HH domains, bispecific antibodies, diabodies, or functional fragments of any of these.
[0291]
[0378] In some embodiments, the extracellular domain further comprises a hinge domain derived from CD8, where the hinge domain is operably linked on the cytoplasmic side to a transmembrane domain and on the extracellular side that binds CD70. operably linked to the sex domain. In some embodiments, the transmembrane domain comprises a sequence set forth in any one of SEQ ID NO: 15, 16, 17, 18, or 19. In some embodiments, the transmembrane domain comprises sequences derived from the CD8 alpha (CD8a) transmembrane domain. In some embodiments, the transmembrane domain is the sequence set forth in SEQ ID NO: 15, or at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93% relative to SEQ ID NO: 15. , 94%, 95%, 96%, 97%, 98%, or 99% sequence identity. In some embodiments, the transmembrane domain is the sequence set forth in SEQ ID NO: 16, or at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93% relative to SEQ ID NO: 16. , 94%, 95%, 96%, 97%, 98%, or 99% sequence identity. In some embodiments, the transmembrane domain comprises sequences derived from the CD2 transmembrane domain. In some embodiments, the transmembrane domain is the sequence set forth in SEQ ID NO: 17, or at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93% relative to SEQ ID NO: 17. , 94%, 95%, 96%, 97%, 98%, or 99% sequence identity. In some embodiments, the transmembrane domain comprises sequences derived from the CD28 transmembrane domain. In some embodiments, the transmembrane domain is the sequence set forth in SEQ ID NO: 18, or at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93% relative to SEQ ID NO: 18. , 94%, 95%, 96%, 97%, 98%, or 99% sequence identity. In some embodiments, the transmembrane domain comprises sequences derived from the CD68 transmembrane domain. In some embodiments, the transmembrane domain is the sequence set forth in SEQ ID NO: 19, or at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93% relative to SEQ ID NO: 19. , 94%, 95%, 96%, 97%, 98%, or 99% sequence identity. In some embodiments, the ECD of CFP is a transmembrane domain selected from any one of the sequences set forth in SEQ ID NO: 15, 16, 17, 18, or 19, or SEQ ID NO: 15, 16. , 17, 18, or 19 at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97 %, 98%, or 99% sequence identity; the amino acid sequence depicted in SEQ ID NO: 32, or at least 70%, 75%, 80% to 32; , 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity.
[0292]
[0379] In some embodiments, the extracellular hinge domain and the transmembrane domain are at least 70%, 75%, 80%, 85% of the sequence of SEQ ID NO: 20 or SEQ ID NO: 21, or each of SEQ ID NO: 20 or SEQ ID NO: 21. , 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity. In some embodiments, the CFP is the transmembrane domain of SEQ ID NO: 20, or at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94% relative to SEQ ID NO: 20. , an extracellular domain fused to a transmembrane domain with 95%, 96%, 97%, 98%, or 99% sequence identity. In some embodiments, the CFP is the transmembrane domain of SEQ ID NO: 21, or at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94% relative to SEQ ID NO: 21. , an extracellular domain fused to a transmembrane domain with 95%, 96%, 97%, 98%, or 99% sequence identity. In some embodiments, the CFP is at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96% relative to SEQ ID NO: 20 or 21; fused to a hinge domain and a transmembrane domain having amino acid sequences with 97%, 98%, 99%, or 100% sequence identity; at least 70%, 75%, 80%, 85 to SEQ ID NO: 32. %, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity.
[0293]
[0380] In some embodiments, the CFP was operably linked to a transmembrane domain comprising the sequence of a CD16 transmembrane domain (e.g., including a short hinge domain) set forth in Table 4; SEQ ID NO: 32 or a sequence having at least 80% sequence identity to the sequence set forth in SEQ ID NO: 32. In some embodiments, the CFP is operably linked to a transmembrane domain comprising a CD64 transmembrane domain sequence; % sequence identity. In some embodiments, the CFP was operably linked to a transmembrane domain comprising the sequence of a CD89 transmembrane domain (e.g., including a short hinge domain) set forth in Table 4; SEQ ID NO: 32 It contains an extracellular domain containing the sequence shown in . In some embodiments, the CFP is an ECD with the sequence set forth in SEQ ID NO: 32, or a sequence having at least 80% sequence identity to the sequence set forth in SEQ ID NO: 32; a transmembrane domain of the CD16 protein; or a transmembrane domain comprising a sequence derived from the TMD of the CD64 protein, or the TMD of the CD89 protein; and optionally in addition to other distinct ICDs described herein, e.g., CD16 protein, CD64 protein, or the corresponding intracellular domain (ICD) or portion thereof from each of the CD89 proteins. Exemplary ICD sequences for CD16 and CD89 are presented in Table 4.
[0294]
[0381] In some embodiments, the CFP comprises one or more intracellular signaling domains, including one intracellular signaling domain. In some embodiments, the intracellular signaling domain comprises a phagocytic signaling domain. In some embodiments, the phagocytic signaling domain comprises an intracellular signaling domain derived from a receptor other than Megf10, MerTk, FcRα, and Bai1. In some embodiments, the phagocytic signaling domain comprises an intracellular signaling domain derived from a receptor other than Megf10, MerTk, FcR, and Bai1. In some embodiments, the intracellular signaling domain comprises a domain derived from a receptor other than CD3ζ. In some embodiments, the phagocytic signaling domain comprises an intracellular signaling domain derived from FcRγ, FcRα, or FcRε.
[0295]
[0382] In some embodiments, the CFP is any one of SEQ ID NO: 22, 23, 24, or 25, or at least 70% relative to any one of SEQ ID NO: 22, 23, 24, or 25. , 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity. It contains an intracellular signaling domain derived from the FcR gamma protein (FcRγ chain). In some embodiments, the one or more intracellular signaling domains further include a pro-inflammatory signaling domain. In some embodiments, the pro-inflammatory signaling domain comprises a PI3 kinase (PI3K) recruitment domain. In some embodiments, the pro-inflammatory signaling domain is the sequence of SEQ ID NO: 26, or at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93% relative to SEQ ID NO: 26. , 94%, 95%, 96%, 97%, 98%, or 99% sequence identity. In some embodiments, the pro-inflammatory signaling domain is derived from the intracellular signaling domain of CD40. In some embodiments, the pro-inflammatory signaling domain is the sequence of SEQ ID NO: 27, or at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93% relative to SEQ ID NO: 27. , 94%, 95%, 96%, 97%, 98%, or 99% sequence identity. In some embodiments, the CFP is the sequence of SEQ ID NO: 28, or at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95% relative to SEQ ID NO: 28. %, 96%, 97%, 98%, or 99% sequence identity. In some embodiments, the CFP is the sequence of SEQ ID NO: 29, or at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95% relative to SEQ ID NO: 29. %, 96%, 97%, 98%, or 99% sequence identity. In some embodiments, the CFP is the sequence of SEQ ID NO: 30, or at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95% relative to SEQ ID NO: 30. %, 96%, 97%, 98%, or 99% sequence identity.
[0296]
[0383] Provided herein is a recombinant nucleic acid encoding a CFP comprising a CD70 binding domain (CD70 binding agent) as described above, which can be expressed in a suitable cell, such as a bone marrow cell. Bone marrow cells can be phagocytes. In some embodiments, the CD70-binding agent activates bone marrow cells that express CD70-binding CFP upon binding to CD70 on the cell. Provided herein is a recombinant nucleic acid sequence encoding a chimeric CD70-binding receptor fusion protein (CFP), referred to as CD70-CFP, as used herein. In some embodiments, a recombinant nucleic acid encoding a chimeric receptor fusion protein, eg, a CD70-binding receptor fusion protein, can be expressed in appropriate cells, such as bone marrow cells. In some embodiments, once CD70-CFP is expressed on appropriate cells, such as bone marrow cells, the CD70-binding agent is capable of binding to target cells that express CD70 and express the binding agent. bone marrow cells are activated. In some embodiments, CD70-CFP, upon engagement with CD70, activates the intracellular signaling domain of CD70-CFP, which activates myeloid cells expressing recombinant nucleic acid encoding CD70-CFP. become In some embodiments, the bone marrow cells are phagocytes. In some embodiments, a bone marrow cell that is a phagocytic cell and expresses a CD70 binding agent is activated and activated when the CD70 binding agent binds to CD70 expressed on another cell (target cell). It is possible to devour. In some embodiments, the target cell can be any cell that expresses CD70. In some embodiments, the target cells are lymphocytes. In some embodiments, the target cells are T lymphocytes (T cells). In some embodiments, the target cell can be a malignant cell. In some embodiments, the target cell can be a malignant T cell. In some embodiments, bone marrow cells expressing CD70-binding CFP can be used to create therapeutic compositions for T-cell lymphoma.
[0297]
[0384] In another embodiment, provided herein is a recombinant protein, such as an extracellular protein, such as a soluble protein, that can bind to the extracellular domain of CD70. In some embodiments, a chimeric fusion protein described herein, such as a soluble protein, may be referred to as a bispecific engager (e.g., bispecific myeloid cell engager: BiME); In this case, the bispecific engager comprises two "engager" parts, where the engager parts are binding domains for two different targets, and the first binding domain is for activated T cells, for example. The second binding domain binds to surface molecules on bone marrow cells, such as on activated NK cells or on cancer cells. In some aspects, the chimeric fusion proteins described herein are referred to as trispecific engagers (trispecific myeloid cell engagers, TRiME), in which case the trispecific engagers are It contains three engager moieties, binding domains for three different targets, the first binding domain binding to CD70. In some embodiments, the recombinant extracellular protein (BiME or TRiME) having a domain capable of binding CD70 further comprises a second domain capable of binding to a surface protein of myeloid cells, such as phagocytes. The surface protein of a bone marrow cell can be a protein expressed on the membrane of a bone marrow cell, such as a phagocytic receptor, a pattern recognition molecule, or a scavenger receptor. Provided herein are recombinant nucleic acids encoding extracellular proteins, such as soluble proteins capable of binding to the extracellular domain of CD70, as described herein.
[0298]
[0385] Provided herein is a therapeutic agent for treating a disease in a subject, wherein the disease is associated with CD70 protein overexpression and which binds to CD70, such as any of the CD70 binding proteins described above. A therapeutic agent is provided that includes at least one recombinant protein having an extracellular binding domain that can bind to the protein. In some embodiments herein, cells expressing a CD70 binding protein are provided. In some embodiments herein, a therapeutic agent for treating a disease in a subject, wherein the disease is associated with CD70 overexpression, at least A therapeutic agent comprising a recombinant nucleic acid is provided. In some embodiments herein, a therapeutic agent for treating a disease in a subject, wherein the disease is associated with CD70 protein overexpression and encodes a CD70 binding agent as described herein. A therapeutic agent comprising a cell comprising a recombinant nucleic acid is provided. In some embodiments, the cells are bone marrow cells. In some embodiments, the disease is cancer, eg, T-cell lymphoma or colorectal cancer (CRC).
[0299]
[0386] An exemplary CD70 binding agent sequence is SEQ ID NO: 32: QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMGWINTYTGEPTYADAFKGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARDYGDYGMDYWGQGTTVTVSSGSTSGSGKPGSSEGSTKGDIVMTQSPDSLAVSLGERATINCRASKSVSTSGYSFMHWYQQKPGQPPKLLIYLASNLESGVPDRFSGSGSGTDFTLT ISSLQAEDVAVYYCQHSREVPWTFGQGTKVEIK (SEQ ID NO: 32) It is.
[0300]
[0387] In some embodiments, the chimeric fusion protein (CFP) has the amino acid sequence of SEQ ID NO: 32, or at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% relative to SEQ ID NO: 32. % sequence identity, an extracellular domain (ECD) targeted to bind to CD70.
[0301] claudin 18.2 binding protein and claudin 18.2 binding domain, and claudin 3 binding protein and claudin 3 binding domain
[0388] The claudin family of proteins are components of tight junctions, which establish paracellular barriers that control the flow of molecules between cells. The transmembrane domain of claudin includes the cytoplasmic, N-terminus and C-terminus. Claudin proteins exhibit tissue-specific expression and alterations in their function are often associated with cancers in specific tissues. Claudin-1 expression has been shown to have prognostic value in colon cancer. Claudin-1 is a strong prognostic indicator in stage II colon cancer, and claudin-18 is a strong prognostic indicator in gastric cancer. In gastric cancer with intestinal phenotype, downregulation of the claudin-18 gene is supported through serial analysis of gene expression data, and in hepatocellular carcinoma, downregulation of claudin-10 is supported. The surface protein claudin represents a useful target for a variety of therapeutic strategies.
[0302]
[0389] Claudin 18 isoform 2 (claudin 18.2) is a highly selective lineage marker. Claudin-18 splice variant 2 is a pan-cancer target amenable to the development of therapeutic antibodies, exhibiting a highly restricted expression pattern in normal tissues, while in gastric, ovarian, and pancreatic cancers. A variety of human cancers, including cancer, are associated with a high frequency of ectopic activation.
[0303]
[0390] Claudin-3 is expressed within tight junctions and has been shown to be regulated during tumorigenesis in numerous organs and tissues, including the mammary gland, ovary, uterus, prostate, and esophagus. Overexpression of claudin 3 increased transepithelial resistance, as measured by paracellular resistance, whereas transcellular resistance was not significantly altered. Overexpression of claudin-3 results in reduced permeability to both sodium and chloride, and expression of the Claudin 3 molecule is associated with ovarian cancer tissue, prostate cancer tissue, breast cancer tissue, uterine cancer tissue, and liver cancer tissue. It is elevated in many cancer tissues, including cancer, lung, pancreatic, stomach, bladder, and colon cancer tissues. Expression of Claudin 3 and Claudin 4 has been shown to be particularly elevated in chemotherapy-resistant uterine cancer. Claudin 3 is a protein with four transmembrane domains, and has a structure that exposes two peptide loops to the outside of the cell.
[0304]
[0391] In one aspect herein, a chimeric fusion protein is provided that has an extracellular binding domain capable of binding claudin 18.2 (Claudin 18.2 binding agent, CFP).
[0305]
[0392] In another aspect, provided herein are chimeric fusion proteins having an extracellular binding domain capable of binding claudin 3.0.
[0306]
[0393] In one embodiment, the extracellular binding domain comprises an scFv specific for human claudin 18.2, or a fragment thereof. In some embodiments, the ECD of the chimeric fusion receptor protein comprises a binding domain that binds to the extracellular loop of Claudin 18.2 on the target cell.
[0307]
[0394] In some embodiments, an exemplary Claudin 18.2 binding domain has the sequence of SEQ ID NO: 33; or at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% to SEQ ID NO: 33. may contain sequences having sequence identity of . QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGYNWHWIRQPPGKGLEWIGYIHYTGSTNYNPALRSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARIYNGNSFPYWGQGTTVTVSSGGGGSGGGGSGGGGSDIVMTQSPDSLAYSLGERATINCKSSQSLFNSGNQKNYLTWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGS GTDIFITISSLQAEDVAVYYCQNAYSFPYTFGGGTKLEIKR (SEQ ID NO: 33)
[0395] In some embodiments, the chimeric fusion protein (CFP) has the amino acid sequence of SEQ ID NO: 33, or at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% relative to SEQ ID NO: 33. contains an extracellular domain (ECD) targeted to bind to Claudin 18.2, containing sequences with % sequence identity.
[0308]
[0396] In some embodiments, the CFP was operably linked to a TM domain comprising the sequence of a CD16 transmembrane domain (e.g., including the short hinge domain) set forth in Table 4; 33. In some embodiments, the CFP is operably linked to a TM domain comprising a CD64 transmembrane domain sequence; the sequence set forth in SEQ ID NO:33, or at least 80% relative to the sequence set forth in SEQ ID NO:33. contains an extracellular domain containing sequences with sequence identity of . In some embodiments, the CFP was operably linked to a TM domain comprising the sequence of a CD89 transmembrane domain (e.g., including the short hinge domain) set forth in Table 4; Contains an extracellular domain containing the indicated sequences. In some embodiments, the CFP is an ECD with the sequence set forth in SEQ ID NO: 33, or a sequence having at least 80% sequence identity to the sequence set forth in SEQ ID NO: 33; the TM domain of the CD16 protein; or a TM domain comprising a sequence derived from the TMD of the CD64 protein, or the TMD of the CD89 protein; and optionally in addition to other distinct ICDs described herein, e.g., CD16 protein, CD64 protein, or the corresponding intracellular domain (ICD) or portion thereof derived from each of the CD89 proteins. Exemplary ICD sequences for CD16 and CD89 are presented in Table 4.
[0309]
[0397] In one embodiment, the extracellular binding domain comprises an scFv specific for human claudin 3.0. In some embodiments, the extracellular binding domain comprises a claudin 3 binding domain comprising the sequence shown in Table 2. Table 2 shows exemplary sequences of human claudin 3.0 binding domains and / or fragments thereof, the disclosure of which is intended to be non-limiting.
[0310] [Table 2-1]
[0311] [Table 2-2]
[0312] [Table 2-3]
[0398] The claudin 3 binding domain may comprise one or more of the sequences according to Table 2. In some embodiments, the claudin 3 binding domain comprises a ScFv comprising the sequence of Table 2. In some embodiments, the binding domain is an antigen binding fragment (Fab), single chain variable fragment (scFv), nanobody, VH domain, VL domain, single domain antibody (sdAb) comprising the sequence of Table 2. ), VNAR domains, and VHH domains, bispecific antibodies, diabodies, or functional fragments of any of these. In some embodiments, antigen-binding fragments (Fabs), single chain variable fragments (scFvs), nanobodies, VH domains, VL domains, single domain antibodies (sdAbs), VNAR domains, and VHH domains, bispecific An antibody, diabody, or functional fragment of any of these specifically binds one or more antigens.
[0313]
[0399] In some embodiments, the chimeric fusion protein comprises an extracellular binding domain, such as an antigen binding domain; the extracellular binding domain may bind to the claudin 18.2 protein described herein; may bind to the claudin 3 proteins described herein; further includes a transmembrane domain, with or without a hinge domain, between the extracellular antigen-binding domain and the intracellular domain. A receptor that may contain a sequence that may contain. In some embodiments, the extracellular domain further comprises a hinge domain derived from CD8, where the hinge domain is operably linked to a transmembrane domain on the cytoplasmic side and Claudin 18.2 on the extracellular side. operably linked to a binding domain. In some embodiments, the transmembrane domain comprises a sequence set forth in any one of SEQ ID NO: 15, 16, 17, 18, or 19. In some embodiments, the transmembrane domain comprises sequences derived from the CD8 alpha (CD8a) transmembrane domain. In some embodiments, the transmembrane domain is the sequence set forth in SEQ ID NO: 15, or at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93% relative to SEQ ID NO: 15. , 94%, 95%, 96%, 97%, 98%, or 99% sequence identity. In some embodiments, the transmembrane domain is the sequence set forth in SEQ ID NO: 16, or at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93% relative to SEQ ID NO: 16. , 94%, 95%, 96%, 97%, 98%, or 99% sequence identity. In some embodiments, the transmembrane domain comprises sequences derived from the CD2 transmembrane domain. In some embodiments, the transmembrane domain is the sequence set forth in SEQ ID NO: 17, or at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93% relative to SEQ ID NO: 17. , 94%, 95%, 96%, 97%, 98%, or 99% sequence identity. In some embodiments, the transmembrane domain comprises sequences derived from the CD28 transmembrane domain. In some embodiments, the transmembrane domain is the sequence set forth in SEQ ID NO: 18, or at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93% relative to SEQ ID NO: 18. , 94%, 95%, 96%, 97%, 98%, or 99% sequence identity. In some embodiments, the transmembrane domain comprises sequences derived from the CD68 transmembrane domain. In some embodiments, the transmembrane domain is the sequence set forth in SEQ ID NO: 19, or at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93% relative to SEQ ID NO: 19. , 94%, 95%, 96%, 97%, 98%, or 99% sequence identity. In some embodiments, the ECD of CFP is a transmembrane domain selected from any one of the sequences set forth in SEQ ID NO: 15, 16, 17, 18, or 19, or SEQ ID NO: 15, 16. , 17, 18, or 19 at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97 %, 98%, or 99% sequence identity; to the amino acid sequences depicted in the sequences in Table 2, or to any of the sequences in Table 2. Sequences with 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity include.
[0314]
[0400] In some embodiments, the extracellular hinge domain and the transmembrane domain are at least 70%, 75%, 80%, 85% of the sequence of SEQ ID NO: 20 or SEQ ID NO: 21, or each of SEQ ID NO: 20 or SEQ ID NO: 21. , 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity. In some embodiments, the CFP is the transmembrane domain of SEQ ID NO: 20, or at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94% relative to SEQ ID NO: 20. , an extracellular domain fused to a transmembrane domain with 95%, 96%, 97%, 98%, or 99% sequence identity. In some embodiments, the CFP is the transmembrane domain of SEQ ID NO: 21, or at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94% relative to SEQ ID NO: 21. , an extracellular domain fused to a transmembrane domain with 95%, 96%, 97%, 98%, or 99% sequence identity. In some embodiments, the CFP is at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96% relative to SEQ ID NO: 20 or 21; fused to a hinge domain and a transmembrane domain having amino acid sequences with 97%, 98%, 99%, or 100% sequence identity; at least 70%, 75 to any of the sequences in Table 2 %, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity. including.
[0315]
[0401] In some embodiments, the CFP comprises one or more intracellular signaling domains, including one intracellular signaling domain. In some embodiments, the intracellular signaling domain comprises a phagocytic signaling domain. In some embodiments, the phagocytic signaling domain comprises an intracellular signaling domain derived from a receptor other than Megf10, MerTk, FcRα, and Bai1. In some embodiments, the phagocytic signaling domain comprises an intracellular signaling domain derived from a receptor other than Megf10, MerTk, FcR, and Bai1. In some embodiments, the intracellular signaling domain comprises a domain derived from a receptor other than CD3ζ. In some embodiments, the phagocytic signaling domain comprises an intracellular signaling domain derived from FcRγ, FcRα, or FcRε.
[0316]
[0402] In some embodiments, the CFP is any one of SEQ ID NO: 22, 23, 24, or 25, or at least 70% relative to any one of SEQ ID NO: 22, 23, 24, or 25. , 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity. contains an intracellular signaling domain derived from the FcR gamma protein (FcRγ chain). In some embodiments, the one or more intracellular signaling domains further include a pro-inflammatory signaling domain. In some embodiments, the pro-inflammatory signaling domain comprises a PI3 kinase (PI3K) recruitment domain. In some embodiments, the pro-inflammatory signaling domain is the sequence of SEQ ID NO: 26, or at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93% relative to SEQ ID NO: 26. , 94%, 95%, 96%, 97%, 98%, or 99% sequence identity. In some embodiments, the pro-inflammatory signaling domain is derived from the intracellular signaling domain of CD40. In some embodiments, the pro-inflammatory signaling domain is the sequence of SEQ ID NO: 27, or at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93% relative to SEQ ID NO: 27. , 94%, 95%, 96%, 97%, 98%, or 99% sequence identity. In some embodiments, the CFP is the sequence of SEQ ID NO: 28, or at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95% relative to SEQ ID NO: 28. %, 96%, 97%, 98%, or 99% sequence identity. In some embodiments, the CFP is the sequence of SEQ ID NO: 29, or at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95% relative to SEQ ID NO: 29. %, 96%, 97%, 98%, or 99% sequence identity. In some embodiments, the CFP is the sequence of SEQ ID NO: 30, or at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95% relative to SEQ ID NO: 30. %, 96%, 97%, 98%, or 99% sequence identity.
[0317]
[0403] Provided herein is a recombinant nucleic acid encoding a CFP comprising a Claudin 18.2 binding domain (Claudin 18.2 binding agent) as described above, which can be expressed in a suitable cell, such as a bone marrow cell. Bone marrow cells can be phagocytes. In some embodiments, the Claudin 18.2 binding agent activates myeloid cells expressing Claudin 18.2-binding CFP upon binding to Claudin 18.2 on the cell. Provided herein are recombinant nucleic acid sequences encoding chimeric Claudin 18.2 binding receptor fusion proteins (CFP). In some embodiments, a recombinant nucleic acid encoding a chimeric receptor fusion protein, eg, a Claudin 18.2 binding receptor fusion protein, can be expressed in a suitable cell, such as a bone marrow cell. In some embodiments, when Claudin 18.2-CFP is expressed on appropriate cells, such as bone marrow cells, the Claudin 18.2 binding agent is capable of binding to the target cell expressing Claudin 18.2, and the binding Bone marrow cells expressing the agent are activated. In some embodiments, Claudin 18.2-CFP activates the intracellular signaling domain of Claudin 18.2-CFP upon engagement with Claudin 18.2, which expresses a recombinant nucleic acid encoding Claudin 18.2-CFP. Activates bone marrow cells. In some embodiments, the bone marrow cells are phagocytes. In some embodiments, a myeloid cell that is a phagocytic cell and expresses a CD137 binding agent is activated when the Claudin 18.2 binding agent binds to Claudin 18.2 expressed on another cell (target cell); It is possible to phagocytose target cells. In some embodiments, the target cell can be any cell that expresses Claudin 18.2. In some embodiments, the target cells are lymphocytes. In some embodiments, the target cells are T lymphocytes (T cells). In some embodiments, the target cell can be a malignant cell. In some embodiments, the target cell can be a malignant T cell. In some embodiments, bone marrow cells expressing Claudin 18.2-binding CFP can be used to create therapeutic compositions for T-cell lymphoma.
[0318]
[0404] In some embodiments, the chimeric fusion protein that is a claudin 18.2 binding agent is an extracellular protein that includes an antigen binding domain that binds claudin 18.2. Provided herein are recombinant proteins, such as extracellular proteins, such as soluble proteins, capable of binding claudin 18.2. In some embodiments, the extracellular protein comprises an antibody described above, a fragment thereof capable of binding claudin 18.2. In some embodiments, the extracellular or soluble protein further comprises a second domain that can bind to surface proteins of myeloid cells, such as phagocytes. The surface protein of a bone marrow cell can be a protein expressed on the membrane of a bone marrow cell, such as a phagocytic receptor, a pattern recognition molecule, or a scavenger receptor.
[0319]
[0405] Provided herein are recombinant nucleic acids encoding extracellular proteins, such as soluble proteins capable of binding to the extracellular domain of claudin 18.2, as described herein.
[0320]
[0406] In some embodiments, the claudin 3 binding agent is an extracellular protein. Provided herein are recombinant proteins, such as extracellular proteins, such as soluble proteins, that can bind claudin 3. In some embodiments, the extracellular protein comprises an antibody of a fragment thereof capable of binding claudin 3, such as any one or more of the sequences depicted in Table 2. In some embodiments, the claudin 3 binding agent extracellular protein further comprises a second domain capable of binding to a surface protein of myeloid cells, such as phagocytes. The surface protein of a bone marrow cell can be a protein expressed on the membrane of a bone marrow cell, such as a phagocytic receptor, a pattern recognition molecule, or a scavenger receptor. Provided herein are recombinant nucleic acids encoding extracellular proteins, such as soluble proteins capable of binding to the extracellular domain of claudin 3, as described herein.
[0321]
[0407] Provided herein is a therapeutic agent for treating a disease in a subject, wherein the disease is associated with claudin protein overexpression, such as claudin 18.2 protein or claudin 3 protein overexpression, and wherein the claudin 18.2 binding protein as described above. or claudin 3 binding protein, the therapeutic agent comprises at least one recombinant protein having an extracellular binding domain capable of binding to claudin 18.2 or claudin 3, respectively. In some embodiments herein, cells expressing claudin 18.2 binding or claudin 3 binding are provided. In some embodiments herein, a therapeutic agent for treating a disease in a subject, wherein the disease is associated with claudin protein overexpression, such as claudin 18.2 protein or claudin 3 protein, A therapeutic agent comprising at least one recombinant nucleic acid encoding a described claudin 18.2 binding agent or claudin 3 binding agent is provided. In some embodiments herein, a therapeutic agent for treating a disease in a subject, wherein the disease is associated with claudin protein overexpression, such as claudin 18.2 protein or claudin 3 protein, A therapeutic agent is provided comprising a cell comprising a recombinant nucleic acid encoding the described claudin 18.2 binding agent or claudin 3 binding agent. In some embodiments, the cells are bone marrow cells.
[0322] TROP2-binding protein and TROP2-binding domain
[0408] TROP2, also known as epithelial glycoprotein 1, gastrointestinal antigen 733-1, membrane component surface marker 1, and tumor-associated calcium signaling factor 2, is the protein product of the TACSTD2 gene. TROP2 is a transmembrane glycoprotein that functions within various cell signaling pathways and was initially elucidated as a mediator of intracellular calcium signals. It has been established that TROP2 expression is dependent on a wide variety of transcription factors. TROP2 regulates proliferation and self-renewal through b-catenin signaling, and TROP2 signaling enhances stem cell-like properties of cancer cells. TROP2 may play a role in tumor progression, given its involvement in several molecular pathways traditionally associated with cancer development. High TROP2 expression is associated with pancreatic cancer, hilar cholangiocarcinoma, cervical cancer, gastric cancer, and other cancers (Fong D et al., Br J Cancer, 2008, 99(8):1290~1295 ;Ning S. et al., J Gastrointest Surg., 2013, 17(2):360~368;Liu T et al., PLoS One, 2013, 8(9):e75864;Zhao W et al., Oncotarget., 2016, 7(5 ):6136-6145) is correlated with poor prognosis. TROP2 is overexpressed on a wide variety of tumors and its expression is upregulated compared to normal cells, so it can be targeted for the development of novel therapeutic agents.
[0323]
[0409] Provided herein are chimeric proteins capable of binding to cancer cells expressing TROP2. Provided herein are chimeric proteins (TROP2 binding agents) that bind to the extracellular domain of TROP2. In some embodiments, the chimeric protein is a chimeric receptor protein with an extracellular protein capable of binding to the extracellular domain, transmembrane domain, and / or cytoplasmic domain of TROP2. In some embodiments, the chimeric protein is a protein that is an extracellular soluble protein that can bind to the extracellular domain of TROP2. In some embodiments, the extracellular soluble chimeric protein that is capable of binding the extracellular domain of TROP2 is capable of binding the extracellular domain of a protein expressed on the surface of bone marrow cells, such as phagocytes. may contain other domains in which it is possible. The chimeric proteins (TROP2 binding agents) described herein are used to prepare therapeutic agents, including pharmaceutical compositions comprising TROP2 binding agents, for treating diseases associated with overexpression of TROP2 protein, such as cancer. It can be used for. Such cancers include, but are not limited to, pancreatic, hilar cholangiocarcinoma, cervical cancer, and gastric cancer.
[0324]
[0410] In one aspect herein, a chimeric fusion receptor (CFP) protein having an extracellular TROP2 binding domain (CFP that is a TROP2 binding agent) is provided. In some embodiments, the extracellular binding domain is an antigen-binding domain of an antibody, or an antigen-binding fragment (Fab) (fragment), single chain variable fragment (scFv), that is capable of binding TROP2. , nanobodies, VH domains, VL domains, single domain antibodies (sdAbs), VNAR domains, and VHH domains, bispecific antibodies, diabodies, or functional fragments of any of these. In some embodiments, antigen-binding fragments (Fabs), single chain variable fragments (scFvs), nanobodies, VH domains, VL domains, single domain antibodies (sdAbs), VNAR domains, and VHH domains, bispecific An antibody, diabody, or functional fragment of any of these specifically binds one or more antigens. In some embodiments, the binding agent is a natural ligand for the TROP2 receptor.
[0325]
[0411] In some embodiments, the extracellular domain further comprises a hinge domain derived from CD8, where the hinge domain is operably linked to a transmembrane domain on the cytoplasmic side and a TROP2-binding domain on the extracellular side. operably linked to the sex domain. In some embodiments, the transmembrane domain comprises a sequence set forth in any one of SEQ ID NO: 15, 16, 17, 18, or 19. In some embodiments, the transmembrane domain comprises sequences derived from the CD8 alpha (CD8a) transmembrane domain. In some embodiments, the transmembrane domain is the sequence set forth in SEQ ID NO: 15, or at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93% relative to SEQ ID NO: 15. , 94%, 95%, 96%, 97%, 98%, or 99% sequence identity. In some embodiments, the transmembrane domain is the sequence set forth in SEQ ID NO: 16, or at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93% relative to SEQ ID NO: 16. , 94%, 95%, 96%, 97%, 98%, or 99% sequence identity. In some embodiments, the transmembrane domain comprises sequences derived from the CD2 transmembrane domain. In some embodiments, the transmembrane domain is the sequence set forth in SEQ ID NO: 17, or at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93% relative to SEQ ID NO: 17. , 94%, 95%, 96%, 97%, 98%, or 99% sequence identity. In some embodiments, the transmembrane domain comprises sequences derived from the CD28 transmembrane domain. In some embodiments, the transmembrane domain is the sequence set forth in SEQ ID NO: 18, or at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93% relative to SEQ ID NO: 18. , 94%, 95%, 96%, 97%, 98%, or 99% sequence identity. In some embodiments, the transmembrane domain comprises sequences derived from the CD68 transmembrane domain. In some embodiments, the transmembrane domain is the sequence set forth in SEQ ID NO: 19, or at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93% relative to SEQ ID NO: 19. , 94%, 95%, 96%, 97%, 98%, or 99% sequence identity. In some embodiments, the ECD of CFP is a transmembrane domain selected from any one of the sequences set forth in SEQ ID NO: 15, 16, 17, 18, or 19, or SEQ ID NO: 15, 16. , 17, 18, or 19 at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97 %, 98%, or 99% sequence identity; to the amino acid sequences depicted in the sequences in Table 2, or to any of the sequences in Table 2. Sequences with 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity include.
[0326]
[0412] In some embodiments, the extracellular hinge domain and the transmembrane domain are at least 70%, 75%, 80%, 85% of the sequence of SEQ ID NO: 20 or SEQ ID NO: 21, or each of SEQ ID NO: 20 or SEQ ID NO: 21. , 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity. In some embodiments, the CFP is the transmembrane domain of SEQ ID NO: 20, or at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94% relative to SEQ ID NO: 20. , an extracellular domain fused to a transmembrane domain with 95%, 96%, 97%, 98%, or 99% sequence identity. In some embodiments, the CFP is the transmembrane domain of SEQ ID NO: 21, or at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94% relative to SEQ ID NO: 21. , an extracellular domain fused to a transmembrane domain with 95%, 96%, 97%, 98%, or 99% sequence identity. In some embodiments, the CFP is at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96% relative to SEQ ID NO: 20 or 21; fused to a hinge domain and a transmembrane domain having amino acid sequences with 97%, 98%, 99%, or 100% sequence identity; at least 70%, 75 to any of the sequences in Table 2 %, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity. including.
[0327]
[0413] In some embodiments, the CFP was operably linked to a TM domain comprising the sequence of a CD16 transmembrane domain (e.g., including a short hinge domain) set forth in Table 4; SEQ ID NO: 34 or The extracellular domain comprises a sequence having at least 80% sequence identity to the sequence set forth in SEQ ID NO: 35, or both, or the sequence set forth in SEQ ID NO: 34 or SEQ ID NO: 35. In some embodiments, the CFP is operably linked to a TM domain comprising a CD64 transmembrane domain sequence; the sequence set forth in SEQ ID NO: 34 or 35; or the sequence set forth in SEQ ID NO: 34 or 35. an extracellular domain containing a sequence with at least 80% sequence identity to. In some embodiments, the CFP was operably linked to a TM domain comprising the sequence of a CD89 transmembrane domain (e.g., including a short hinge domain) set forth in Table 4; SEQ ID NO: 34 or It contains an extracellular domain containing the sequence shown in 35. In some embodiments, the CFP is an ECD with a sequence set forth in SEQ ID NO: 34 or 35, or a sequence having at least 80% sequence identity to the sequence set forth in SEQ ID NO: 34 or 35; a TM domain, or a TM domain comprising a sequence derived from the TMD of the CD64 protein, or the TMD of the CD89 protein; and optionally in addition to other distinct ICDs described herein, e.g., the CD16 protein , the corresponding intracellular domain (ICD) or portion thereof from the CD64 protein, or the CD89 protein, respectively. Exemplary ICD sequences for CD16 and CD89 are presented in Table 4.
[0328]
[0414] In some embodiments, the CFP comprises one or more intracellular signaling domains, including one intracellular signaling domain. In some embodiments, the intracellular signaling domain comprises a phagocytic signaling domain. In some embodiments, the phagocytic signaling domain comprises an intracellular signaling domain derived from a receptor other than Megf10, MerTk, FcRα, and Bai1. In some embodiments, the phagocytic signaling domain comprises an intracellular signaling domain derived from a receptor other than Megf10, MerTk, FcR, and Bai1. In some embodiments, the intracellular signaling domain comprises a domain derived from a receptor other than CD3ζ. In some embodiments, the phagocytic signaling domain comprises an intracellular signaling domain derived from FcRγ, FcRα, or FcRε.
[0329]
[0415] In some embodiments, the CFP is any one of SEQ ID NO: 22, 23, 24, or 25, or at least 70% relative to any one of SEQ ID NO: 22, 23, 24, or 25. , 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity. contains an intracellular signaling domain derived from the FcR gamma protein (FcRγ chain). In some embodiments, the one or more intracellular signaling domains further include a pro-inflammatory signaling domain. In some embodiments, the pro-inflammatory signaling domain comprises a PI3 kinase (PI3K) recruitment domain. In some embodiments, the pro-inflammatory signaling domain is the sequence of SEQ ID NO: 26, or at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93% relative to SEQ ID NO: 26. , 94%, 95%, 96%, 97%, 98%, or 99% sequence identity. In some embodiments, the pro-inflammatory signaling domain is derived from the intracellular signaling domain of CD40. In some embodiments, the pro-inflammatory signaling domain is the sequence of SEQ ID NO: 27, or at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93% relative to SEQ ID NO: 27. , 94%, 95%, 96%, 97%, 98%, or 99% sequence identity. In some embodiments, the CFP is the sequence of SEQ ID NO: 28, or at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95% relative to SEQ ID NO: 28. %, 96%, 97%, 98%, or 99% sequence identity. In some embodiments, the CFP is the sequence of SEQ ID NO: 29, or at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95% relative to SEQ ID NO: 29. %, 96%, 97%, 98%, or 99% sequence identity. In some embodiments, the CFP is the sequence of SEQ ID NO: 30, or at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95% relative to SEQ ID NO: 30. %, 96%, 97%, 98%, or 99% sequence identity.
[0330]
[0416] Provided herein is a recombinant nucleic acid encoding a CFP comprising a TROP2 binding domain (TROP2 binding agent) as described above, which can be expressed in a suitable cell, such as a bone marrow cell. Bone marrow cells can be phagocytes. In some embodiments, the recombinant nucleic acid comprises a TROP2-binding domain as described above; an intracellular domain comprising one or more of the sequences derived from SEQ ID NOs: 21-30; and SEQ ID NOs: 15-30. encodes a CFP comprising a transmembrane domain comprising a sequence having a sequence selected from any one of 21.
[0331]
[0417] In another embodiment, provided herein is a recombinant protein, such as an extracellular protein, such as a soluble protein, that can bind to the extracellular domain of TROP2. In some embodiments, a recombinant extracellular protein having a domain capable of binding to TROP2, e.g., a domain capable of binding to the extracellular domain of TROP2, is a domain capable of binding to a surface protein of a myeloid cell, such as a phagocyte. Contains 2 additional domains. The surface protein of a bone marrow cell can be a protein expressed on the membrane of a bone marrow cell, such as a phagocytic receptor, a pattern recognition molecule, or a scavenger receptor. Provided herein are recombinant nucleic acids encoding extracellular proteins, such as soluble proteins capable of binding to the extracellular domain of TROP2, as described herein.
[0332]
[0418] Provided herein is a therapeutic agent for treating a disease in a subject, wherein the disease is associated with TROP2 protein overexpression and which binds to TROP2, such as any of the TROP2 binding proteins described above. A therapeutic agent is provided that includes at least one recombinant polynucleic acid encoding a protein having an extracellular binding domain capable of binding to a protein. In some embodiments, the recombinant polynucleic acid encoding the protein is mRNA. In some embodiments, the recombinant polynucleic acid encoding the protein is DNA. In some embodiments, the recombinant polynucleic acid is a chimeric fusion receptor protein (CFP) comprising a TROP2-binding extracellular domain, an optional transmembrane domain, and one or more intracellular domains. Encodes TROP2 binding protein. In some embodiments, the one or more intracellular domains include one or more intracellular signaling domains. In some embodiments, the one or more intracellular signaling domains include a PI3 kinase recruitment domain, a CD40 intracellular domain, an FcR domain, as described herein. In some embodiments, the recombinant polynucleic acid is contained intracellularly. In some embodiments, recombinant mRNA comprising a sequence encoding the TROP2 binding agent CFP is expressed in bone marrow cells. In some embodiments herein, cells expressing TROP2 binding proteins are provided. In some embodiments herein, a therapeutic agent for treating a disease in a subject, wherein the disease is associated with TROP2 overexpression, at least A therapeutic agent comprising a recombinant nucleic acid is provided. In some embodiments herein, a therapeutic agent for treating a disease in a subject, wherein the disease is associated with TROP2 protein overexpression, encodes a TROP2 binding agent as described herein. A therapeutic agent comprising a cell comprising a recombinant nucleic acid is provided. In some embodiments, the cells are bone marrow cells. In some embodiments, the disease is cancer, including but not limited to pancreatic cancer, hilar cholangiocarcinoma, cervical cancer, gastric cancer, and lung cancer. In some embodiments, the disease is non-small cell lung cancer.
[0333]
[0419] In some embodiments, a therapeutic agent described herein comprises an extracellular binding domain capable of binding TROP2 and, optionally, a CD8 hinge domain that is properly expressed and localized on the membrane of bone marrow cells. at least one recombinant chimeric fusion protein (CFP), or a polynucleotide encoding the recombinant CFP, having a transmembrane domain capable of binding to endogenous proteins within bone marrow cells for localization. For example, in some embodiments, the TROP2 binding agent comprises a transmembrane region that dimerizes or oligomerizes with another transmembrane protein of myeloid cells. In some embodiments, the TROP2 binding agent comprises a transmembrane protein that can dimerize with Fc gamma receptors on bone marrow cell membranes and thus be expressed only within bone marrow cells. In some embodiments, the TROP2 binding agent is designed to be functional only if the protein dimerizes (or oligomerizes) with an endogenous protein that is expressed only in bone marrow cells. be done. In some embodiments, the TROP2 binding agent comprises an Fc alpha transmembrane domain. In some embodiments, the TROP2 binding agent comprises a transmembrane domain selected from a CD64 (FcγR1) protein transmembrane domain, a CD89 (FcαR1) protein transmembrane domain, a CD16a (FcγRIIIA) protein transmembrane domain. In some embodiments, the TROP2 binding agent comprises an Fc epsilon transmembrane domain. In some embodiments herein, a TROP2-binding extracellular domain, optionally a short hinge region, including, for example, a CD8 hinge domain, a CD89 transmembrane domain, and optionally a CD40 intracellular A TROP2-binding CFP (TROP2 binding agent) is provided, comprising a CD89 intracellular region and a CD89 intracellular region fused to one or more intracellular signaling domains, such as a PI3 kinase recruitment domain. In some embodiments herein, a TROP2-binding extracellular domain, optionally a short hinge region, including, for example, a CD8 hinge domain, a CD64 transmembrane domain, and optionally a CD40 intracellular A TROP2-binding CFP (TROP2 binding agent) is provided, comprising a CD64 intracellular region and a CD64 intracellular region fused to one or more intracellular signaling domains, such as a PI3 kinase recruitment domain. TROP2 CFP may contain one or more human or humanized domains. Described herein are sequences encoding TROP2 CFP constructs comprising an anti-TROP2 ScFv (TROP2 antigen binding agent) fused to a CD8 hinge domain, operably linked to a CD89 transmembrane domain and an intracellular domain. Polynucleotides, such as mRNA or DNA, are provided.
[0334]
[0420] In some embodiments, the TROP2 CFP described herein exhibits myeloid cell-specific expression. In some embodiments, the TROP2 CFPs described herein exhibit Fc gamma-dependent expression. In some embodiments, the TROP2 CFP described herein is effective when the polynucleotide is administered in vivo to T cells, B cells, epithelial cells, myocytes, neuronal cells, or any non- It exhibits undetectable expression in bone marrow cells. In one embodiment, a TROP2 binding agent having a CD16 transmembrane domain, a CD89 transmembrane domain, or a CD64 transmembrane domain described herein encoded by a polynucleotide described herein is When a polynucleotide is administered in vivo, it is primarily expressed within CD14+ cells. In one embodiment, a TROP2-binding agent having a CD16 transmembrane domain, a CD89 transmembrane domain, or a CD64 transmembrane domain encoded by a polynucleotide described herein is administered in vivo. is expressed only in CD14+ cells when
[0335]
[0421] Provided herein are pharmaceutical compositions comprising CD14+ cells expressing CFP having a TROP2 binding domain. In some embodiments, the pharmaceutical composition comprises a cell population in which at least 50% of the cells are CD14+ cells that express the TROP2 binding agent, CFP. In some embodiments, the pharmaceutical composition comprises at least 50% cells that are CD14+ and CD16-. In some embodiments, the pharmaceutical composition comprises at least 50% of the cells that are CD16-, express CD14+ cells, and express TROP2-CFP (CFP with a TROP2-binding extracellular domain).
[0336]
[0422] As used herein, a recombinant polynucleotide (polynucleic acid) encoding a transmembrane polypeptide comprising a CD64 transmembrane domain, or a CD89 transmembrane domain, or a CD16a transmembrane domain, wherein the recombinant polynucleotide is LNP A pharmaceutical composition encapsulated therein is provided. In some embodiments, the transmembrane polypeptide is CFP with an extracellular binding domain specific for binding to antigen on cancer cells. In some embodiments, the CFP includes an extracellular binding domain specific for binding to TROP2.
[0337]
[0423] Provided herein is a pharmaceutical composition for treating cancer in a human subject, comprising cells, such as CD14+ bone marrow cells, expressing a TROP2 binding agent, CFP, as described herein. Compositions are provided for cancer, lung cancer. In some embodiments, the lung cancer is NSCLC.
[0338]
[0424] Provided herein is a pharmaceutical composition for treating cancer in a human subject comprising a recombinant CFP encoding a TROP2-binding extracellular domain capable of expression in bone marrow cells in vivo. a CFP comprising a TROP2-binding extracellular domain comprises a CD64 transmembrane domain, a CD16a transmembrane domain, or a CD89 transmembrane domain, as described herein; A composition is provided in which the cancer is lung cancer. In some embodiments, the lung cancer is NSCLC.
[0339]
[0425] An exemplary TROP2 binding domain sequence can be the amino acid sequence of SEQ ID NO: 34, or a sequence that shares at least 80% sequence identity to SEQ ID NO: 34. DIQLTQSPSSLSASVGDRVSITCKASQDVSIAVAWYQQKPGKAPKLLIYSASYRYTGVPDRFSGSGSGTDFTLTISSLQPEDFAVYYCQQHYITPLTFGAGTKVEIKRGGGGSGGGGSGGGGSQVQLQQSGSELKKPGASVKVSCKASGYTFTNYGMNWVKQAPGQGLKWMGWINTYTGEPTYTDDFKGRFAFSLDTSVSTAYLQ ISSLKADDTAVYFCARGGFGSSYWYFDVWGQGSLVTVSS (SEQ ID NO: 34).
[0340]
[0426] In some embodiments, the chimeric fusion protein (CFP) has the amino acid sequence of SEQ ID NO: 34, or at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% relative to SEQ ID NO: 34. contains an extracellular domain (ECD) targeted to bind to TROP2, containing sequences with % sequence identity.
[0341]
[0427] An exemplary TROP2 binding domain can be the sequence depicted in SEQ ID NO:35.
[0342]
[0428] QVQLQQSGSELKKPGASVKVSCKASGYTFTNYGMNWVKQAPGQGLKWMGWINTYTGEPTYTDDFKGRFAFSLDTSVSTAYLQISSLKADDTAVYFCARGGFGSSYWYFDVWGQGSLVTVSSGGGGSGGGGSGGGGSDIQLTQSPSSLSASVGDRVSITCKASQDVSIAVAWYQQKPGKAPKLLIYSASYRYTGVPDRFSGSGSGTDFT LTISSLQPEDFAVYYCQQHYITPLTFGAGTKVEIKR (SEQ ID NO: 35).
[0343]
[0429] In some embodiments, the chimeric fusion protein (CFP) has the amino acid sequence of SEQ ID NO: 35, or at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% relative to SEQ ID NO: 35. contains an extracellular domain (ECD) targeted to bind to TROP2, containing sequences with % sequence identity.
[0344] TMPRSS3 binding protein and TMPRSS3 binding domain
[0430] Approximately 50% of prostate cancers contain an androgen-regulated gene, transmembrane protease, serine 2 (TMPRSS2), and a transcription factor of the erythroblastosis virus E26 transforming sequence (ETS) family, typically It has a gene fusion linked to the erythroblast transformation-specific related gene (ERG). Recent evidence has established that TMPRSS2:ERG fusions typically occur early in tumor development and are often evenly distributed throughout the cancer mass. In a recent study, abnormalities in ERG findings were observed in the lymph nodes of 30% of 84 prostate cancer cases. The TMPRSS2:ERG fusion protein is highly specific for prostate cancer cells and may therefore be an ideal target for novel therapies. In one aspect herein, a chimeric fusion receptor (CFP) protein is provided that has an extracellular TMPRSS binding domain (TMPRSS binding agent CFP).
[0345]
[0431] In some embodiments, the extracellular binding domain is an antigen-binding domain of an antibody, or an antigen-binding fragment (Fab) (fragment), single chain variable fragment (scFv), that is capable of binding to TMPRSS. , nanobodies, VH domains, VL domains, single domain antibodies (sdAbs), VNAR domains, and VHH domains, bispecific antibodies, diabodies, or functional fragments of any of these. In some embodiments, antigen-binding fragments (Fabs), single chain variable fragments (scFvs), nanobodies, VH domains, VL domains, single domain antibodies (sdAbs), VNAR domains, and VHH domains, bispecific An antibody, diabody, or functional fragment of any of these specifically binds one or more antigens.
[0346]
[0432] In some embodiments, the extracellular domain further comprises a hinge domain derived from CD8, in which the hinge domain is operably linked to a transmembrane domain on the cytoplasmic side and on the extracellular side that binds TMPRSS. operably linked to the sex domain. In some embodiments, the transmembrane domain comprises a sequence set forth in any one of SEQ ID NO: 15, 16, 17, 18, or 19. In some embodiments, the transmembrane domain comprises sequences derived from the CD8 alpha (CD8a) transmembrane domain. In some embodiments, the transmembrane domain is the sequence set forth in SEQ ID NO: 15, or at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93% relative to SEQ ID NO: 15. , 94%, 95%, 96%, 97%, 98%, or 99% sequence identity. In some embodiments, the transmembrane domain is the sequence set forth in SEQ ID NO: 16, or at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93% relative to SEQ ID NO: 16. , 94%, 95%, 96%, 97%, 98%, or 99% sequence identity. In some embodiments, the transmembrane domain comprises sequences derived from the CD2 transmembrane domain. In some embodiments, the transmembrane domain is the sequence set forth in SEQ ID NO: 17, or at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93% relative to SEQ ID NO: 17. , 94%, 95%, 96%, 97%, 98%, or 99% sequence identity. In some embodiments, the transmembrane domain comprises sequences derived from the CD28 transmembrane domain. In some embodiments, the transmembrane domain is the sequence set forth in SEQ ID NO: 18, or at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93% relative to SEQ ID NO: 18. , 94%, 95%, 96%, 97%, 98%, or 99% sequence identity. In some embodiments, the transmembrane domain comprises sequences derived from the CD68 transmembrane domain. In some embodiments, the transmembrane domain is the sequence set forth in SEQ ID NO: 19, or at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93% relative to SEQ ID NO: 19. , 94%, 95%, 96%, 97%, 98%, or 99% sequence identity. In some embodiments, the ECD of CFP is a transmembrane domain selected from any one of the sequences set forth in SEQ ID NO: 15, 16, 17, 18, or 19, or SEQ ID NO: 15, 16. , 17, 18, or 19 at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97 %, 98%, or 99% sequence identity; to the amino acid sequences depicted in the sequences in Table 2, or to any of the sequences in Table 2. Sequences with 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity include.
[0347]
[0433] In some embodiments, the extracellular hinge domain and the transmembrane domain are at least 70%, 75%, 80%, 85% of the sequence of SEQ ID NO: 20 or SEQ ID NO: 21, or each of SEQ ID NO: 20 or SEQ ID NO: 21. , 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity. In some embodiments, the CFP is the transmembrane domain of SEQ ID NO: 20, or at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94% relative to SEQ ID NO: 20. , an extracellular domain fused to a transmembrane domain with 95%, 96%, 97%, 98%, or 99% sequence identity. In some embodiments, the CFP is the transmembrane domain of SEQ ID NO: 21, or at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94% relative to SEQ ID NO: 21. , an extracellular domain fused to a transmembrane domain with 95%, 96%, 97%, 98%, or 99% sequence identity. In some embodiments, the CFP is at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96% relative to SEQ ID NO: 20 or 21; fused to a hinge domain and a transmembrane domain having amino acid sequences with 97%, 98%, 99%, or 100% sequence identity; at least 70%, 75 to any of the sequences in Table 2 %, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity. including.
[0348]
[0434] In some embodiments, a CFP comprising an ECD domain capable of binding to a TMPRSS protein or portion thereof is accompanied by a TMD and a hinge domain, optionally with one or more other ICDs, as described herein. , optionally comprising a short cytoplasmic domain of a CD16 protein, a CD64 protein, or a CD89 protein.
[0349]
[0435] In some embodiments, the CFP comprises one or more intracellular signaling domains, including one intracellular signaling domain. In some embodiments, the intracellular signaling domain comprises a phagocytic signaling domain. In some embodiments, the phagocytic signaling domain comprises an intracellular signaling domain derived from a receptor other than Megf10, MerTk, FcRα, and Bai1. In some embodiments, the phagocytic signaling domain comprises an intracellular signaling domain derived from a receptor other than Megf10, MerTk, FcR, and Bai1. In some embodiments, the intracellular signaling domain comprises a domain derived from a receptor other than CD3ζ. In some embodiments, the phagocytic signaling domain comprises an intracellular signaling domain derived from FcRγ, FcRα, or FcRε.
[0350]
[0436] In some embodiments, the CFP is any one of SEQ ID NO: 22, 23, 24, or 25, or at least 70% relative to any one of SEQ ID NO: 22, 23, 24, or 25. , 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity. It contains an intracellular signaling domain derived from the FcR gamma protein (FcRγ chain). In some embodiments, the one or more intracellular signaling domains further include a pro-inflammatory signaling domain. In some embodiments, the pro-inflammatory signaling domain comprises a PI3 kinase (PI3K) recruitment domain. In some embodiments, the pro-inflammatory signaling domain is the sequence of SEQ ID NO: 26, or at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93% relative to SEQ ID NO: 26. , 94%, 95%, 96%, 97%, 98%, or 99% sequence identity. In some embodiments, the pro-inflammatory signaling domain is derived from the intracellular signaling domain of CD40. In some embodiments, the pro-inflammatory signaling domain is the sequence of SEQ ID NO: 27, or at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93% relative to SEQ ID NO: 27. , 94%, 95%, 96%, 97%, 98%, or 99% sequence identity. In some embodiments, the CFP is the sequence of SEQ ID NO: 28, or at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95% relative to SEQ ID NO: 28. %, 96%, 97%, 98%, or 99% sequence identity. In some embodiments, the CFP is the sequence of SEQ ID NO: 29, or at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95% relative to SEQ ID NO: 29. %, 96%, 97%, 98%, or 99% sequence identity. In some embodiments, the CFP is the sequence of SEQ ID NO: 30, or at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95% relative to SEQ ID NO: 30. %, 96%, 97%, 98%, or 99% sequence identity.
[0351]
[0437] Provided herein is a recombinant nucleic acid encoding a CFP comprising a TMPRSS binding domain (TMPRSS2 binding agent) as described above, which can be expressed in a suitable cell, such as a bone marrow cell. Bone marrow cells can be phagocytes. In some embodiments, the recombinant nucleic acid comprises a TMPRSS binding domain as described above; an intracellular domain comprising one or more of the sequences derived from SEQ ID NOs: 21-30; and SEQ ID NOs: 15-30. encodes a CFP comprising a transmembrane domain comprising a sequence having a sequence selected from any one of 21.
[0352]
[0438] In another embodiment, provided herein is a recombinant protein, such as an extracellular protein, such as a soluble protein, that can bind to the extracellular domain of a TMPRSS. In some embodiments, a recombinant extracellular protein having a domain capable of binding to TMPRSS, e.g., a domain capable of binding to the extracellular domain of TMPRSS, is a domain capable of binding to a surface protein of a myeloid cell, such as a phagocyte. Contains 2 additional domains. The surface protein of a bone marrow cell can be a protein expressed on the membrane of a bone marrow cell, such as a phagocytic receptor, a pattern recognition molecule, or a scavenger receptor. Provided herein are recombinant nucleic acids encoding extracellular proteins, such as soluble proteins capable of binding to the extracellular domain of a TMPRSS, as described herein.
[0353]
[0439] Provided herein is a therapeutic agent for treating a disease in a subject, wherein the disease is associated with overexpression of a TMPRSS protein, and wherein the disease binds to a TMPRSS, such as any of the TMPRSS-binding proteins described above. A therapeutic agent is provided that includes at least one recombinant protein having an extracellular binding domain capable of binding. In some embodiments herein, cells expressing a TMPRSS binding protein are provided. In some embodiments herein, a therapeutic agent for treating a disease in a subject, wherein the disease is associated with overexpression of TMPRSS, encodes a TMPRSS binding agent as described herein. A therapeutic agent is provided that includes at least one recombinant nucleic acid. In some embodiments herein, a therapeutic agent for treating a disease in a subject, wherein the disease is associated with overexpression of a TMPRSS protein encoding a TMPRSS binding agent as described herein. , a therapeutic agent comprising a cell comprising a recombinant nucleic acid is provided. In some embodiments, the cells are bone marrow cells. In some embodiments, the disease is cancer, such as prostate cancer.
[0354] BiME and TRiME structures
[0440] As used herein, the binding domain comprises any one of the therapeutic agent binding domains described above, wherein the binding domain is an antibody binding domain, a functional fragment of an antibody, a variable domain thereof, V H domain, V L domain, VNAR domain, V HH Bispecific engagers (BiMEs) comprising domains, single chain variable fragments (scFvs), Fabs, single domain antibodies (sdAbs), nanobodies, bispecific antibodies, diabodies, or functional fragments or combinations thereof. Alternatively, a trispecific engager (TRiME) is provided. In some embodiments, the antigen on the target cell that the first binding domain binds is a cancer or pathogenic antigen on the target cell, or an autoimmune antigen. In some embodiments, the first therapeutic agent comprises a polypeptide that is less than 1000 amino acids or 1000 nm in length. In some embodiments, the first therapeutic agent comprises a polypeptide that is less than 500 amino acids or 500 nm in length. In some embodiments, the first therapeutic agent comprises a polypeptide that is 200-1000 amino acids or 200-1000 nm in length.
[0355]
[0441] In some embodiments, engagement of the binding domain of the first therapeutic agent contacts the cancer cell with the bone marrow cell. In some embodiments, the second binding domain specifically interacts with myeloid cells and promotes phagocytic activity of myeloid cells. In some embodiments, the second binding domain specifically interacts with myeloid cells and promotes inflammatory signaling in myeloid cells. In some embodiments, the second binding domain specifically interacts with myeloid cells or adhesion molecules and promotes adhesion of myeloid cells to target cells. In some embodiments, the second binding domain specifically interacts with myeloid cells and inhibits antiphagocytic activity of myeloid cells mediated by target cells. In some embodiments, the second binding domain specifically interacts with myeloid cells and inhibits anti-inflammatory activity of myeloid cells mediated by target cells. In some embodiments, the second binding domain and / or the third binding domain promotes phagocytic activity of myeloid cells. In some embodiments, the second binding domain and / or the third binding domain promote inflammatory signaling in myeloid cells. In some embodiments, the second binding domain and / or the third binding domain specifically interacts with bone marrow cells or adhesion molecules and promotes adhesion of bone marrow cells to target cells. In some embodiments, the second binding domain and / or the third binding domain inhibits anti-phagocytic activity of myeloid cells mediated by target cells. In some embodiments, the second binding domain and / or the third binding domain inhibits anti-inflammatory activity of myeloid cells mediated by target cells.
[0356]
[0442] In some embodiments, the third binding domain or additional therapeutic agent is a CD47 antagonist, CD47 blocker, antibody, chimeric CD47 receptor, sialidase, cytokine, pro-inflammatory gene, procaspase, or anti-cancer agent. include. In some embodiments, the first binding domain, the second binding domain, and the third binding domain bind distinct, non-identical target antigens. In some embodiments, the first binding domain, second binding domain, or third binding domain is a ligand binding domain.
[0357]
[0443] In some embodiments, the first, second or third binding domain is operably linked by one or more linkers. In some embodiments, the linker is a polypeptide. In some embodiments, the linker is a functional peptide. In some embodiments, the linker is a ligand for a receptor. In some embodiments, the linker is a ligand for a monocyte or macrophage receptor. In some embodiments, the linker activates the receptor. In some embodiments, the linker inhibits the receptor. In some embodiments, the linker is a ligand for the macrophage M2 receptor. In some embodiments, the linker is a ligand for a TLR receptor, such as TLR4. In some embodiments, the linker activates a TLR receptor. In some embodiments, the first, second and / or third binding domain is associated with a mask that binds to the binding domain. In some embodiments, the mask is an inhibitor that inhibits the interaction of a binding domain with its target when the mask remains associated with its respective binding domain. In some embodiments, the mask is associated with the binding domain via a peptide linker. In some embodiments, the peptide linker includes a cleavable moiety. In some embodiments, the cleavable moiety is cleaved by a protein or enzyme that is selectively abundant at the site of the cancer or tumor.
[0358] therapeutic composition
[0444] In one aspect herein, CD14+ cells, CD14+ / CD16- cells, CD14+ / CD16+ cells, CD14- / CD16+ cells, CD14- / CD16- cells, dendritic cells, M0 macrophages, M2 macrophages, M1 macrophages, or mosaic cells. Bone marrow cells such as bone marrow cells / macrophages / dendritic cells are provided. Some embodiments herein provide therapeutic compositions comprising at least 20%, at least 30%, at least 40%, or at least 50% CD14+ cells. In some embodiments, the therapeutic composition comprises at least 20%, at least 30%, at least 40%, or at least 50% CD14+ / CD16- cells. Some embodiments herein provide therapeutic compositions comprising less than 20%, less than 15%, less than 10%, or less than 5% dendritic cells. The bone marrow cells for the therapeutic compositions described herein are recombinant nucleic acids encoding a chimeric fusion protein encoding a CFP receptor protein or an engager protein, as described herein. Contains recombinant nucleic acids. Bone marrow cells for the therapeutic compositions described herein express CFP encoded by a recombinant nucleic acid or contain an engager protein encoded by a recombinant nucleic acid described herein. manifest.
[0359]
[0445] Some embodiments herein include a chimeric fusion protein, such as a chimeric fusion receptor protein (CFP), wherein the CFP is: (a)(i) any one of the targets disclosed herein; and (ii) an extracellular domain comprising at least a portion of a hinge domain derived from CD8, a hinge domain derived from CD28; or an extracellular domain derived from CD68; (b) an extracellular domain that specifically binds to CD8; a transmembrane domain, a CD28 transmembrane domain, a CD2 transmembrane domain, or a CD68 transmembrane domain; and (c) at least two intracellular signaling domains, wherein the at least two intracellular signaling domains are (i) FcRγ or a first intracellular signaling domain derived from FcRε; and (ii) (A) comprising a PI3K recruitment domain; or (B) a second intracellular signaling domain derived from CD40. A therapeutic composition is provided comprising an intracellular domain comprising.
[0360]
[0446] Some embodiments herein provide therapeutic compositions comprising bispecific or trispecific engagers disclosed herein.
[0361]
[0447] In one aspect herein, one or more recombinant polypeptides encode one or more recombinant proteins, which can be chimeric fusion proteins, such as receptors or engagers, as described herein. Nucleic acid(s) are provided. In some embodiments, the recombinant polynucleic acid(s) is mRNA. In some embodiments, the recombinant polynucleic acid comprises circRNA. In some embodiments, the recombinant polynucleic acid is incorporated into a viral vector. In some embodiments, recombinant polynucleic acids are delivered via viral vectors.
[0362]
[0448] Some embodiments herein include a recombinant nucleic acid encoding a chimeric fusion protein, such as a chimeric fusion receptor protein (CFP), wherein the CFP (a) (i) targets a target disclosed herein; and (ii) an extracellular compound comprising at least a portion of a hinge domain derived from CD8, a hinge domain derived from CD28; or an extracellular domain derived from CD68. (b) a CD8 transmembrane domain, a CD28 transmembrane domain, a CD2 transmembrane domain, or a CD68 transmembrane domain; and (c) at least two intracellular signaling domains; , (i) a first intracellular signaling domain derived from FcRγ or FcRε, and (ii) a second intracellular signaling domain, wherein (A) comprises a PI3K recruitment domain, or (B) is derived from CD40. A therapeutic composition is provided that includes an intracellular domain that includes an intracellular signaling domain.
[0363]
[0449] Some embodiments herein provide therapeutic compositions comprising recombinant nucleic acids encoding bispecific or trispecific engagers disclosed herein.
[0364] Other therapeutic compositions for co-administration
[0450] In some embodiments, the therapeutic composition comprises a CD47 agonist, an agent that inhibits Rac, an agent that inhibits Cdc42, an agent that inhibits GTPases, an agent that promotes F-actin disassembly, PFP of PI3K. drugs that promote recruitment to PI3K, drugs that promote PI3K activity, drugs that promote phosphatidylinositol 3,4,5-trisphosphate production, drugs that promote ARHGAP12 activity, drugs that promote ARHGAP25 activity, Agents that promote SH3BP1 activity, agents that promote lymphocyte sequestration in primary and / or secondary lymphoid organs, concentrations of naïve T cells and central memory T cells in secondary lymphoid organs and any combination thereof.
[0365]
[0451] In some embodiments, the bone marrow cells contain (a) an endogenous peptide or protein that dimerizes with CFP; (b) a non-endogenous peptide or protein that dimerizes with CFP. and / or (c) further comprising a second recombinant polynucleic acid sequence, where the second recombinant polynucleic acid sequence comprises a sequence encoding a peptide or protein that interacts with CFP; conjugation or interaction enhances phagocytosis by bone marrow cells that express CFP compared to bone marrow cells that do not express CFP.
[0366]
[0452] In some embodiments, the bone marrow cells have the following characteristics: (i) effector activity, cross-presentation, respiratory burst, production of ROS, production of iNOS, inflammatory mediators, production of extracellular vesicles, phosphatidylinositol 3,4,5- increased production of triphosphate, interaction with antigen-expressing target cells, resistance to CD47-mediated inhibition of phagocytosis, resistance to LILRB1-mediated inhibition of phagocytosis, or any combination thereof; and / or ( ii) IL-1, IL3, IL-6, IL-10, IL-12, IL-13, IL-23, TNFα, TNF family of cytokines, CCL2, CXCL9, CXCL10, CXCL11, IL-18, IL-23 , IL-27, CSF, MCSF, GMCSF, IL-17, IP-10, RANTES, interferon, MHC class I protein, MHC class II protein, CD40, CD48, CD58, CD80, CD86, CD112, CD155, TRAIL / TNF family of death receptors, TGFβ, B7-DC, B7-H2, LIGHT, HVEM, TL1A, 41BBL, OX40L, GITRL, CD30L, TIM1, TIM4, SLAM, PDL1, MMPs (e.g., MMP2, MMP7, and MMP9), or exhibit increased expression of any combination thereof.
[0367]
[0453] In some embodiments, the intracellular signaling domain is derived from phagocytosis or a tethered receptor (PR), or the intracellular signaling domain comprises a phagocytosis activation domain. In some embodiments, the intracellular signaling domain is derived from a receptor other than a phagocytic receptor selected from Megf10, MerTk, FcR alpha, or Bai1. In some embodiments, the intracellular signaling domain is TNFR1, MDA5, CD40, lectin, Dectin1, CD206, scavenger receptor A1 (SRA1), MARCO, CD36, CD163, MSR1, SCARA3, COLEC12, SCARA5, SCARB1 , SCARB2, CD68, OLR1, SCARF1, SCARF2, CXCL16, STAB1, STAB2, SRCRB4D, SSC5D, CD205, CD207, CD209, RAGE, CD14, CD64, F4 / 80, CCR2, CX3CR1, CSF1R, Tie2, HuCRIg(L), A receptor selected from the group consisting of CD64, CD32a, CD16a, CD89, Fcα receptor I, CR1, CD35, CD3ζ, complement receptor, CR3, CR4, Tim-1, Tim-4, and CD169 (e.g. It is derived from proteins such as phagocytic receptors). In some embodiments, the intracellular signaling domain comprises a pro-inflammatory signaling domain. In some embodiments, the intracellular signaling domain comprises a pro-inflammatory signaling domain that is not a PI3K recruitment domain.
[0368]
[0454] In some embodiments, the intracellular signaling domain is derived from a receptor that contains an ITAM domain. In some embodiments, the recombinant intracellular signaling domain comprises a first portion derived from a phagocytic receptor and a second portion derived from a non-phagocytic receptor, in which case the non-phagocytic The second portion, derived from the receptor, contains phosphorylation sites. In some embodiments, the phosphorylation site includes an amino acid sequence suitable for an autophosphorylation site. In some embodiments, the amino acid residue that is phosphorylated is tyrosine. In some embodiments, the phosphorylation site includes an amino acid sequence suitable for phosphorylation by Src family kinases. In some embodiments, the phosphorylation site comprises an amino acid sequence that, upon phosphorylation, is capable of binding to an SH2 domain within the kinase. In some embodiments, a receptor tyrosine kinase domain is fused at the cytoplasmic end of the chimeric receptor in addition to the first cytoplasmic portion.
[0369]
[0455] In some embodiments, the phosphorylation site is a tyrosine phosphorylation site.
[0370]
[0456] In some embodiments, the second intracellular domain is an immunoreceptor tyrosine activation motif (ITAM). Exemplary ITAM motifs are present within mammalian immunoglobulin alpha and immunoglobulin beta proteins, within TCRγ receptors, within FCRγ receptor subunits, within CD3 chain receptors, and within NFAT activation molecules.
[0371]
[0457] In some embodiments, the intracellular domain of the chimeric receptor comprises one ITAM motif. In some embodiments, the intracellular domain of the chimeric receptor comprises more than one ITAM motif. In some embodiments, the intracellular domain of the chimeric receptor comprises two or more ITAM motifs. In some embodiments, the intracellular domain of the chimeric receptor comprises three or more ITAM motifs. In some embodiments, the intracellular domain of the chimeric receptor comprises four or more ITAM motifs. In some embodiments, the intracellular domain of the chimeric receptor comprises five or more ITAM motifs. In some embodiments, the intracellular domain of the chimeric receptor comprises six or more ITAM motifs. In some embodiments, the intracellular domain of the chimeric receptor comprises seven or more ITAM motifs. In some embodiments, the intracellular domain of the chimeric receptor comprises eight or more ITAM motifs. In some embodiments, the intracellular domain of the chimeric receptor comprises nine or more ITAM motifs. In some embodiments, the intracellular domain of the chimeric receptor comprises 10 or more ITAM motifs.
[0372]
[0458] As used herein, PR subunits include a transmembrane domain, and an intracellular domain that includes an intracellular signaling domain; and an extracellular domain that includes an antigen-binding domain specific for an antigen of a target cell; and an extracellular domain; the intracellular signaling domain is derived from a phagocytic receptor other than a phagocytic receptor selected from Megf10, MerTk, FcRα, or Bai1. Compositions are provided that include recombinant nucleic acids encoding CFP, such as (PR) fusion proteins (PFP).
[0373] 459. In some embodiments, upon binding of CFP to a target cell antigen, the killing activity of cells expressing CFP is at least 5%, 6%, 7% compared to cells that do not express CFP. , 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 25%, 30%, 35%, 40 %, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 100%, 150%, 200%, 250%, 300%, 350%, Increased by more than 400%, 450%, 500%, 550%, 600%, 650%, 700%, 750%, 800%, 850%, 900%, 950%, or 1000%. In some embodiments, CFP is functionally integrated into the plasma membrane of the cell when CFP is expressed within the cell. In some embodiments, upon binding of CFP to a target cell antigen, the killing activity of cells expressing CFP is at least 1.1-fold, 1.5-fold, 2-fold, 2.5-fold compared to cells that do not express CFP. x, 3x, 3.5x, 4x, 4.5x, 5x, 5.5x, 6x, 6.5x, 7x, 7.5x, 8x, 8.5x, 9x, 9.5x, 10x, 11x, Increased by 12x, 13x, 14x, 15x, 16x, 17x, 18x, 19x, 20x, 25x, 30x, 40x, 50x, 75x, or 100x.
[0374]
[0460] In some embodiments, the intracellular signaling domain is TNFR1, MDA5, CD40, lectin, Dectin1, CD206, scavenger receptor A1 (SRA1), MARCO, CD36, CD163, MSR1, SCARA3, COLEC12, SCARA5, SCARB1 , SCARB2, CD68, OLR1, SCARF1, SCARF2, CXCL16, STAB1, STAB2, SRCRB4D, SSC5D, CD205, CD207, CD209, RAGE, CD14, CD64, F4 / 80, CCR2, CX3CR1, CSF1R, Tie2, HuCRIg(L), from a receptor such as a phagocytic receptor selected from the group consisting of CD64, CD32a, CD16a, CD89, Fcα receptor I, CR1, CD35, CD3ζ, CR3, CR4, Tim-1, Tim-4, and CD169 . In some embodiments, the intracellular signaling domain comprises a pro-inflammatory signaling domain.
[0375]
[0461] As used herein, PR subunits include a transmembrane domain, and an intracellular domain that includes an intracellular signaling domain; and an extracellular domain that includes an antigen-binding domain specific for an antigen of a target cell; and the extracellular domain; the intracellular signaling domain includes TNFR1, MDA5, CD40, lectin, Dectin 1, CD206, scavenger receptor A1 (SRA1), MARCO, CD36, CD163, MSR1, SCARA3, COLEC12, SCARA5, SCARB1, SCARB2, CD68, OLR1, SCARF1, SCARF2, CXCL16, STAB1, STAB2, SRCRB4D, SSC5D, CD205, CD207, CD209, RAGE, CD14, CD64, F4 / 80, CCR2, CX3CR1, CSF1R, Phagocytic receptor selected from the group consisting of Tie2, HuCRIg(L), CD64, CD32a, CD16a, CD89, Fcα receptor I, CR1, CD35, CD3ζ, CR3, CR4, Tim-1, Tim-4, and CD169 Compositions are provided that include a recombinant nucleic acid encoding a CFP, such as a phagocytic or tethered receptor (PR) fusion protein (PFP), derived from a receptor such as a phagocytic or tethered receptor (PR) fusion protein (PFP).
[0376]
[0462] In some embodiments, upon binding of CFP to a target cell antigen, the killing activity of cells expressing CFP is at least 5%, 6%, 7%, 8 %, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 100%, 150%, 200%, 250%, 300%, 350%, 400% , 450%, 500%, 550%, 600%, 650%, 700%, 750%, 800%, 850%, 900%, 950%, or increased by more than 1000%. In some embodiments, the intracellular signaling domain is derived from a phagocytic receptor other than a phagocytic receptor selected from Megf10, MerTk, FcRα, or Bai1. In some embodiments, the intracellular signaling domain comprises a pro-inflammatory signaling domain. In some embodiments, the intracellular signaling domain comprises a PI3K recruitment domain, such as a PI3K recruitment domain derived from CD19. In some embodiments, the intracellular signaling domain comprises a pro-inflammatory signaling domain that is not a PI3K recruitment domain.
[0377]
[0463] In some embodiments, cells expressing CFP exhibit increased phagocytosis of target cells expressing the antigen compared to cells that do not express CFP. In some embodiments, cells expressing CFP exhibit at least a 1.1-fold increase in phagocytosis of target cells expressing the antigen compared to cells that do not express CFP. In some embodiments, cells expressing CFP are at least 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold more phagocytic of target cells expressing the antigen compared to cells that do not express CFP. exhibits a 1-fold, 8-fold, 9-fold, 10-fold, 20-fold, 30-fold, or 50-fold increase. In some embodiments, cells expressing CFP exhibit increased production of cytokines compared to cells that...
Claims
1. 1. A pharmaceutical composition for treating cancer in a subject in need thereof, comprising an engineered nucleic acid encapsulated in a nanoparticle delivery vehicle, the engineered nucleic acid comprising a sequence encoding a chimeric fusion protein (CFP), the CFP comprising: (a) an extracellular domain comprising an anti-TROP2 binding domain; and (b) a transmembrane domain operably linked to an extracellular domain, the transmembrane domain comprising the sequence of a transmembrane domain derived from CD16a, CD64, CD68, or CD89; The chimeric fusion protein comprising:
2. The pharmaceutical composition of claim 1 , wherein the engineered nucleic acid is RNA.
3. The pharmaceutical composition of claim 1 , wherein the anti-TROP2 binding domain comprises a Fab fragment or an scFv domain comprising a heavy chain variable domain and a light chain variable domain.
4. 2. The pharmaceutical composition of claim 1, wherein the CFP is expressed on the surface of myeloid cells, monocytes, or macrophages of the subject, and is not substantially expressed on the surface of T cells of the subject.
5. The pharmaceutical composition of claim 1 , wherein the CFP further comprises an intracellular domain comprising one or more intracellular signaling domains.
6. 6. The pharmaceutical composition of claim 5, wherein the intracellular signaling domain comprises at least one immunoreceptor tyrosine-based activation motif (ITAM) domain, and at least one ITAM domain is derived from an intracellular domain of a protein or polypeptide selected from the group consisting of CD3ζ TCR subunit, CD3ε TCR subunit, CD3γ TCR subunit, CD3δ TCR subunit, TCRζ chain, Fcε receptor 1 chain, Fcε receptor 2 chain, Fcγ receptor 1 chain, Fcγ receptor 2a chain, Fcγ receptor 2b1 chain, Fcγ receptor 2b2 chain, Fcγ receptor 3a chain, Fcγ receptor 3b chain, Fcβ receptor 1 chain, TYROBP (DAP12), CD5, CD16a, CD16b, CD22, CD23, CD32, CD64, CD79a, CD79b, CD89, CD278, CD66d, and functional fragments thereof.
7. The pharmaceutical composition of claim 5 , wherein the one or more intracellular signaling domains comprise an intracellular signaling domain derived from CD16a, CD64, CD68, CD89, FCERIG, CD40, or CD3ζ.
8. 6. The pharmaceutical composition of claim 5, wherein the one or more intracellular signaling domains comprise an intracellular domain derived from a CD16 protein, a CD64 protein, or a CD89 protein, or a fragment thereof.
9. The pharmaceutical composition of claim 5, wherein the one or more intracellular signaling domains further comprise a phosphoinositide 3-kinase (PI3K) recruitment domain, and the PI3K recruitment domain comprises a sequence having at least 90% sequence identity to SEQ ID NO:
26.
10. The pharmaceutical composition of claim 1 , wherein the extracellular domain further comprises an extracellular hinge domain derived from CD16a, CD64, CD68, or CD89.
11. The pharmaceutical composition of claim 1 , wherein the extracellular hinge domain derived from CD16a, CD64, CD68, or CD89 comprises the amino acid sequence IHQDYTTQN (SEQ ID NO: 82).
12. 2. The pharmaceutical composition of claim 1, wherein the transmembrane domain derived from CD16a, CD64, CD68, or CD89 comprises the amino acid sequence of LIRMAVAGLVLVALLAILV (SEQ ID NO: 83).
13. 6. The pharmaceutical composition of claim 5, wherein the intracellular domain comprises the amino acid sequence ENWHSHTALNKEASADVAEPSWSQQMCQPGLTFARTPSVCK (SEQ ID NO: 84).
14. The pharmaceutical composition of claim 1 , wherein the CFP comprises one or more linkers.
15. 2. The pharmaceutical composition of claim 1, wherein the anti-TROP2 binding domain comprises heavy chain complementarity determining region 1 (HC CDR1), HC CDR2, and HC CDR3 of SEQ ID NO:34, and light chain complementarity determining region 1 (LC CDR1), LC CDR2, and LC CDR3 of SEQ ID NO:
34.
16. 2. The pharmaceutical composition of claim 1, wherein the anti-TROP2 binding domain comprises HC CDR1, HC CDR2, and HC CDR3 of SEQ ID NO:35, and LC CDR1, LC CDR2, and LC CDR3 of SEQ ID NO:
35.
17. 2. The pharmaceutical composition of claim 1, wherein the anti-TROP2 binding domain comprises an scFv domain comprising a sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:34, or at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:
35.
18. The pharmaceutical composition of claim 1 , wherein the anti-TROP2 binding domain comprises the sequence set forth in SEQ ID NO: 34 or SEQ ID NO:
35.
19. 10. The pharmaceutical composition of claim 1, wherein the nanoparticle delivery vehicle comprises a lipid nanoparticle.
20. 20. The pharmaceutical composition of claim 19, wherein the lipid nanoparticles comprise polar lipids and non-polar lipids, and the lipid nanoparticles comprise cationic lipids, non-cationic lipids, neutral lipids, or PEGylated lipids.
21. The pharmaceutical composition of claim 19, wherein the lipid nanoparticles have a diameter of 100 to 300 nm.
22. 2. The pharmaceutical composition of claim 1, wherein the cancer is selected from the group consisting of gastric cancer, ovarian cancer, renal cancer, breast cancer, prostate cancer, liver cancer, brain cancer, lymphoma, leukemia, skin cancer, pancreatic cancer, colorectal cancer, glioblastoma, and lung cancer.
23. The pharmaceutical composition according to claim 1 , wherein the cancer is a cancer that expresses TROP2.
24. 1. A composition comprising an engineered nucleic acid encoding a chimeric fusion protein (CFP), the CFP comprising a GMCSF signal peptide sequence, an extracellular domain comprising an anti-TROP2 binding domain, a transmembrane domain operably linked to the extracellular domain, and an intracellular domain; the transmembrane domain is derived from a protein that dimerizes with an endogenous FcRγ receptor expressed on myeloid cells, monocytes, or macrophages; the transmembrane domain is derived from CD16a, CD64, CD68, or CD89; and the intracellular domain comprises the amino acid sequence of ENWHSHTALNKEASADVAEPSWSQQMCQPGLTFARTPSVCK (SEQ ID NO: 84).
25. 1. A composition comprising an engineered nucleic acid encoding a chimeric fusion protein (CFP), the CFP comprising a GMCSF signal peptide sequence, an extracellular domain comprising an anti-TROP2 binding domain, and a transmembrane domain operably linked to the extracellular domain; the transmembrane domain is derived from a protein that dimerizes with an endogenous FcRγ receptor expressed on a myeloid cell, monocyte, or macrophage; the CFP is expressed on the surface of a myeloid cell expressing an endogenous FcR-γ receptor; the transmembrane domain is derived from CD89 comprising the amino acid sequence of LIRMAVAGLVLVALLAILV (SEQ ID NO:83); and the intracellular domain comprises one or more intracellular signaling domains comprising an intracellular domain derived from a CD16 protein, a CD64 protein, or a CD89 protein, or a fragment thereof.
26. 1. A composition comprising an engineered polynucleic acid, the engineered polynucleic acid comprising a sequence encoding a chimeric fusion protein (CFP), the CFP comprising: (a) an extracellular domain comprising an anti-TROP2 binding domain; and (b) a transmembrane domain operably linked to the extracellular domain; Including, the transmembrane domain is a transmembrane domain derived from a protein that dimerizes with endogenous FcR-γ receptors expressed on myeloid cells, monocytes, or macrophages of the subject; The CFP is expressed on the surface of myeloid cells expressing endogenous FcRγ receptors, and the anti-TROP2 binding domain comprises a Fab fragment or an scFv domain comprising a heavy chain variable domain and a light chain variable domain in a single polypeptide chain linked via a linker; and The anti-TROP2 binding domain is (a) heavy chain complementarity determining region 1 (HC CDR1), HC CDR2, and HC CDR3 of SEQ ID NO:34, and light chain complementarity determining region 1 (LC CDR1), LC CDR2, and LC CDR3 of SEQ ID NO:34; or (b) a HC CDR1, a HC CDR2, and a HC CDR3 of SEQ ID NO: 35, and a LC CDR1, a LC CDR2, and a LC CDR3 of SEQ ID NO: 35; The composition comprising:
27. 1. A composition comprising an engineered nucleic acid encoding a chimeric fusion protein (CFP), the CFP comprising: (a) an extracellular domain comprising: (I) an anti-TROP2 binding domain comprising an scFv comprising a heavy chain and a light chain, wherein the scFv comprises a sequence selected from the group consisting of SEQ ID NOs: 34 and 35; (II) a hinge domain comprising the amino acid sequence of IHQDYTTQN (SEQ ID NO: 82); (b) a transmembrane domain having the amino acid sequence of LIRMAVAGLVLVALLAILV (SEQ ID NO: 83); and (c) an intracellular domain comprising the amino acid sequence of ENWHSHTALNKEASADVAEPSWSQQMCQPGLTFARTPSVCK (SEQ ID NO: 84); The composition comprising:
28. The composition of any one of claims 24 to 27, wherein the engineered nucleic acid is mRNA.
29. The composition of any one of claims 24 to 27, wherein the mRNA is encapsulated in a nanoparticle delivery vehicle.
